N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

Abstract

Compound of Formula 1 JPEG2023520006000312.jpg44158 and pharmaceutically acceptable salts thereof (wherein n, R 1 , R 4 , R 5 、 R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , X 2 , X 3 and X 12 (wherein SSTR4 is defined herein) is disclosed. The disclosure also relates to materials and methods for preparing the compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating SSTR4-related diseases, disorders, and conditions.

Description

[Technical Field]

[0001] The present invention relates to N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives that are modulators of somatostatin receptor 4 (SSTR4), pharmaceutical compositions containing them, and their use for treating diseases, disorders, and conditions associated with SSTR4, including Alzheimer's disease. [Background technology]

[0002] Somatostatin receptor 4 (SSTR4) is a G-protein-coupled receptor for the peptide somatostatin. SSTR4 binds to the inhibitory G protein, Gi, and inhibits cyclic AMP production. SSTR4 is highly expressed in the central nervous system (CNS) and to a lesser extent in the dorsal root ganglia and intestine. See MA Meyer, “Highly Expressed Genes within Hippocampal Sector CA1: Implications for the Physiology of Memory,” Neurology International 6(2):5388 (2014). SSTR4 is highly conserved across species. For example, the SSTR4 protein sequences of humans, mice, and rats share over 87% identity at the amino acid level. Its predominant expression in the brain and high sequence homology across species suggest an important physiological role for SSTR4.

[0003] Experiments using bacTRAP technology have shown that SSTR4 is most strongly expressed in pyramidal neurons of the cerebral cortex and the CA1 region of the hippocampus. This CNS expression is conserved in humans, non-human primates, and mice. The hippocampus is important for learning and memory. See L.Squire and A.J.Dede, “Conscious and Unconscious Memory Systems,” Cold Spring Harbor Perspectives in Biology 7:a021667 (2015). In fact, the CA1 region of the hippocampus is the final stop of the trisynaptic circuit responsible for learning. This circuit begins in the entorhinal cortex (which also contains SSTR4), continues through the dentate gyrus, and reaches the CA3, ultimately reaching the CA1 region of the hippocampus. CA1 projects outward from the hippocampus through the subiculum. This circuit encodes all kinds of information from the external world to generate memories and learn new knowledge.

[0004] Alzheimer's disease is characterized by neuronal degeneration within this circuitry, primarily within the entorhinal cortex and the CA1 region of the hippocampus. See A. Serrano-Pozo et al., "Neuropathological Alterations in Alzheimer's Disease," Cold Spring Harbor Perspectives in Medicine 1:a006189 (2011). Additionally, hippocampal SSTR4 receptors appear to selectively control cognitive strategy use by switching from multiple hippocampal-based associations to simple striatal-based behavioral responses. See F. Gastambide et al., "Hippocampal SSTR4 Somatostatin Receptors Control the Selection of Memory Strategies," Psychopharmacology (Berl) 202(1-3):153-63 (2009). This finding provides strong support for the use of SSTR4 agonists as a pharmacological approach to improve striatal-based learning. Ibid.

[0005] Furthermore, recent studies have pointed to hippocampal hyperactivity as a major factor in disease progression and cognitive decline in Alzheimer's patients. See MA Busche et al., "Decreased Amyloid-β and Increased Neuronal Hyperactivity by Immunotherapy in Alzheimer's Models," Nature Neuroscience 18(12):1725-27 (2015). See also K. Yamamoto et al., "Chronic Optogenetic Activation Augments Aβ Pathology in a Mouse Model of Alzheimer's Disease," Cell Reports 11(6):859-65 (2015). Activation of the SSTR4 receptor has been shown to play a role in regulating neuronal activity. See C. Qiu et al., "Somatostatin Receptor Subtype 4 Couples to the M-Current to Regulate Seizures," Journal of Neuroscience 28(14):3567-76 (2008). Therefore, agonists for this receptor may be excellent pharmacological tools to inhibit and control neuronal activity in the cerebral cortex and hippocampus.

[0006] SSTR4 agonists are expected to be useful in the treatment of Alzheimer's disease and other CNS disorders such as epilepsy and depression. Summary of the Invention

[0007] The present invention provides N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions containing the N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives and their use for treating SSTR4-related diseases, disorders, and conditions, including Alzheimer's disease and other CNS disorders.

[0008] One aspect of the present invention is a compound of formula 1

[0009] [ka]

[0010] or a pharmaceutically acceptable salt thereof, X 2 is CR 2 and X 3 N and CR 3 or X 2 is N and X 3 is N, R 1 and R 2 is hydrogen, halo, cyano, R a , -OR b , -C(O)R b , -C(O)OR b , -C(O)N(R c )R b and -C(O)N(R c ) OR b or R 1 and R 2 taken together with the carbon atom to which they are attached may be unsubstituted or may be substituted with halo, hydroxy, cyano, amino, and C 1-4 forming a benzene ring substituted with 1 to 4 optional substituents independently selected from alkyl (each occurrence of which is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); where Ra is C 1-4 Alkyl, C 3-6 Cycloalkyl, C 2-6 Heterocyclyl and C 1-5 heteroaryl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R b is hydrogen, as well as C 1-4 Alkyl, C 3-6 Cycloalkyl, C 2-6 Heterocyclyl and C 1-5 heteroaryl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R c is hydrogen and C 1-4 alkyl, where R a and R b About C 2-6 Heterocyclyl substituents are monocyclic rings of 3 to 8 ring members, of which 1 or 2 ring members are heteroatoms, each of which is independently selected from N, O and S; C 1-5 The heteroaryl substituent is a 5- or 6-membered monocyclic ring of which 1-4 ring members are heteroatoms, each of which is independently selected from N, O, and S, provided that only one of the ring members is O or S; R 3 is hydrogen, halo, cyano and C 1-4alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); R 4 and R 5 is hydrogen, halo and C 1-4 alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo), or R 4 and R 5 together with the carbon atoms to which they are attached, form C 3-5 forming a cycloalkylidene, X 12 is bonded and CR 12 R 13 is selected from (a)R 6 is hydrogen, halo and C 1-4 alkyl, R 7 and R 8 together with the carbon and nitrogen atoms to which they are respectively attached, form a ring heteroatom C 3-5 forming a heterocyclyl, R 9 But hydrogen and C 1-4 alkyl, R 10 , R 11 , R 12 and R 13 is hydrogen, halo and C 1-4 alkyl; or (b)R 6 and R 7 is hydrogen, halo and C 1-4 alkyl, or R 6 and R 7 together with the carbon atoms to which they are attached, form C 3-5 forming a cycloalkylidene, R 8 and R 9 But together with the nitrogen atom to which they are bonded, they form C 3-5heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 10 , R 11 , R 12 and R 13 is hydrogen, halo and C 1-4 alkyl; or (c)R 6 and R 7 is hydrogen, halo and C 1-4 are each independently selected from alkyl, R 8 But hydrogen and C 1-4 alkyl, R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 11 , R 12 and R 13 is hydrogen, halo and C 1-4 are each independently selected from alkyl, n is selected from 0, 1, 2, 3, 4 and 5; Each R 14 Ha, Halo, C 1-4 Alkyl and C 1-4 alkoxy, wherein C 1-4 Alkyl and C 1-4 each alkoxy substituent is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; However, X 2 is CR 2 and X 3 is N and X 12 is a bond, n is 1, and R 1 , R 4 , R5 , R 6 , R 7 , R 8 , and R 11 are hydrogen and R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached form an unsubstituted pyrrolidin-2-yl, R 14 is methoxy, R 2 cannot be unsubstituted pyridin-3-yl or unsubstituted pyrimidin-5-yl).

[0011] Another aspect of the present invention provides a compound selected from the group of compounds described in the Examples and their pharmaceutically acceptable salts.

[0012] A further aspect of the present invention provides a pharmaceutical composition comprising a compound of Formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds or pharmaceutically acceptable salts defined in the preceding paragraph, and a pharmaceutically acceptable excipient.

[0013] An additional aspect of the present invention provides a compound of Formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds and pharmaceutically acceptable salts defined in the preceding paragraph, for use as a medicament.

[0014] Another aspect of the present invention provides a compound of Formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds or pharmaceutically acceptable salts defined in the preceding paragraph, for treating a disease, disorder or condition associated with SSTR4.

[0015] A further aspect of the present invention provides the use of a compound of formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds or pharmaceutically acceptable salts defined in the preceding paragraph, for the manufacture of a medicament for the treatment of a disease, disorder or condition associated with SSTR4.

[0016] An additional aspect of the present invention provides a method for treating a disease, disorder, or condition associated with SSTR4, comprising administering an effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds or pharmaceutically acceptable salts defined in the preceding paragraph.

[0017] Another aspect of the invention provides a method of treating a disease, disorder, or condition in a subject, comprising administering to the subject an effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds or pharmaceutically acceptable salts defined in the preceding paragraph, wherein the disease, disorder, or condition is selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

[0018] A further aspect of the present invention provides an effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof, or any one of the compounds or pharmaceutically acceptable salts defined in the preceding paragraph, and at least one additional pharmacologically active agent. DETAILED DESCRIPTION OF THE INVENTION

[0019] Unless otherwise indicated, this disclosure uses the definitions provided below.

[0020] "Substituted" refers to a chemical substituent or moiety (e.g., C 1-6 When used in connection with an alkyl group, it means that one or more hydrogen atoms of a substituent or moiety are replaced with one or more non-hydrogen atoms or groups, provided that valency requirements are met and the substitution results in a chemically stable compound.

[0021] "About" or "approximately," when used in connection with a measurable, numerical variable, refers to the value of the variable indicated and all values ​​of the variable that are within experimental error of the indicated value or within ±10 percent of the indicated value, whichever is greater.

[0022] "Alkyl" refers to straight- and branched-chain saturated hydrocarbon groups, generally having a specified number of carbon atoms (e.g., C 1-4 Alkyl refers to an alkyl group having 1 to 4 (i.e., 1, 2, 3, or 4) carbon atoms, C 1-6 (Alkyl refers to an alkyl group having 1 to 6 carbon atoms, etc.) Examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, pent-1-yl, pent-2-yl, pent-3-yl, 3-methylbut-1-yl, 3-methylbut-2-yl, 2-methylbut-2-yl, 2,2,2-trimethyleth-1-yl, n-hexyl, and the like.

[0023] "Alkanediyl" refers to a divalent alkyl group, where alkyl is defined above and generally has a specified number of carbon atoms (e.g., C 1-4 Alkanediyl refers to an alkanediyl group having 1 to 4 (i.e., 1, 2, 3, or 4) carbon atoms, C 1-6 (Alkanediyl refers to an alkanediyl group having 1 to 6 carbon atoms, etc.) Examples of alkanediyl groups include methylene, ethane-1,1-diyl, ethane-1,2-diyl, propane-1,3-diyl, propane-1,2-diyl, propane-1,1-diyl, propane-2,2-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, butane-1,1-diyl, isobutane-1,3-diyl, isobutane-1,1-diyl, isobutane-1,2-diyl, and the like.

[0024] "Alkenyl" refers to straight- and branched-chain hydrocarbon groups having one or more carbon-carbon double bonds and generally having a specified number of carbon atoms. Examples of alkenyl groups include ethenyl, 1-propen-1-yl, 1-propen-2-yl, 2-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 3-buten-1-yl, 3-buten-2-yl, 2-buten-1-yl, 2-buten-2-yl, 2-methyl-1-propen-1-yl, 2-methyl-2-propen-1-yl, 1,3-butadien-1-yl, 1,3-butadien-2-yl, and the like.

[0025] "Alkynyl" refers to a straight or branched chain hydrocarbon group having one or more triple carbon-carbon bonds and generally having a specified number of carbon atoms. Examples of alkynyl groups include ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, 3-butyn-1-yl, 3-butyn-2-yl, 2-butyn-1-yl, and the like.

[0026] "Halo," "halogen," and "halogeno" may be used interchangeably and refer to fluoro, chloro, bromo, and iodo.

[0027] "Haloalkyl," "haloalkenyl," and "haloalkynyl" refer to alkyl, alkenyl, and alkynyl groups, respectively, substituted with one or more halogen atoms, where alkyl, alkenyl, and alkynyl are defined above and generally have the specified number of carbon atoms. Examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 1-fluoroethyl, 1,1-difluoroethyl, 1-chloroethyl, 1,1-dichloroethyl, 1-fluoro-1-methylethyl, 1-chloro-1-methylethyl, and the like.

[0028] "Cycloalkyl" refers to saturated monocyclic and bicyclic hydrocarbon groups, generally having a specified number of carbon atoms containing one or more rings (e.g., C 3-8Cycloalkyl refers to a cycloalkyl group having 3 to 8 carbon atoms as ring members. Bicyclic hydrocarbon groups can include independent rings (where the two rings share no carbon atoms), spiro rings (where the two rings share one carbon atom), fused rings (where the two rings share two carbon atoms with a bond between the two common carbon atoms), and bridged rings (where the two rings share two carbon atoms but no common bond). Cycloalkyl groups may be bonded through any ring atom, provided that such bonding does not violate valence requirements, and, where indicated, may optionally contain one or more non-hydrogen substituents, provided that such substitution does not violate valence requirements.

[0029] Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. Examples of fused bicyclic cycloalkyl groups include bicyclo[2.1.0]pentanyl (i.e., bicyclo[2.1.0]pentan-1-yl, bicyclo[2.1.0]pentan-2-yl, and bicyclo[2.1.0]pentan-5-yl), bicyclo[3.1.0]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.3.0]octanyl, bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, etc. Examples of bridged cycloalkyl groups include bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[3.2.1]octanyl, bicyclo[4.1.1]octanyl, bicyclo[3.3.1]nonanyl, bicyclo[4.2.1]nonanyl, bicyclo[3.3.2]decanyl, bicyclo[4.2.2]decanyl, bicyclo[4.3.1]decanyl, bicyclo[3.3.3]undecanyl, bicyclo[4.3.2]undecanyl, bicyclo[4.3.3]dodecanyl, and the like. Examples of spirocycloalkyl groups include spiro[3.3]heptanyl, spiro[2.4]heptanyl, spiro[3.4]octanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, etc. Examples of isolated bicyclic cycloalkyl groups include those derived from bi(cyclobutane), cyclobutanecyclopentane, bi(cyclopentane), cyclobutanecyclohexane, cyclopentanecyclohexane, and bi(cyclohexane).

[0030] "Cycloalkanediyl" refers to a divalent cycloalkyl group, where cycloalkyl is defined above and generally has a specified number of carbon atoms (e.g., C 3-4 Cycloalkanediyl refers to a cycloalkanediyl group having 3 to 4 (i.e., 3 or 4) carbon atoms, C 3-6(Cycloalkanediyl refers to a cycloalkanediyl group having 3 to 6 carbon atoms, etc.) Examples of cycloalkanediyl groups include cyclopropane-1,1-diyl, cyclopropane-1,2-diyl, cyclobutane-1,1-diyl, cyclobutane-1,2-diyl, and the like.

[0031] "Cycloalkylidene" refers to a divalent monocyclic cycloalkyl group, where cycloalkyl is defined above and is attached through one carbon atom of the group, and generally has a specified number of carbon atoms comprising the ring (e.g., C 3-6 Cycloalkylidene refers to a cycloalkylidene group having 3 to 6 carbon atoms as ring members.) Examples include cyclopropylidene, cyclobutylidene, cyclopentylidene, and cyclohexylidene.

[0032] "Cycloalkenyl" refers to partially unsaturated monocyclic and bicyclic hydrocarbon groups, generally having a specified number of carbon atoms, including one or more rings. Similar to cycloalkyl groups, bicyclic cycloalkenyl groups can include independent, spirocyclic, fused, or bridged rings. Similarly, cycloalkenyl groups may be bonded via any ring atom and, where indicated, may optionally include one or more non-hydrogen substituents, provided such bonding or substitution does not violate valence requirements. Examples of cycloalkenyl groups include partially unsaturated analogs of the above cycloalkyl groups, such as cyclobutenyl (i.e., cyclobuten-1-yl and cyclobuten-3-yl), cyclopentenyl, cyclohexenyl, and bicyclo[2.2.1]hept-2-enyl.

[0033] "Aryl" refers to fully unsaturated monocyclic aromatic hydrocarbons and polycyclic hydrocarbons having at least one aromatic ring, and both monocyclic and polycyclic aryl groups generally have a specified number of carbon atoms comprising their ring members (e.g., C 6-14Aryl refers to an aryl group having 6 to 14 carbon atoms as ring members. The group may be attached via any ring atom and, where indicated, may optionally contain one or more non-hydrogen substituents, provided such attachment or substitution does not violate valence requirements. Examples of aryl groups include phenyl, biphenyl, cyclobutabenzenyl, indenyl, naphthalenyl, benzocycloheptanyl, biphenylenylfluorenyl, and those derived from cycloheptatriene cations.

[0034] "Arylene" refers to a divalent aryl group, where aryl is as defined above. Examples of arylene groups include o-phenylene (i.e., benzene-1,2-diyl).

[0035] "Heterocycle" and "heterocyclyl" may be used interchangeably and refer to a saturated or partially unsaturated monocyclic or bicyclic group having ring atoms composed of carbon atoms and from 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Both monocyclic and bicyclic groups generally have a specified number of carbon atoms in one or more rings (e.g., C 2-6Heterocyclyl refers to a heterocyclyl group having 2 to 6 carbon atoms and 1 to 4 heteroatoms as ring members. Like bicyclic cycloalkyl groups, bicyclic heterocyclyl groups can include independent rings, spirocyclic rings, fused rings, and bridged rings. Heterocyclyl groups may be attached via any ring atom and, where indicated, can optionally contain one or more non-hydrogen substituents, provided that such attachment or substitution does not violate valence requirements or result in a chemically unstable compound. Examples of heterocyclyl groups include oxiranyl, thiiranyl, aziridinyl (e.g., aziridin-1-yl and aziridin-2-yl), oxetanyl, thietanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl, morpholinyl, 1,4-dithianyl, piperazinyl, 1,4-azathianyl, oxepanyl, thiepanyl, azepanyl, 1,4-dioxepanyl, Examples include 1,4-oxathiepanyl, 1,4-oxazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl, 1,4-diazepanyl, 3,4-dihydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, 2H-pyranyl, 1,2-dihydropyridinyl, 1,2,3,4-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, 1,6-dihydropyrimidinyl, 1,2,3,4-tetrahydropyrimidinyl, and 1,2-dihydropyrazolo[1,5-d][1,2,4]triazinyl.

[0036] "Heterocyclyldiyl" refers to a heterocyclyl group that is bonded through two ring atoms of the group, where heterocyclyl is defined above. These generally have a specified number of carbon atoms in one or more rings (e.g., C 2-6Heterocyclyldiyl refers to a heterocyclyldiyl group having 2 to 6 carbon atoms and 1 to 4 heteroatoms as ring members.) Examples of heterocyclyldiyl groups include polyvalent analogs of the above heterocyclyl groups, such as morpholin-3,4-diyl, pyrrolidin-1,2-diyl, 1-pyrrolidinyl-2-ylidene, 1-pyridinyl-2-ylidene, 1-(4H)-pyrazolyl-5-ylidene, 1-(3H)-imidazolyl-2-ylidene, 3-oxazolyl-2-ylidene, 1-piperidinyl-2-ylidene, and 1-piperazinyl-6-ylidene.

[0037] The terms "heteroaromatic" and "heteroaryl" may be used interchangeably and refer to unsaturated monocyclic aromatic groups and polycyclic groups having at least one aromatic ring, each of which has ring atoms composed of carbon atoms and from 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Both monocyclic and polycyclic groups generally have a specific number of carbon atoms as ring members (e.g., C 1-9Heteroaryl refers to heteroaryl groups having 1 to 9 carbon atoms and 1 to 4 heteroatoms as ring members, and can include any bicyclic group in which any of the monocyclic heterocycles listed above is fused to a benzene ring. Heteroaryl groups may be bonded through any ring atom (or multiple ring atoms in the case of fused rings) and, where indicated, can optionally contain one or more non-hydrogen substituents, provided that such bonding or substitution does not violate valence requirements or result in a chemically unstable compound. Examples of heteroaryl groups include monocyclic groups such as pyrrolyl (e.g., pyrrol-1-yl, pyrrol-2-yl, and pyrrol-3-yl), furanyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl.

[0038] Examples of heteroaryl groups also include benzofuranyl, isobenzofuranyl, benzothienyl, benzo[c]thienyl, 1H-indolyl, 3H-indolyl, isoindolyl, 1H-isoindolyl, indolinyl, isoindolinyl, benzimidazolyl, 1H-indazolyl, 2H-indazolyl, benzotriazolyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 3H-imidazo[4,5 ... 1H-pyrazolo[4,5-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 1H-pyrazolo[4,3-c]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[3,4-b]pyridinyl, 7H-purinyl, indolizinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, quinolinyl, isoquinolinylcinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1,6-naphthyridinyl 1,7-naphthyridinyl, 1,8-naphthyridinyl, 1,5-naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazino[2,3-b]pyrazinyl, pyrimido[4,5-d]pyrimidinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, 2,3-di Hydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, 2,3-dihydro-1H-benzo[d]imidazolyl, benzo[d]thiazolyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, 2,3-dihydro-1H-imidazo[4,5-b]pyridinyl, tetrazolo[1,5-a]pyridinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyrimidinyl, 4,Bicyclic groups include 5-dihydro-1H-pyrazolo[3,4-d]pyrimidinyl, 2,3,6,7-tetrahydro-1H-purinyl, 5H-pyrrolo[2,3-b]pyrazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-b]pyridazinyl, and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl.

[0039] "Heteroarylene" refers to a heteroaryl group that is bonded through two ring atoms of the group, where heteroaryl is defined above. They generally have a specified number of carbon atoms in one or more rings (e.g., C 3-5 Heteroarylene refers to a heteroarylene group having 3 to 5 carbon atoms and 1 to 4 heteroatoms as ring members.) Examples of heteroarylene groups include polyvalent analogs of the above heteroaryl groups, such as pyridine-2,3-diyl, pyridine-3,4-diyl, pyrazole-4,5-diyl, and pyrazole-3,4-diyl.

[0040] "Oxo" refers to a double-bonded oxygen (=O).

[0041] "Leaving group" refers to any group that leaves a molecule during a fragmentation process, including substitution, elimination, and addition-elimination reactions. Leaving groups can be nucleofugal, meaning that the group leaves with the electron pair that originally served as the bond between the leaving group and the molecule, or electrofugal, meaning that the group leaves without the electron pair. The ability of a nucleofugal leaving group to leave depends on its base strength, with the strongest bases being the weakest leaving groups. Common nucleofugal leaving groups include sulfonates containing nitrogen (e.g., from diazonium salts); alkyl sulfonates (e.g., mesylates), fluoroalkyl sulfonates (e.g., triflates, hexaflates, nonaflates, and tresylates), and aryl sulfonates (e.g., tosylates, brosylates, closylates, and nosylates). Others include carbonates, halide ions, carboxylate anions, phenolate ions, and alkoxides. NH2 - and OH -Some strong bases, such as , can be made better leaving groups by treatment with acid. Common electrofugal leaving groups include the proton, CO2, and metals.

[0042] "Reverse enantiomer" refers to a molecule that is a non-superimposable mirror image of a reference molecule, obtained by inverting all stereocenters of the reference molecule. For example, if the reference molecule has S absolute stereochemical configuration, then the opposite enantiomer has R absolute stereochemical configuration. Similarly, if the reference molecule has S,S absolute stereochemical configuration, then the opposite enantiomer has R,R stereochemical configuration, etc.

[0043] A "stereoisomer" and "stereoisomers" of a compound having a given stereochemical configuration refer to the opposite enantiomer of the compound and any diastereoisomers, including geometric isomers (Z / E) of the compound. For example, if a compound has an S,R,Z stereochemical configuration, then the stereoisomers include the opposite enantiomer having the R,S,Z configuration, as well as diastereomers having the S,S,Z configuration, the R,R,Z configuration, the S,R,E configuration, the R,S,E configuration, the S,S,E configuration, and the R,R,E configuration. If the stereochemical configuration of the compound is not specified, "stereoisomer" refers to any one of the possible stereochemical configurations of the compound.

[0044] "Substantially pure stereoisomer" and variants thereof refer to a sample containing a compound with a particular stereochemical configuration, the sample comprising at least about 95% of the sample.

[0045] "Pure stereoisomer" and variants thereof refer to a sample containing a compound with a particular stereochemical configuration, comprising at least about 99.5% of the sample.

[0046] "Subject" refers to a mammal, including a human.

[0047] A "pharmaceutically acceptable" substance refers to a substance that is suitable for administration to a subject.

[0048] "Treating" refers to ameliorating, alleviating, inhibiting the progression of, or preventing the disease, disorder, or condition to which the term applies, or ameliorating, alleviating, inhibiting the progression of, or preventing one or more symptoms of such disease, disorder, or condition.

[0049] "Treatment" refers to the act of treating, as defined immediately above.

[0050] "Drug," "drug substance," "active pharmaceutical ingredient," and the like refer to compounds (e.g., including compounds of Formula 1, its subgeneric compounds, and compounds specifically named herein) that can be used to treat a subject in need thereof.

[0051] An "effective amount" of a drug, a "therapeutically effective amount" of a drug, and the like refer to the amount of drug that can be used to treat a subject, and can depend, inter alia, on the weight and age of the subject and the route of administration.

[0052] "Excipient" refers to any diluent or vehicle for a drug.

[0053] A "pharmaceutical composition" refers to a combination of one or more drug substances and one or more excipients.

[0054] "Drug," "pharmaceutical dosage form," "dosage form," "final dosage form," and the like refer to a pharmaceutical composition suitable for treating a subject in need thereof, and may generally be in the form of a tablet, capsule, sachet containing powder or granules, liquid or suspension, patch, film, and the like.

[0055] "Condition associated with SSTR4" and similar phrases refer to a disease, disorder or condition in a subject in which activation of SSTR4 can provide a therapeutic or prophylactic benefit.

[0056] The following abbreviations may be used herein: Ac (acetyl); ACN (acetonitrile); AIBN (azo-bis-isobutyronitrile); API (active pharmaceutical ingredient); aq (aqueous solution); BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl); Boc (tert-butoxycarbonyl); Cbz (carbobenzyloxy); dba (dibenzylideneacetone); DBU (1,8-diazabicyclo[5.4.0]undec-7-ene); DCC (1,3-dicyclohexylcarbodiimide); DCE (1,1 -Dichloroethane; DCM (dichloromethane); DEA (diethylamine); DIAD (diisopropyl azodicarboxylate); DIPEA (N,N-diisopropylethylamine, Hunig's base); DMA (N,N-dimethylacetamide); DMAP (4-dimethylaminopyridine); DME (1,2-dimethoxyethane); DMF (N,N-dimethylformamide); DMP (Dess-Martin periodinane); DMSO (dimethyl sulfoxide); dppf (1,1'-bis(diphenylphosphino)ferrocene); DTT (dithiothreitol); EC 50 (Half-maximum effective concentration); EDA (ethoxylated dodecyl alcohol, Brj® 35); EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide); EDTA (ethylenediaminetetraacetic acid); ee (enantiomeric excess); eq (equivalent); Et (ethyl); EtN (triethylamine); EtOAc (ethyl acetate); EtOH (ethanol); HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate(V)); HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid); AcOH (acetic acid); HOBt (1H-benzo[d][1,2,3]triazol-1-ol); IC 50(50% inhibitory concentration); IPA (isopropanol); IPAc (isopropyl acetate); IPE (isopropyl ether); LDA (lithium diisopropylamide); LiHMDS (lithium bis(trimethylsilyl)amide); mCPBA (m-chloroperoxybenzoic acid); Me (methyl); MeOH (methanol); MTBE (methyl tert-butyl ether); mp (melting point); NaOt-Bu (sodium tertiary butoxide); NMM (N-methylmorpholine); NMP (N-methyl-pyrrolidone); OTf (triflate); PE (petroleum ether); Ph (phenyl); pEC 50 (-log 10 (EC 50 ), where EC 50 is given in molar (M) units); pIC 50 (-log 10 (I C 50 ), where IC 50 are given in moles (M); Pr (propyl); c-Pr (cyclopropyl), i-Pr (isopropyl); PTFE (polytetrafluoroethylene); PyBOP ((benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate); PyBroP® (bromotripyrrolidinophosphonium hexafluorophosphate); RT (room temperature, approximately 20°C to 25°C); SFC (supercritical fluid chromatography); T3P (2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide); TCEP (tris(2-carboxyethyl)phosphine); TFA (trifluoroacetic acid); TFAA (2,2,2-trifluoroacetic anhydride); THF (tetrahydrofuran); TMS (trimethylsilyl); and Tris buffer (2-amino-2-hydroxymethyl-propane-1,3-diol buffer).

[0057] As described below, the present disclosure relates to compounds of Formula 1 and their pharmaceutically acceptable salts. The present disclosure also provides materials and methods for preparing the compounds of Formula 1, pharmaceutical compositions containing them, and the use of the compounds of Formula 1 and their pharmaceutically acceptable salts (optionally in combination with other pharmacologically active agents) for treating diseases, disorders, or conditions of the CNS, including Alzheimer's disease, and other diseases, disorders, or conditions associated with SSTR4.

[0058] Compounds of Formula 1 include those that are: (1)X 2 But, CR 2 and X 3 However, N and CR 3 or X 2 is N and X 3 is N, R 1 and R 2 But hydrogen, halo, cyano, R a , -OR b , -C(O)R b , -C(O)OR b , -C(O)N(R c )R b and -C(O)N(R c ) OR b or R 1 and R 2 together with the carbon atom to which they are attached are unsubstituted or substituted with halo, hydroxy, cyano, amino, and C 1-4 forming a benzene ring substituted with 1 to 4 optional substituents independently selected from alkyl (each occurrence of which is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); R a But C 1-4 Alkyl, C 3-6 Cycloalkyl, C 2-6 Heterocyclyl and C 1-5 heteroaryl, each of which is unsubstituted or selected from halo, C 1-4Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R b However, hydrogen and C 1-4 Alkyl, C 3-6 Cycloalkyl, C 2-6 Heterocyclyl and C 1-5 heteroaryl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R c But hydrogen and C 1-4 alkyl, where R a and R b About C 2-6 Heterocyclyl substituents are monocyclic rings of 3 to 8 ring members, of which 1 or 2 ring members are heteroatoms, each of which is independently selected from N, O and S; C 1-5 The heteroaryl substituent is a 5- or 6-membered monocyclic ring of which 1-4 ring members are heteroatoms, each of which is independently selected from N, O, and S, provided that only one of the ring members is O or S; R 3 is hydrogen, halo, cyano and C 1-4 alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); R 4 and R 5 but hydrogen, halo and C 1-4alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo), or R 4 and R 5 together with the carbon atom to which they are bonded, form C 3-5 forming a cycloalkylidene, X 12 But bonding and CR 12 R 13 is selected from (a)R 6 but hydrogen, halo and C 1-4 alkyl, R 7 and R 8 together with the carbon and nitrogen atoms to which they are respectively attached, form a ring heteroatom C 3-5 forming a heterocyclyl, R 9 But hydrogen and C 1-4 alkyl, R 10 , R 11 , R 12 and R 13 but hydrogen, halo and C 1-4 alkyl; or (b)R 6 and R 7 but hydrogen, halo and C 1-4 alkyl, or R 6 and R 7 together with the carbon atom to which they are bonded, form C 3-5 forming a cycloalkylidene, R 8 and R 9 But together with the nitrogen atom to which they are bonded, they form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 10 , R 11 , R 12 and R13 but hydrogen, halo and C 1-4 alkyl; or (c)R 6 and R 7 but hydrogen, halo and C 1-4 are each independently selected from alkyl, R 8 But hydrogen and C 1-4 alkyl, R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 11 , R 12 and R 13 but hydrogen, halo and C 1-4 are each independently selected from alkyl, n is selected from 0, 1, 2, 3, 4 and 5; Each R 14 But, Halo, C 1-4 Alkyl and C 1-4 alkoxy, wherein C 1-4 Alkyl and C 1-4 each alkoxy substituent is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; However, X 2 is CR 2 and X 3 is N and X 12 is a bond, n is 1, and R 1 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 11 are hydrogen and R 9 and R 10together with the nitrogen and carbon atoms to which they are respectively attached form an unsubstituted pyrrolidin-2-yl, R 14 is methoxy, R 2 cannot be unsubstituted pyridin-3-yl or unsubstituted pyrimidin-5-yl.

[0059] In addition to embodiment (1) of the preceding paragraph, compounds of Formula 1 include those in which: (2)R 2 and R 2 together with the carbon atom to which they are attached are unsubstituted or substituted with halo, hydroxy, cyano, amino, and C 1-4 those forming a benzene ring substituted with 1 to 4 optional substituents independently selected from alkyl (which for each occurrence is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo).

[0060] In addition to embodiment (2) of the preceding paragraph, compounds of Formula 1 may also include R 1 and R 2 taken together with the carbon atom to which they are attached to form a benzene ring that is unsubstituted or substituted with 1 to 4 optional substituents independently selected from: (3) Halo, cyano, and C 1-4 alkyl (which for each occurrence is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (4) Halo and C 1-4 alkyl (which for each occurrence is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (5) C 1-4 alkyl (which for each occurrence is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (6) C 1-4 alkyl (which is independently unsubstituted at each occurrence); or (7) Methyl;

[0061] In addition to embodiments (1)-(7) of the preceding paragraph, compounds of Formula 1 may also include R 1 and R 2 which, taken together with the carbon atom to which they are attached, form a benzene ring that is unsubstituted or substituted with: (8) 1 to 3 optional substituents; (9) 1 to 2 optional substituents; (10) one optional substituent; or (11) 0 optional substituents.

[0062] In addition to embodiment (1) above, the compound of formula 1 may also be R 1 and R 2 are each independently selected from the following: (12) Hydrogen, Halo, Cyano, R a , -OR b , -C(O)R b , -C(O)OR b , -C(O)N(R c )R b and -C(O)N(R c ) OR b ; (13) Hydrogen, Cyano, R a , -OR b , -C(O)R b , -C(O)OR b , -C(O)N(R c )R b and -C(O)N(R c ) OR b ; (14) Hydrogen, Cyano, R a , -OR b , -C(O)R b , -C(O)OR b and -C(O)N(R c )R b ;or (15) Hydrogen, R a , -OR b , -C(O)R b , -C(O)OR b and -C(O)N(R c )R b .

[0063] In addition to embodiments (12)-(15) of the preceding paragraph, compounds of Formula 1 include those in which: (16)R a But C 1-4 Alkyl, C 3-6 Cycloalkyl, C 3-5 Heterocyclyl and C 1-5 heteroaryl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R b However, hydrogen and C 1-4 Alkyl, C 3-6 Cycloalkyl, C 3-5 Heterocyclyl and C 1-5 heteroaryl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R c But hydrogen and C 1-4 alkyl, where R a and R b About C 3-5 Heterocyclyl substituents are monocyclic rings of 4 to 7 ring members, of which 1 or 2 ring members are heteroatoms, each of which is independently selected from N, O and S; C 1-5Heteroaryl substituents are 5- or 6-membered monocyclic rings in which 1-4 ring members are heteroatoms, each of which is independently selected from N, O, and S, provided that only one of the ring members is O or S.

[0064] In addition to embodiment (16) of the preceding paragraph, the compound of Formula 1 may also be R a and R b About C 3-5 Included are those in which the heterocyclyl substituent is a monocyclic ring having: (17) 4 to 6 ring members.

[0065] In addition to embodiments (15) and (16) of the preceding paragraph, compounds of Formula 1 may also be prepared by adding R a and R b About C 3-5 Included are those in which the heterocyclyl substituent is a monocyclic ring having: (18) One or two ring members are heteroatoms, each of which is independently selected from N and O.

[0066] In addition to embodiment (16) above, compounds of formula 1 may also be R a and R b About C 3-5 Heterocyclyl substituents include those selected from: (19) azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, and morpholinyl; or (20) Azetidin-1-yl, pyrrolidin-1-yl, piperidinyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, and morpholin-4-yl; or

[0067] In addition to embodiments (12)-(20) of the preceding paragraph, compounds of Formula 1 may also be R a and R b Regarding, including those that are: (21)C 1-5The heteroaryl substituent is a 5-membered monocyclic ring of which 1 to 4 ring members are heteroatoms, each of which is independently selected from N, O, and S, provided that only one of the ring members is O or S.

[0068] In addition to embodiment (21) of the preceding paragraph, compounds of Formula 1 may also include R a and R b About C 1-5 Heteroaryl substituents include those selected from the following: (22) pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, and tetrazolyl; (23) pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl and thiazolyl; or (24) Imidazol-2-yl, oxazol-2-yl and thiazol-2-yl;

[0069] In addition to the above embodiments (12) to (20), the compound of formula 1 may also be R a and R b About C 1-5 Heteroaryl substituents include those selected from the following: (25) Pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl.

[0070] In addition to embodiments (1)-(25) above, compounds of Formula 1 include those in which: (26)X 2 is CR 2 and X 3 is N.

[0071] In addition to embodiments (1)-(25) above, compounds of Formula 1 include those in which: (27)X 2 is CR 2 and X 3 is CR 3 Something that is.

[0072] In addition to embodiment (27) of the preceding paragraph, compounds of Formula 1 may also include R 3 but includes those selected from the following: (28) Hydrogen, halo, cyano and C 1-3 alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (29) hydrogen, halo, cyano, and methyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (30) hydrogen, halo, cyano, and methyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from fluoro); (31) Hydrogen, halo, cyano and methyl; (32) Hydrogen, halo and methyl; (33) hydrogen and halo; or (34) Hydrogen.

[0073] In addition to embodiment (1) above, compounds of Formula 1 include those in which: (35)X 2 is N and X 3 is N.

[0074] In addition to embodiments (1)-(35) of the preceding paragraph, compounds of Formula 1 may also include R 1 but includes those selected from the following: (36) Hydrogen, R a , -OR b , -C(O)R b , -C(O)OR b and -C(O)N(R c )R b (In the formula, R a is C 1-4 Alkyl and C 3-6 cycloalkyl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R b is hydrogen, as well as C 1-4 Alkyl and C 3-6 cycloalkyl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R c is hydrogen and C 1-4 alkyl).

[0075] In addition to embodiment (36) of the preceding paragraph, compounds of Formula 1 may also include R 1 but includes those selected from the following: (37) Hydrogen, R a , -OR b , -C(O)R b , -C(O)OR b and -C(O)N(R c )R b ;or (38) Hydrogen, R a, -OR b and -C(O)N(R c )R b .

[0076] In addition to embodiments (36)-(38) of the preceding paragraph, compounds of Formula 1 may also be R 1 Regarding, including those that are: (39)R a But C 1-3 Alkyl and C 3-5 cycloalkyl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R b However, hydrogen and C 1-3 Alkyl and C 3-5 cycloalkyl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R c But hydrogen and C 1-3 Selected from alkyl.

[0077] In addition to the above embodiments (36) to (38), the compound of formula 1 may also be R 1 Regarding, including those that are: (40)R a is selected from methyl, ethyl, propyl, isopropyl, and cyclopropyl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R b is selected from hydrogen, methyl, ethyl, propyl, isopropyl, and cyclopropyl, each of which is unsubstituted or selected from halo, C 1-4 Alkyl and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein C 1-4 Alkyl and C 1-4 The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R c is selected from hydrogen and methyl.

[0078] In addition to embodiments (1)-(40) of the preceding paragraph, compounds of Formula 1 may also include R 4 and R 5 are each independently selected from the following: (41) Hydrogen, Halo and C 1-4 alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (42) Hydrogen, Halo and C 1-3 alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (43) hydrogen, halo, and methyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (44) hydrogen, halo and methyl; and (45) Hydrogen and methyl.

[0079] In addition to embodiments (1)-(40) above, compounds of Formula 1 include those in which: (46)R 4 is hydrogen and R5 is methyl or (47)R 4 and R 5 are each methyl, or (48)R 4 and R 5 are each hydrogen.

[0080] In addition to embodiments (1)-(40) above, compounds of Formula 1 include those in which: (49)R 4 and R 5 together with the carbon atom to which they are bonded, form C 3-5 forming a cycloalkylidene, or (50)R 4 and R 5 together with the carbon atom to which they are attached to form a cyclopropylidene.

[0081] In addition to embodiments (1) through (50) of the preceding paragraph, compounds of Formula 1 include those in which: (51)X 12 is a bond, (a)R 6 but hydrogen, halo and C 1-4 alkyl, R 7 and R 8 together with the carbon and nitrogen atoms to which they are respectively attached, form a ring heteroatom C 3-5 forming a heterocyclyl, R 9 But hydrogen and C 1-4 alkyl, R 10 and R 11 but hydrogen, halo and C 1-4 alkyl; or (b)R 6 and R 7 but hydrogen, halo and C 1-4 alkyl, or R 6 and R 7together with the carbon atom to which they are bonded, form C 3-5 forming a cycloalkylidene, R 8 and R 9 But together with the nitrogen atom to which they are bonded, they form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 10 and R 11 but hydrogen, halo and C 1-4 alkyl; or (c)R 6 and R 7 but hydrogen, halo and C 1-4 are each independently selected from alkyl, R 8 But hydrogen and C 1-4 alkyl, R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 11 but hydrogen, halo and C 1-4 Selected from alkyl.

[0082] In addition to embodiments (1) through (50) above, compounds of Formula 1 include those in which: (52)X 12 is a bond, (b)R 6 and R 7 but hydrogen, halo and C 1-4 alkyl, or R 6 and R 7 together with the carbon atoms to which they are attached, form C 3-5forming a cycloalkylidene, R 8 and R 9 But together with the nitrogen atom to which they are bonded, they form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 10 and R 11 but hydrogen, halo and C 1-4 alkyl; or (c)R 6 and R 7 but hydrogen, halo and C 1-4 are each independently selected from alkyl, R 8 But hydrogen and C 1-4 alkyl, R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 11 but hydrogen, halo and C 1-4 Selected from alkyl.

[0083] In addition to embodiments (1) through (50) above, compounds of Formula 1 include those in which: (53)X 12 is a bond, R 6 and R 7 but hydrogen, halo and C 1-4 alkyl, or R 6 and R 7 together with the carbon atom to which they are bonded, form C 3-5 forming a cycloalkylidene, R 8 and R9 But together with the nitrogen atom to which they are bonded, they form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 10 and R 11 but hydrogen, halo and C 1-4 each independently selected from alkyl.

[0084] In addition to embodiment (53) of the preceding paragraph, compounds of Formula 1 may also include R 6 and R 7 are each independently selected from the following: (54) Hydrogen, Halo and C 1-4 Alkyl, or R 6 and R 7 together with the carbon atom to which they are attached to form a cyclopropylidene; (55) Hydrogen, Halo and C 1-4 alkyl; (56) Hydrogen and C 1-4 alkyl; (57) Hydrogen and C 1-3 alkyl; or (58) Hydrogen and methyl.

[0085] In addition to embodiment (53) above, compounds of Formula 1 include those in which: (59)R 6 is methyl and R 7 is hydrogen or (60)R 6 and R 7 are each methyl, (61)R 6 and R 7 are each hydrogen, or (62)R 6 and R 7 together with the carbon atom to which they are attached to form a cyclopropylidene.

[0086] In addition to embodiments (53)-(62) of the preceding paragraph, compounds of Formula 1 may also be R 8 and R 9 together with the nitrogen atom to which they are attached, form the following C 3-5 Including those forming heterocyclyl: (63) Unsubstituted or halo and C 1-4 azetidinyl substituted with 1 to 3 optional substituents independently selected from alkyl; (64) Unsubstituted or halo and C 1-4 pyrrolidinyl, substituted with 1 to 3 optional substituents independently selected from alkyl; or (65) Unsubstituted or halo and C 1-4 piperidinyl substituted with 1 to 3 optional substituents independently selected from alkyl;

[0087] In addition to embodiments (53)-(65) of the preceding paragraph, compounds of Formula 1 may also be R 8 and R 9 and the nitrogen atom to which they are bonded. 3-5 Includes heterocyclyl where: (66) Unsubstituted or halo and C 1-3 substituted with 1 to 3 optional substituents independently selected from alkyl; (67) Unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo and methyl; (68) unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; (69) unsubstituted or substituted with 1 to 3 optional substituents independently selected from fluoro; or (70) Unsubstituted.

[0088] In addition to embodiments (53)-(70) of the preceding paragraph, compounds of Formula 1 may also be R 10 and R 11are each independently selected from the following: (71) Hydrogen, Halo and C 1-3 alkyl; (72) Hydrogen and C 1-3 alkyl; (73) Hydrogen and methyl; (74) Methyl; or (75) Hydrogen.

[0089] In addition to embodiments (1) through (50) above, compounds of Formula 1 include those in which: (76)X 12 is a bond, R 6 and R 7 but hydrogen, halo and C 1-4 are each independently selected from alkyl, R 8 But hydrogen and C 1-4 alkyl, R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 11 but hydrogen, halo and C 1-4 Selected from alkyl.

[0090] In addition to embodiment (76) of the preceding paragraph, the compound of Formula 1 may further comprise R 6 and R 7 are each independently selected from the following: (77) Hydrogen and C 1-4 alkyl; (78) Hydrogen and C 1-3 alkyl; or (79) Hydrogen and methyl.

[0091] In addition to embodiments (76)-(79) of the preceding paragraph, compounds of Formula 1 include those in which: (80)R 6 is methyl and R 7 is hydrogen or (81)R 6 and R 7 are each methyl, or (82)R 6 and R 7 are each hydrogen.

[0092] In addition to embodiments (76)-(82) of the preceding paragraph, compounds of Formula 1 may also be R 8 but includes those selected from the following: (83) Hydrogen and C 1-3 alkyl; (84) Hydrogen and methyl; (85) Methyl; or (86) Hydrogen.

[0093] In addition to embodiments (76)-(86) of the preceding paragraph, compounds of Formula 1 may also be R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, is C 3-5 Including those forming heterocyclyl: (87) Unsubstituted or halo and C 1-4 azetidinyl substituted with 1 to 3 optional substituents independently selected from alkyl; (88) Unsubstituted or halo and C 1-4 pyrrolidinyl substituted with 1 to 3 optional substituents independently selected from alkyl; (89) Unsubstituted or halo and C 1-4 piperidinyl substituted with 1 to 3 optional substituents independently selected from alkyl;

[0094] In addition to embodiments (76)-(89) of the preceding paragraph, compounds of Formula 1 may also be R 9 and R 10 and the nitrogen and carbon atoms to which they are respectively bonded. 3-5Includes heterocyclyl where: (90) Unsubstituted or halo and C 1-3 substituted with 1 to 3 optional substituents independently selected from alkyl; (91) Unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo and methyl; (92) unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; (93) unsubstituted or substituted with 1 to 3 optional substituents independently selected from fluoro; or (94) Unsubstituted.

[0095] In addition to embodiments (76)-(94) of the preceding paragraph, compounds of Formula 1 may also be R 11 but includes those selected from the following: (95) Hydrogen, Halo and C 1-3 alkyl; (96) Hydrogen and methyl; (97) Methyl; or (98)Hydrogen.

[0096] In addition to embodiments (1) through (50) above, compounds of Formula 1 include those in which: (99)X 12 But, CR 12 R 13 and (a)R 6 but hydrogen, halo and C 1-4 alkyl, R 7 and R 8 together with the carbon and nitrogen atoms to which they are respectively attached, form a ring heteroatom C 3-5 forming a heterocyclyl, R 9 But hydrogen and C 1-4 alkyl, R 10 , R 11 , R 12 and R13 but hydrogen, halo and C 1-4 alkyl; or (b)R 6 and R 7 but hydrogen, halo and C 1-4 alkyl, or R 6 and R 7 together with the carbon atoms to which they are attached, form C 3-5 forming a cycloalkylidene, R 8 and R 9 But together with the nitrogen atom to which they are bonded, they form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 10 , R 11 , R 12 and R 13 but hydrogen, halo and C 1-4 alkyl; or (c)R 6 and R 7 but hydrogen, halo and C 1-4 are each independently selected from alkyl, R 8 But hydrogen and C 1-4 alkyl, R 9 and R 10 together with the nitrogen and carbon atoms to which they are respectively attached, form C 3-5 heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C 1-4 substituted with 1 to 3 optional substituents independently selected from alkyl; R 11 , R 12 and R 13 but hydrogen, halo and C 1-4 each independently selected from alkyl.

[0097] In addition to embodiments (1) through (50) above, compounds of Formula 1 include those in which: (100)X 12 But, CR 12 R 13 and R 6 but hydrogen, halo and C 1-4 alkyl, R 7 and R 8 together with the carbon and nitrogen atoms to which they are respectively attached, form a ring heteroatom C 3-5 forming a heterocyclyl, R 9 But hydrogen and C 1-4 alkyl, R 10 , R 11 , R 12 and R 13 but hydrogen, halo and C 1-4 each independently selected from alkyl.

[0098] In addition to embodiment (100) of the preceding paragraph, the compound of Formula 1 may further comprise R 6 but includes those selected from the following: (101) Hydrogen, Halo and C 1-3 alkyl; (102) Hydrogen, halo and methyl; (103) hydrogen and methyl; or (104) Hydrogen.

[0099] In addition to embodiments (100)-(104) of the preceding paragraph, compounds of Formula 1 may also be R 7 and R 8 together with the carbon and nitrogen atoms to which they are respectively attached, is C 3-5 Including those forming heterocyclyl: (105) Azetidinyl; (106) Azetidin-2-yl; (107) Pyrrolidinyl; (108) Pyrrolidin-3-yl; (109) piperidinyl; or (110) Piperidin-4-yl.

[0100] In addition to embodiments (100)-(110) of the preceding paragraph, compounds of Formula 1 include those in which: (111)R 9 But hydrogen and C 1-3 alkyl, R 10 , R 11 , R 12 and R 13 but hydrogen, halo and C 1-3 alkyl; (112)R 9 is selected from hydrogen and methyl; R 10 , R 11 , R 12 and R 13 but hydrogen, halo and C 1-3 alkyl; (113)R 9 is selected from hydrogen and methyl; R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen, halo, methyl and ethyl.

[0101] In addition to embodiments (100)-(113) of the preceding paragraph, compounds of Formula 1 include those in which: (114)R 10 and R 11 are each independently selected from hydrogen, halo, and methyl; (115)R 10 and R 11 are each independently selected from hydrogen, fluoro and methyl; (116)R 10 and R 11 are each independently selected from hydrogen and methyl; (117)R 10 is methyl and R 11 is hydrogen or (118)R 10 and R 11 are each methyl, or (119)R 10 and R 11 are each hydrogen.

[0102] In addition to embodiments (100)-(119) of the preceding paragraph, compounds of Formula 1 include those in which: (120)R 12 and R 13 are each independently selected from hydrogen, fluoro, methyl and ethyl; (121)R 12 and R 13 are each independently selected from hydrogen, fluoro, methyl and ethyl; (122)R 12 and R 13 are each independently selected from hydrogen and methyl; (123)R 12 is methyl and R 13 is hydrogen or (124)R 12 and R 13 are each methyl, or (125)R 12 and R 13 are each hydrogen.

[0103] In addition to embodiments (1) through (125) of the preceding paragraph, compounds of Formula 1 may also comprise: 14 , including those independently selected from the following: (126) Halo, C 1-3 Alkyl and C 1-3 Alkoxy (where C 1-3 Alkyl and C 1-3 each alkoxy substituent is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; (127) halo, methyl, and methoxy (wherein the methyl and methoxy substituents are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); (128) fluoro, methyl, and methoxy (wherein the methyl and methoxy substituents are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from fluoro); (129) fluoro, methyl and methoxy (wherein the methyl and methoxy substituents are unsubstituted); or (130)Fluoro.

[0104] In addition to embodiments (126)-(130) of the preceding paragraph, compounds of Formula 1 include those where n is selected from: (131)0, 1, 2 and 3; (132) 0, 1, and 2; or (133)0 and 1.

[0105] In addition to embodiments (126)-(133) of the preceding paragraph, compounds of Formula 1 include those in which: (134) n is 1.

[0106] In addition to embodiments (1) through (125) of the preceding paragraph, compounds of Formula 1 include those in which: (135) n is 0.

[0107] Compounds of Formula 1 include embodiments (1) through (135) described in the preceding paragraphs, and compounds specifically named in the examples may exist as salts, complexes, solvates, hydrates, and liquid crystals. Similarly, compounds of Formula 1 that are salts may exist as complexes, solvates, hydrates, and liquid crystals.

[0108] The compounds of Formula 1 can form pharmaceutically acceptable complexes, salts, solvates, and hydrates. These salts include acid addition salts (including diacids) and base salts. Pharmaceutically acceptable acid addition salts include salts derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, hydrofluoric acid, and phosphorous acid, as well as non-toxic salts derived from organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, and aliphatic and aromatic sulfonic acids. Such salts include acetate, adipate, aspartate, benzoate, besylate, bicarbonate, carbonate, bisulfate, sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methyl sulfate, napsylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate, hydrogen phosphate, dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, and xinofoate salts.

[0109] Pharmaceutically acceptable base salts include salts derived from bases containing metal cations such as alkali or alkaline earth metal cations and amines. Examples of suitable metal cations include sodium, potassium, magnesium, calcium, zinc, and aluminum. Examples of suitable amines include arginine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethylamine, diethanolamine, dicyclohexylamine, ethylenediamine, glycine, lysine, N-methylglucamine, olamine, 2-amino-2-hydroxymethyl-propane-1,3-diol, and procaine. For a discussion of useful acid addition salts and base salts, see S.M. Berge et al., J. Pharm. Sci. (1977) 66:1-19; see also Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use (2002).

[0110] Pharmaceutically acceptable salts can be prepared using various methods. For example, a compound of Formula 1 can be reacted with an appropriate acid or base to obtain the desired salt. Alternatively, a precursor of the compound of Formula 1 can be reacted with an acid or base to remove an acid- or base-labile protecting group or to open the lactone or lactam group of the precursor. Furthermore, a salt of the compound of Formula 1 can be converted to another salt (or free form) by treatment with an appropriate acid or base or by contact with an ion exchange resin. After the reaction, if the salt precipitates from solution, it can be isolated by filtration, or the salt can be recovered by evaporation. The degree of ionization of the salt can vary from completely ionized to almost non-ionized.

[0111] Compounds of Formula 1 can exist in a continuum of solid states ranging from completely amorphous to completely crystalline. The term "amorphous" refers to a state of matter that lacks long-range order at the molecular level and can exhibit the physical properties of either a solid or a liquid, depending on temperature. Typically, such materials do not give a distinctive X-ray diffraction pattern and are more formally described as liquids, while exhibiting the properties of a solid. Upon heating, a change in properties from solid to liquid occurs, characterized by a typical second-order change of state ("glass transition"). The term "crystalline" refers to a solid phase in which the material has a regular, ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with distinct peaks. Such materials, when heated sufficiently, also exhibit the properties of a liquid, but the change from solid to liquid is characterized by a phase transition, typically first-order ("melting point").

[0112] The compound of formula 1 can exist in both unsolvated and solvated forms. The term "solvate" describes a molecular complex containing a compound and one or more pharmaceutically acceptable solvent molecules (e.g., ethanol). The term "hydrate" refers to a solvate in which the solvent is water. Pharmaceutically acceptable solvates include those in which the solvent may be isotopically substituted (e.g., DO, acetone-d6, DMSO-d6).

[0113] A currently accepted classification system for solvates and hydrates of organic compounds distinguishes between isolated-site, channel, and metal-ion coordinated solvates and hydrates. See, for example, KR Morris (HGBrittain ed.) Polymorphism in Pharmaceutical Solids (1995). Isolated-site solvates and hydrates are those in which the solvent (e.g., water) molecules are isolated from direct contact with each other by intervening molecules of the organic compound. In channel solvates, the solvent molecules are arranged in lattice channels next to other solvent molecules. In metal-ion coordinated solvates, the solvent molecules are bound to the metal ion.

[0114] When the solvent or water is tightly bound, the complex has a well-defined stoichiometry independent of humidity. On the other hand, when the solvent or water is weakly bound, such as in channel solvates and hygroscopic compounds, the water or solvent content may depend on humidity and drying conditions. In such cases, non-stoichiometry is typically observed.

[0115] The compounds of Formula 1 may also exist as multicomponent complexes (other than salts and solvates) in which the compound (drug) and at least one other component are present in stoichiometric or non-stoichiometric amounts. This type of complex includes clathrates (drug-host inclusion complexes) and cocrystals. The latter is typically defined as a crystalline complex of neutral molecular components bound through non-covalent interactions, but may also be a complex of a neutral molecule and a salt. Cocrystals can be prepared by melt crystallization, recrystallization from a solvent, or physical grinding of the components. See, for example, O. Almarsson and MJ Zaworotko, Chem. Commun. (2004) 17:1889-1896. For a review of multicomponent complexes, see JK Haleblian, J. Pharm. Sci. (1975) 64(8):1269-88.

[0116] When subjected to suitable conditions, compounds of Formula 1 can exist in a mesophase state (mesophase or liquid crystal). The mesophase state is between the true crystalline state and the true liquid state (either melt or molten). Mesophases that result from a change in temperature are described as "thermotropic," while mesophases obtained by adding a second component, such as water or another solvent, are described as "lyotropic." Compounds that can form lyotropic mesophases are described as "amphiphilic," and contain polar ionic moieties (e.g., -COO - Na + , -COO - K + , -SO3 - Na + ) or polar nonionic moiety (-N - N +(CH3)3, etc. See, for example, N.H. Hartshorne and A. Stuart, Crystals and the Polarizing Microscope (4th ed., 1970).

[0117] Each compound of Formula 1 may exist as polymorphs, stereoisomers, tautomers, or some combination thereof; may be isotopically labeled; may result from administration of a prodrug; or may form a metabolite following administration.

[0118] A "prodrug" refers to a compound with little or no pharmacological activity that can be converted into a compound with the desired pharmacological activity upon metabolism in vivo. Prodrugs can be prepared by replacing appropriate functional groups present in a pharmacologically active compound with a "promoiety," as described, for example, in H. Bundgaar, Design of Prodrugs (1985). Examples of prodrugs include ester, ether, or amide derivatives of the compounds of Formula 1, which contain carboxylic acid, hydroxy, or amino functional groups, respectively. For further discussion of prodrugs, see, for example, T. Higuchi and V. Stella, "Prodrugs as Novel Delivery Systems," ACS Symposium Series 14 (1975) and EB Roche ed., Bioreversible Carriers in Drug Design (1987).

[0119] "Metabolites" refer to compounds formed in vivo upon administration of a pharmacologically active compound. Examples include hydroxymethyl, hydroxy, secondary amino, primary amino, phenol, and carboxylic acid derivatives of compounds of Formula 1 that contain methyl, alkoxy, tertiary amino, secondary amino, phenyl, and amide groups, respectively.

[0120] The compounds of Formula 1 may exist as stereoisomers resulting from the presence of one or more stereocenters, one or more double bonds, or both. The stereoisomers may be pure, substantially pure, or a mixture. Such stereoisomers may also occur when the counterion is an optically active acid addition salt or base salt, for example, when the counterion is D-lactate or L-lysine.

[0121] Compounds of Formula 1 may exist as tautomers, which are isomers resulting from tautomerization, including, for example, imine-enamine, keto-enol, oxime-nitroso, and amide-imidic acid tautomerization.

[0122] Compounds of formula 1 may exhibit more than one isomer.

[0123] Geometric (cis / trans) isomers may be separated by conventional techniques such as chromatography and fractional crystallization.

[0124] Conventional techniques for preparing or isolating compounds of a specific stereochemical configuration include chiral synthesis from suitable optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-performance liquid chromatography (HPLC). Alternatively, the racemate (or racemic precursor) can be reacted with a suitable optically active compound, for example, an alcohol, or, if the compound of Formula 1 contains an acidic or basic moiety, with an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture can be separated by chromatography, fractional crystallization, or the like, and the appropriate diastereoisomer can be converted to a compound with the required stereochemical configuration. For a further discussion of techniques for separating stereoisomers, see E.L. Eliel and S.H. Wilen, Stereochemistry of Organic Compounds (1994).

[0125] Compounds of Formula 1 may also have isotopic variations in which at least one atom is replaced with an atom having the same atomic number but an atomic mass different from the atomic mass normally found in nature. Suitable isotopes contained in compounds of Formula 1 include, for example: 2 H and 3 Isotopes of hydrogen such as H; 11 C. 13 C and 14 isotopes of carbon such as C; 13 N and 15 isotopes of nitrogen such as N; 15 O. 17 O and 18 isotopes of oxygen such as O; 35 isotopes of sulfur such as S; 18 isotopes of fluorine, such as F; 36 Isotopes of chlorine, such as Cl, and 123 I and 125 Iodine isotopes such as I. Isotopic variations (e.g., deuterium, 2 The use of H) may offer several therapeutic advantages resulting from increased metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Additionally, certain isotopic variations of the compounds of the present disclosure may be substituted with radioactive isotopes (e.g., tritium, 3 H, or 14 C) can be incorporated and may be useful for drug and / or substrate tissue distribution studies. 11 C. 18 F, 15 O and 13 Substitution with positron-emitting isotopes, such as N, can be useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can be prepared by processes similar to those described elsewhere in this disclosure, employing appropriate isotopically labeled reagents in place of unlabeled reagents.

[0126] Compounds of Formula 1 can be prepared using the techniques described below. Some of the schemes and examples may omit details of common reactions, including oxidations, reductions, and the like, separation techniques (extraction, evaporation, precipitation, chromatography, filtration, trituration, crystallization, and the like), and analytical procedures known to those skilled in the art of organic chemistry. Details of such reactions and techniques can be found in several specialized texts, including Richard Larock's Comprehensive Organic Transformations (1999) and the multivolume series Compendium of Organic Synthetic Methods (1974 et seq.), edited by Michael B. Smith et al. Starting materials and reagents may be obtained from commercial sources or prepared using literature methods. Some of the reaction schemes may omit minor products resulting from chemical transformations (e.g., alcohols from the hydrolysis of esters, CO from the decarboxylation of diacids, and the like). Additionally, in some cases, reaction intermediates may be used in subsequent steps without isolation or purification (i.e., in situ).

[0127] In some of the reaction schemes and examples that follow, certain compounds can be prepared using protecting groups, which can prevent undesired chemical reactions at reactive sites. Protecting groups can also be used to improve solubility or modify the physical properties of a compound. For a discussion of protecting group strategies, a description of materials and methods for installing and removing protecting groups, and a resource for useful protecting groups for common functional groups, including amines, carboxylic acids, alcohols, ketones, aldehydes, and the like, see T.W. Greene and P.G. Wuts, Protecting Groups in Organic Chemistry (1999) and P. Kocienski, Protective Groups (2000).

[0128] Generally, chemical transformations described throughout this specification can be carried out using substantially stoichiometric amounts of reactants, although certain reactions may benefit from using an excess of one or more of the reactants. Furthermore, while many of the reactions disclosed throughout this specification can be carried out at about room temperature (RT) and atmospheric pressure, some reactions may be carried out at elevated pressures or employ elevated temperatures (e.g., reflux conditions) or reduced temperatures (e.g., −78° C. to 0° C.), depending on reaction kinetics, yield, etc. Any reference in this disclosure and claims to a stoichiometric range, temperature range, pH range, etc., includes the endpoints indicated, regardless of whether the word “range” is explicitly used.

[0129] Many chemical transformations may use one or more compatible solvents, which can affect the reaction rate and yield. Depending on the nature of the reactants, the one or more solvents may be polar protic solvents (including water), polar aprotic solvents, nonpolar solvents, or some combination. Representative solvents include saturated aliphatic hydrocarbons (e.g., n-pentane, n-hexane, n-heptane, n-octane, cyclohexane, methylcyclohexane); aromatic hydrocarbons (e.g., benzene, toluene, xylene); halogenated hydrocarbons (e.g., methylene chloride, chloroform, carbon tetrachloride); aliphatic alcohols (e.g., methanol, ethanol, propan-1-ol, propan-2-ol, butan-1-ol, 2-methyl-propan-1-ol, butan-2-ol, 2-methyl-propan-2-ol, pentan-1-ol, 3-methyl-butan-1-ol, hexane-1-ol, 2-methoxy-ethanol, 2-ethoxy-ethanol, 2-butoxy-ethanol, 2-(2-methoxy-ethoxy)-ethanol, 2-(2-ethoxy-ethoxy)-ethanol, 2-(2-but ... ethers (e.g., diethyl ether, diisopropyl ether, dibutyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, 1-methoxy-2-(2-methoxy-ethoxy)-ethane, 1-ethoxy-2-(2-ethoxy-ethoxy)-ethane, tetrahydrofuran, 1,4-dioxane); ketones (e.g., acetone, methyl ethyl ketone); esters (methyl acetate, ethyl acetate); nitrogen-containing solvents (e.g., formamide, N,N-dimethylformamide, acetonitrile, N-methyl-pyrrolidone, pyridine, quinoline, nitrobenzene); sulfur-containing solvents (e.g., carbon disulfides, dimethyl sulfoxide, tetrahydro-thiophene-1,1-dioxide); and phosphorus-containing solvents (e.g., hexamethylphosphoric acid triamide).

[0130] In the following scheme, the substituent identifiers (n, R 1 , R 4 , R 5 、 R 6 , R 7 , R8 , R 9 , R 10 , R 11 , R 14 , X 2 , X 3 and X 12 ) are as defined above for Formula 1. However, as noted above, some of the starting materials and intermediates may contain protecting groups that are removed prior to the final product. In such cases, the substituent identifiers refer to the moiety as defined in Formula 1 and that includes the appropriate protecting group. For example, a starting material or intermediate in the scheme may contain an R 1 group having a potentially reactive amine. 2 In such cases, R 2 may include moieties with or without a group attached to the amine, such as a Boc or Cbz group.

[0131] Schemes A and B show general methods for preparing compounds of Formula 1. According to Scheme A, a heteroaryl halide (A1, Y = Cl, Br, I) is reacted with a primary amine (A2) in the presence of a non-nucleophilic base (e.g., DIPEA, Et3N, CsF, K2CO3, etc.) and a polar aprotic solvent (e.g., dioxane, DMSO, DMF, THF, etc.). N The Ar reaction can be carried out at room temperature or above (e.g., 25-130°C), and the compound of formula 1 is obtained directly or indirectly, for example, after removal of protecting groups, further transformation of functional groups, etc.

[0132] [ka]

[0133] Scheme B is R 4 is methyl and R 5 is hydrogen (Formula 1A) or R 4 and R 5A general method for preparing compounds of Formula 1 where each R is hydrogen (Formula 1B) is shown. According to Scheme B, a heteroaromatic dihalide (B1, Y = Cl, Br, I) is reacted with a primary amine (A2) in the presence of a non-nucleophilic base (e.g., DIPEA, EtN, CsF, KCO, etc.) and a polar aprotic solvent (e.g., dioxane, DMSO, DMF, THF, etc.) to give a heteroaromatic amine (B2). Amine (B2) is converted to a 2-(trimethylsilyl)vinylboronic acid or ester (e.g., 2-(trimethylsilyl)vinylboronic acid) in the presence of a palladium catalyst (e.g., RuPhos Pd G, Pd(dppf)Cl, PdCl(dtbpf), etc.), a base (e.g., KCO, NaCO, KF, EtN, etc.), and one or more polar solvents (e.g., dioxane, DMF, water, etc.). 15 is H or C 1-4 The amine (B2) is then reacted with a benzylboronic acid or ester (B3), which is an alkyl group. A palladium-catalyzed cross-coupling reaction is carried out at elevated temperatures (e.g., 75-110°C) to provide the ethene-1,1-diyl diaryl intermediate (B4). Subsequent reduction of the ethene moiety (e.g., catalytic hydrogenation) provides compound A of Formula 1. Alternatively, amine (B2) can be reacted with a benzylboronic acid or ester (B5) in the presence of a palladium catalyst, a base, and one or more polar solvents to provide compound B of Formula 1.

[0134] The methods shown in the schemes may be modified as desired. For example, protecting groups may be added or removed, and the products may be further modified, for example, by alkylation, acylation, hydrolysis, oxidation, reduction, amidation, sulfonation, alkynation, etc., to obtain the desired final product. Furthermore, any intermediate or final product containing a mixture of stereoisomers can optionally be purified by chiral column chromatography (e.g., supercritical fluid chromatography) as described above, or derivatization with an optically pure reagent to obtain the desired stereoisomer.

[0135] Compounds of Formula 1, including those named above, and their pharmaceutically acceptable complexes, salts, solvates, and hydrates, should be evaluated for biopharmaceutical properties, such as solubility and solution stability over pH, permeability, etc., to select an appropriate dosage form and route of administration. Compounds intended for pharmaceutical use may be administered as crystalline or amorphous products, and may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, evaporative drying, microwave drying, or radio frequency drying.

[0136] [ka]

[0137] The compounds of Formula 1 can be administered alone, in combination with each other, or in combination with one or more pharmacologically active compounds different from the compounds of Formula 1. Generally, one or more of these compounds are administered as a pharmaceutical composition (formulation) together with one or more pharmaceutically acceptable excipients. The choice of excipient depends, among other things, on the mode of administration, the excipient's effect on solubility and stability, and the nature of the dosage form. Pharmaceutical compositions and methods useful for their preparation can be found, for example, in A. R. Gennaro (ed.), Remington: The Science and Practice of Pharmacy (20th ed., 2000).

[0138] The compound of formula 1 can be administered orally. Oral administration involves swallowing, in which case the compound enters the bloodstream through the digestive tract. Alternatively or additionally, oral administration can include mucosal administration (e.g., buccal, sublingual, supragingual), whereby the compound enters the bloodstream through the oral mucosa.

[0139] Formulations suitable for oral administration include solid, semi-solid, and liquid systems such as tablets; soft or hard capsules containing multiparticulates or nanoparticles, liquids, or powders; liquid-filled lozenges; chews; gels; fast-dispersing dosage forms; films; ovules; sprays; and buccal or mucoadhesive patches. Liquid formulations include suspensions, solutions, syrups, and elixirs. Such formulations can be used as fillers in soft or hard capsules (e.g., made from gelatin or hydroxypropylmethylcellulose) and typically contain a carrier (e.g., water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil) and one or more emulsifiers, suspending agents, or both. Liquid formulations can also be prepared by the reconstitution of a solid (e.g., a sachet).

[0140] The compounds of Formula 1 may also be used in fast-dispersing, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents (2001) 11(6):981-986.

[0141] For tablet dosage forms, depending on the dosage, the active pharmaceutical ingredient (API) may comprise from about 1 wt% to about 80 wt% of the dosage form, more typically from about 5 wt% to about 60 wt% of the dosage form. In addition to the API, tablets may contain one or more disintegrants, binders, diluents, surfactants, glidants, lubricants, antioxidants, colorants, flavoring agents, preservatives, and flavoring agents. Examples of disintegrants include sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methylcellulose, microcrystalline cellulose, C 1-6 Included are alkyl-substituted hydroxypropylcellulose, starch, pregelatinized starch, and sodium alginate. Generally, disintegrants may comprise from about 1 wt% to about 25 wt% or from about 5 wt% to about 20 wt% of the dosage form.

[0142] Binders are generally used to impart cohesion to tablet formulations. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose, and hydroxypropyl methylcellulose. Tablets may also contain diluents such as lactose (monohydrate, spray-dried monohydrate, anhydrous), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch, and calcium hydrogen phosphate dihydrate.

[0143] Tablets may also include surfactants such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surfactants may comprise from about 0.2 wt% to about 5 wt% of the tablet, and glidants may comprise from about 0.2 wt% to about 1 wt% of the tablet.

[0144] Tablets may also contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulfate. Lubricants may comprise from about 0.25 wt% to about 10 wt% or from about 0.5 wt% to about 3 wt% of the tablet.

[0145] Tablet blends can be compressed directly or by roller compaction to form tablets. Alternatively, tablet blends or portions of blends can be wet-, dry-, or melt-granulated, melt-congealed, or extruded prior to tableting. If desired, one or more components can be classified by screening or milling, or both, prior to blending. The final dosage form can comprise one or more layers and can be coated or uncoated or encapsulated. An exemplary tablet can contain up to about 80 wt% API, about 10 wt% to about 90 wt% binder, about 0 wt% to about 85 wt% diluent, about 2 wt% to about 10 wt% disintegrant, and about 0.25 wt% to about 10 wt% lubricant. For considerations of blending, granulating, milling, screening, tableting, coating, and descriptions of alternative techniques for preparing drug products, see A.R. Gennaro (ed.), Remington: The Science and Practice of Pharmacy (20th ed., 2000); H.A. Lieberman et al. (ed.), Pharmaceutical Dosage Forms: Tablets, Vol. 1-3 (2nd ed., 1990); and D.K. Parikh & C.K. Parikh, Handbook of Pharmaceutical Granulation Technology, Vol. 81 (1997).

[0146] Consumable oral films for humans or animals are flexible, water-soluble or water-swellable thin-film dosage forms that can be fast-dissolving or mucoadhesive. In addition to the API, typical films contain one or more film-forming polymers, binders, solvents, humectants, plasticizers, stabilizers or emulsifiers, viscosity modifiers, and solvents. Other film ingredients may include antioxidants, colorants, flavors and flavor enhancers, preservatives, salivation stimulants, cooling agents, cosolvents (including oils), emollients, bulking agents, antifoaming agents, surfactants, and flavor masking agents. Some components of the formulation may perform more than one function.

[0147] In addition to dosage requirements, the amount of API in the film can depend on its solubility. If water-soluble, the API can typically comprise about 1 wt% to about 80 wt% of the non-solvent components (solutes) in the film, or about 20 wt% to about 50 wt% of the solutes in the film. Less soluble APIs can comprise a larger proportion of the composition, typically up to about 88 wt% of the non-solvent components in the film.

[0148] The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and may typically comprise from about 0.01 wt% to about 99 wt% or from about 30 wt% to about 80 wt% of the film.

[0149] Film dosage forms are typically prepared by evaporative drying of a thin aqueous film coated onto a peelable backing support or paper, which can be carried out in a drying oven or tunnel (e.g., a combined coating and drying apparatus), a freeze-drying apparatus, or a vacuum oven.

[0150] Solid formulations useful for oral administration may include immediate release formulations and modified release formulations. Modified release formulations include delayed release, sustained release, pulsed release, controlled release, targeted release, and programmed release. For a general description of suitable modified release formulations, see U.S. Patent No. 6,106,864. For details of other useful release technologies, such as high-energy dispersions and osmotic and coated particles, see Verma et al., Pharmaceutical Technology Online (2001) 25(2):1-14.

[0151] The compound of Formula 1 may also be administered directly into the subject's bloodstream, muscle, or internal organs. Suitable techniques for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intravenous, intraurethral, ​​intrasternal, intracranial, intramuscular, intrasynovial, and subcutaneous administration. Suitable devices for parenteral administration include needle injectors, including microneedle injectors, needleless injectors, and infusion devices.

[0152] Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates, and buffers (e.g., pH of about 3 to about 9). However, for some applications, the compounds of Formula 1 may be more conveniently formulated as sterile non-aqueous solutions or as a dry form for use in combination with a suitable vehicle such as sterile, pyrogen-free water. Preparation of parenteral formulations under sterile conditions (e.g., by lyophilization) can be readily accomplished using standard pharmaceutical techniques.

[0153] The solubility of compounds used in the preparation of parenteral solutions can be increased by appropriate formulation techniques, such as the incorporation of solubility-enhancing agents. Formulations for parenteral administration can be formulated for immediate or modified release. Modified release formulations include delayed-release, sustained-release, pulsed-release, controlled-release, targeted-release, and programmed-release. Thus, the compound of Formula 1 may be formulated as a suspension, solid, semisolid, or thixotropic solution for administration as an implanted depot that provides modified release of the active compound. Examples of such formulations include drug-coated stents and semisolids and suspensions containing drug-loaded poly(DL-lactic-co-glycolic) acid (PGLA) microspheres.

[0154] The compounds of Formula 1 can also be administered topically, intradermally, or transdermally to the skin or mucosa. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages, and microemulsions. Liposomes may also be used. Typical carriers may include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol, and propylene glycol. Topical formulations may also include penetration enhancers. See, for example, Finnin and Morgan, J. Pharm. Sci. 88(10):955-958 (1999).

[0155] Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g., Powderject™ and Bioject™) injection. Formulations for topical administration may be formulated to be immediate or modified release, as described above.

[0156] The compounds of Formula 1 can also be administered intranasally or by inhalation, typically in the form of a dry powder, aerosol spray, or nasal drops. Inhalers can be used to administer dry powders, including API alone, powder blends of API with a diluent such as lactose, or mixed-component particles containing API and a phospholipid such as phosphatidylcholine. For intranasal use, the powder can contain a bioadhesive agent, such as chitosan or cyclodextrin. A pressurized container, pump, sprayer, atomizer, or nebulizer can be used to generate an aerosol spray from a solution or suspension containing the API, one or more agents for dispersing, solubilizing, or extending the release of the API (e.g., EtOH with or without water), one or more solvents that function as propellants (e.g., 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane), and an optional surfactant, such as sorbitan trioleate, oleic acid, or oligolactic acid. An electrohydrodynamic atomizer may be used to generate a fine mist.

[0157] Before being used in a dry powder or suspension formulation, the drug product is usually milled to a particle size suitable for delivery by inhalation (typically 90% of the particles, on a volume basis, have a largest dimension of less than 5 microns). This can be achieved by any suitable milling method, such as spiral jet milling, fluidized bed jet milling, supercritical fluid processing, high pressure homogenizers, or spray drying.

[0158] Capsules, blisters, and cartridges (made, for example, from gelatin or hydroxypropylmethylcellulose) for use in an inhaler or insufflator can be formulated containing a powder mix of the active compound, a suitable powder base such as lactose or starch, and a performance modifier such as L-leucine, mannitol, or magnesium stearate. The lactose can be anhydrous or the monohydrate. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.

[0159] Solution formulations suitable for use in atomizers that use electrohydrodynamics to generate a fine mist can contain about 1 μg to about 20 mg of API per actuation, and actuation volumes can vary from about 1 μL to about 100 μL. A typical formulation can include one or more compounds of Formula 1, propylene glycol, sterile water, EtOH, and NaCl. Alternative solvents that can be used in place of propylene glycol include glycerol and polyethylene glycol.

[0160] Formulations for inhaled administration, intranasal administration, or both, may be formulated to be immediate or modified release using, for example, PGLA. Formulations intended for inhaled / intranasal administration may contain suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium.

[0161] For dry powder inhalers and aerosols, the dosage unit is determined by a valve that delivers a metered amount. The unit is typically arranged to administer a metered dose or "puff" containing from about 10 μg to about 1000 μg of API. The overall daily dose typically ranges from about 100 μg to about 10 mg and may be administered as a single dose or, more usually, as divided doses throughout the day.

[0162] Active compound can be administered rectally or vaginally, for example, in the form of suppository, pessary or enema.Cocoa butter is the traditional suppository base, but various alternatives can be used if appropriate.The preparation for rectal or vaginal administration can be formulated as described above into immediate release or modified release form.

[0163] The compounds of Formula 1 may also be administered directly to the eye or ear, typically in the form of droplets of a micronized suspension or solution in pH-adjusted, isotonic, sterile saline. Other formulations suitable for administration to the eye and ear include ointments, gels, biodegradable implants (e.g., absorbent gel sponges, collagen), non-biodegradable implants (e.g., silicone), wafers, lenses, and particulate or vesicular systems such as niosomes or liposomes. The formulation may contain one or more polymers and a preservative, such as benzalkonium chloride. Typical polymers include cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, cellulosic polymers (e.g., hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose), and heteropolysaccharide polymers (e.g., gellan gum). Such formulations may also be delivered by iontophoresis. Formulations for administration to the eye or ear may be formulated for immediate or modified release, as described above.

[0164] To improve solubility, dissolution rate, taste masking, bioavailability, or stability, the compound of Formula 1 may be combined with soluble macromolecular entities, including cyclodextrin and its derivatives and polyethylene glycol-containing polymers. For example, API-cyclodextrin complexes are generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes can be used. Apart from direct complexation with the API, cyclodextrins can also be used as auxiliary additives, i.e., carriers, diluents, or solubilizers. Alpha-, beta-, and gamma-cyclodextrins are commonly used for such purposes. See, for example, WO91 / 11172, WO94 / 02518, and WO98 / 55148.

[0165] As described above, one or more compounds of Formula 1, including the compounds specifically named above, as well as their pharmaceutically active complexes, salts, solvates, and hydrates, may be combined with each other or with one or more other active pharmaceutically active compounds for treating various diseases, conditions, and disorders. In such cases, the active compounds may be formulated into a single dosage form, as described above, or may be provided in the form of a kit suitable for coadministration of the compositions. A kit includes (1) three or more different pharmaceutical compositions (at least one of which contains a compound of Formula 1) and (2) a device for separately holding the two pharmaceutical compositions, such as a divided bottle or divided foil packet. An example of such a kit is the familiar blister pack used to package tablets or capsules. A kit is suitable for administering different types of dosage forms (e.g., oral and parenteral), or for administering different pharmaceutical compositions at separate dosing intervals, or for dosing different pharmaceutical compositions relative to one another. To aid patient compliance, the kit typically includes instructions for administration, and a memory aid may be provided.

[0166] For administration to human patients, the total daily dose of the claimed and disclosed compounds typically ranges from about 0.1 mg to about 3000 mg, depending on the route of administration. For example, oral administration may require a total daily dose of about 1 mg to about 3000 mg, while intravenous administration may require a total daily dose of only about 0.1 mg to about 300 mg. The total daily dose may be administered in single or multiple doses and, at the physician's discretion, may fall outside the typical ranges set forth above. These dosages are based on an average human subject having a mass of about 60 kg to about 70 kg, although a physician can determine appropriate doses for patients (e.g., infants) whose mass falls outside this weight range.

[0167] As described above, the compounds of Formula 1 can be used to treat diseases, disorders, and conditions for which activation of SSTR4 is indicated. Such diseases, disorders, and conditions generally relate to any unhealthy or abnormal condition in a subject for which activation of SSTR4 provides therapeutic benefit. More specifically, the compounds of Formula 1 can be used to treat CNS diseases, disorders, or conditions, including Alzheimer's disease and other forms of dementia (i.e., severe or mild neurocognitive disorders) associated with one or more medical conditions, such as frontotemporal lobar degeneration, Lewy body disease, vascular disease, traumatic brain injury, substance or drug use, HIV infection, prion disease, Parkinson's disease, and Huntington's disease. The compounds of Formula 1 can also be used to treat severe or mild neurocognitive disorders associated with depression, schizophrenia, bipolar disorder, and autism. In addition, the compounds of Formula 1 can be used to treat anxiety and epilepsy.

[0168] The claimed and disclosed compounds may be combined with one or more other pharmacologically active compounds or therapies for treating one or more disorders, diseases, or conditions for which SSTR4 is indicated. Such combinations may provide significant therapeutic benefits, including reduced side effects, improved therapeutic potential for underserved patient populations, or synergistic activity. For example, a compound of Formula 1 may be administered simultaneously, sequentially, or separately with one or more compounds or therapeutic agents for treating Alzheimer's disease, including the compounds specifically named above, as well as pharmaceutically acceptable complexes, salts, solvates, and hydrates thereof, such as beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., Apazone, aspirin, celecoxib, diclofenac (with and without misoprostol), diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, choline and magnesium salicylate, salsalate, and sulindac), vitamin E, and anti-amyloid antibodies. Specific examples of compounds used to treat Alzheimer's disease include donepezil, rivastigmine, memantine, and galantamine.

[0169] In addition to drugs used to enhance cognition, the compounds of Formula 1 can be used in combination with sedatives, hypnotics, anxiolytics, antipsychotics, tranquilizers, and other drugs used to treat Alzheimer's disease. For example, the compounds of Formula 1 can be used in combination with one or more drugs for treating depression (antidepressants) and / or schizophrenia (atypical or typical antipsychotics), such as amitriptyline, amoxapine, aripiprazole, asenapine, bupropion, chlordiazepoxide, citalopram, chlorpromazine, clozapine, desipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, fluphenazine, haloperidol, It may also be combined with iloperidone, imipramine, isocarboxazid, lamotrigine, levomilnacipran, lurasidone, mirtazapine, nefazodone, nortriptyline, olanzapine, paliperidone, paroxetine, perphenazine, phenelzine, protriptyline, quetiapine, risperidone, selegiline, sertraline, tranylcypromine, trazodone, trimipramine, venlafaxine, vilazodone, and vortioxetine, and ziprasidone.

[0170] Similarly, the compounds of Formula 1 may be combined with one or more agents for treating anxiety (antianxiety agents), such as benzodiazepines (alprazolam, chlordiazepoxide, clobazepam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, prazepam, quazepam, temazepam, and triazolam), antihistamines (hydroxyzine), non-benzodiazepines (eszopiclone, zaleplon, zolpidem, and zopiclone), and buspirone.

[0171] The compounds of Formula 1 may also be combined with one or more agents for treating epilepsy (antiepileptic or anticonvulsant drugs), such as acetazolamide, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide.

[0172] biological activity

[0173] The biological activity of the compounds of formula 1 with respect to SSTR4 may be determined using the following in vitro and in vivo methods.

[0174] Inhibition of forskolin-stimulated cAMP in SSTR4-overexpressing cells

[0175] This cell-based assay measures the ability of compounds to inhibit forskolin-stimulated cAMP in CHO-K1 cells overexpressing SSTR4. CHO-K1 cells overexpressing SSTR4 (CHO-SSTR4) were purchased from DiscoveRx (product code 95-0059C2). CHO-SSTR4 cells were maintained in F12K medium containing 10% fetal bovine serum (Hyclone), 1% Pen / Strep (Life Technologies), and 800 μg / mL G418 (Life Technologies). To perform the assay, 3000 cells per well were plated in 50 μL of complete medium in a white 384-well plate (Corning 3570). The cells were allowed to attach for 16 hours in a 37°C, 5% CO2 incubator. The following day, the medium was removed from the cells and the cells were washed with (and then removed from) Krebs Ringer Buffer (ZenBio, KRB-1000mL). Test compounds are suspended in DMSO and diluted in stimulation buffer: Krebs Ringer Buffer + 0.5% BSA (Roche), 300 μM IBMX (Sigma), and 350 nM forskolin (Sigma). Cells are incubated in 10 μL of compound / stimulation buffer at room temperature for 30 minutes. Intracellular cAMP levels are detected using the HTRF LANCE Ultra cAMP kit (Perkin Elmer, catalog number TRF0264).

[0176] The assay is performed according to the manufacturer's instructions. 5 μL of Eu-W8044 labeled streptavidin dilution (1:50 diluted in cAMP detection buffer) is added to each well. Then, 5 μL of biotin cAMP dilution (1:150 diluted in cAMP detection buffer) is added to each well. The plate is covered and incubated for 60 minutes at room temperature on a shaker. HTRF (665 nm / 615 nm) is read on a Perkin Elmer ENVISION plate reader. Activity Base for Screening Data Management is used to analyze pEC 50 Give a value.

[0177] SSTR4I-125 somatostatin competitive binding assay

[0178] This membrane-based assay measures the ability of compounds to competitively inhibit the binding of I-125 labeled somatostatin to SSTR4 in membranes of CHO-K1 cells overexpressing SSTR4. Membranes of CHO-K1 cells overexpressing SSTR4 are purchased from Perkin Elmer (catalog number ES-524-M400UA). Test compounds are suspended in DMSO and then diluted with assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) + 0.2 nM I-125 labeled somatostatin (Perkin Elmer catalog number NEX389). 50 μL of compound / I-125 somatostatin in assay buffer is added to each well of a 96-well polypropylene plate. 1 μg of SSTR4 membranes in 50 μL of assay buffer is then added to each well. The plate is incubated at room temperature for 60 minutes. FilterMat A filters (Perkin Elmer Catalog No. 1450-421) are presoaked in 0.5% PEI (Sigma Catalog No. P3143). The contents of the assay plate are transferred to the filters with a TomTech harvester and washed five times with 20 mM HEPES, 100 mM NaCl. The filters are dried in a microwave oven and then transferred to a sample bag containing a scintillator sheet (Perkin Elmer Catalog No. 1450-441). A heat block is used to dissolve the scintillator sheet into the filter. The filters are then read in a MicroBeta scintillation counter. Binding K curves are generated using Screening Data Management and the results are expressed as pIC 50 Report at.

[0179] SSTR1 I-125 somatostatin competitive binding assay for selectivity against SSTR1

[0180] This membrane-based assay measures the ability of compounds to competitively inhibit the binding of I-125 labeled somatostatin to SSTR1 in membranes of CHO-K1 cells overexpressing SSTR1. Membranes of CHO-K1 cells overexpressing SSTR1 are purchased from Perkin Elmer (catalog number ES-520-M400UA). Test compounds are suspended in DMSO and then diluted with assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) + 0.4 nM I-125 labeled somatostatin (Perkin Elmer catalog number NEX389). 50 μL of compound / I-125 somatostatin in assay buffer is added to each well of a 96-well polypropylene plate. 10 μg of SSTR1 membranes in 50 μL of assay buffer are then added to each well. The plate is incubated at room temperature for 60 minutes. FilterMat A filters (Perkin Elmer Catalog No. 1450-421) are presoaked in 0.5% PEI (Sigma Catalog No. P3143). The contents of the assay plate are transferred to the filters with a TomTech harvester and washed five times with 20 mM HEPES, 100 mM NaCl. The filters are dried in a microwave oven and then transferred to a sample bag containing a scintillator sheet (Perkin Elmer Catalog No. 1450-441). A heat block is used to dissolve the scintillator sheet into the filter. The filters are then read in a MicroBeta scintillation counter. Binding K curves are generated using Screening Data Management and the results are expressed as pIC 50 Report at.

[0181] In vivo screening using subcutaneous pentylenetetrazole (PTZ)

[0182] Six- to eight-week-old Swiss-Webster mice are used in the subcutaneous PTZ seizure model. PTZ is a GABAergic drug that blocks GABA receptors, thereby disinhibiting the CNS system and inducing seizures in animals. Seizures can be assessed and quantified by observation of the test animals. Therefore, this model provides a screening model for testing compounds for their anticonvulsant activity in mice, resulting from their activity at the inhibitory receptor SSTR4. According to this method, six- to eight-week-old Swiss-Webster mice are allowed to acclimate to the testing room (1 h) before the start of the experiment. Animals (n = 6 per group) are then blindly administered vehicle or test compound, followed 15 minutes later by subcutaneous administration of PTZ. Animals are scored based on the time it takes for a seizure to occur, which impairs the ability to stand. This time is scored as the seizure latency. The number and severity of seizures are also scored but are not used in the final data. [Example]

[0183] The following examples are intended to be illustrative and non-limiting and represent specific embodiments of the present invention.

[0184] For many of the compounds in the examples below, 1 H nuclear magnetic resonance (NMR) spectra were obtained. Characteristic chemical shifts (δ) are given in parts per million downfield from tetramethylsilane using conventional abbreviations for major peak names, including s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). The following abbreviations are used for common solvents: CDCl3 (deuterated chloroform), DMSO-d6 (deuterated dimethyl sulfoxide), CD3OD (deuterated methanol), CD3CN (deuterated acetonitrile), and THF-d8 (deuterated tetrahydrofuran). Mass spectra ([M+H] + m / z) for was recorded using either electrospray ionization (ESI-MS) mass spectrometry or atmospheric pressure chemical ionization (APCI-MS) mass spectrometry.

[0185] Where indicated, products of particular preparations and examples are purified by mass-triggered HPLC, flash chromatography, preparative TLC, or SFC. Reverse-phase chromatography is typically performed on columns (e.g., Gemini™ 5 μm C18 110 Å, Axia™, 30 × 75 mm, 5 μm) under acidic conditions ("acid mode"), eluting with mobile phases of ACN and water containing 0.035% and 0.05% trifluoroacetic acid (TFA), respectively, or under basic conditions ("basic mode"), eluting with mobile phases of water and 20 / 80 (v / v) water / acetonitrile, both containing 10 mM NH4HCO3. Preparative TLC is typically performed on silica gel 60 F. 254 The reaction is carried out on a plate. Preparations and examples may employ SFC to separate enantiomers. After chromatographic isolation, the product is obtained by removing the solvent and drying using a centrifugal evaporator (e.g., GeneVac™), a rotary evaporator, an evacuated flask, or the like. Reactions in an inert atmosphere (e.g., nitrogen) or a reactive atmosphere (e.g., H2) are typically carried out at about 1 atmosphere (14.7 psi).

[0186] Preparation 1: Methyl 5,6-dichloropyrazine-2-carboxylate

[0187] [ka]

[0188] Step A: Methyl 5-hydroxypyrazine-2-carboxylate

[0189] [ka]

[0190] To a solution of 5-hydroxypyrazine-2-carboxylic acid (200 g, 1.43 mol) in MeOH (1.5 L) was added SOCl (339.68 g, 2.86 mol, 207.12 mL) dropwise at 0 °C. The mixture was stirred at 70 °C for 16 h and then concentrated under reduced pressure. The resulting residue was triturated with EtOAc (500 mL) and filtered to give the title compound as a black-brown solid (229 g, 98.9% yield, 95% purity). 1 H NMR (400 MHz, CD3OD) δ ppm 3.90 (s, 3 H), 8.04 (s, 1 H), 8.19 (s, 1 H), 8.87 (s, 1 H).

[0191] Step B: Methyl 6-bromo-5-hydroxypyrazine-2-carboxylate

[0192] [ka]

[0193] To a solution of methyl 5-hydroxypyrazine-2-carboxylate (114 g, 739.67 mmol) in DMF (1.1 L) was added NBS (138.23 g, 776.65 mmol) in portions at 0° C. The mixture was stirred at 20° C. for 16 h, then diluted with water (1 L) and extracted with EtOAc (1 L×6). The combined organic layers were washed with brine (500 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give the title compound as a red gum (195 g, containing 36% DMF). 1 H NMR (400 MHz, CD3OD) δ ppm 3.89 (s, 3 H), 8.17 (s, 1 H).

[0194] Step C: Methyl 5,6-dichloropyrazine-2-carboxylate

[0195] To methyl 6-bromo-5-hydroxypyrazine-2-carboxylate (100 g, 429.15 mmol) was added SOCl (445.18 mL, 6.14 mol). The mixture was stirred at 80 °C for 16 h, at which point TLC (petroleum ether / EtOAc = 5 / 1) indicated the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue, which was diluted with EtOAc (1000 mL × 2), followed by the addition of water (500 mL). The combined organic layers were washed with saturated aqueous NaHCO (1000 mL) and then with brine (300 mL). The organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO) using a petroleum ether / EtOAc (100:1 to 10:1) gradient to give the title compound as a pale yellow solid (22.2 g, 24.3% yield, 97% purity). 1 H NMR (400 MHz, CDCl3) δ ppm 4.02 (s, 3 H), 8.98 (s, 1 H);ESI-MS m / z [M+H] + 207.0.

[0196] Preparation 2: (Z)-(2-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)trimethylsilane

[0197] [ka]

[0198] A mixture of CuCl (514.8 mg, 5.20 mmol, 124.35 μL), t-BuONa (2 g, 20.80 mmol), and Xantphos (3.61 g, 6.24 mmol) in THF (50 mL) was stirred at 25° C. for 0.5 h. A solution of 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (15.85 g, 62.40 mmol) in THF (30 mL) was added to the mixture, which was stirred at 25° C. for an additional 0.5 h. To the resulting dark brown solution was added ((4-fluorophenyl)ethynyl)trimethylsilane (10 g, 52.00 mmol) in THF (30 mL), followed by MeOH (4.21 mL). The mixture was stirred at 50°C for an additional 16 hours, then diluted with THF (50 mL) and filtered through a pad of Celite®. The filtrate was concentrated in vacuo, and the solid phase was triturated with petroleum ether (50 mL) for 0.5 hours. The filter cake was discarded. The filtrate was concentrated in vacuo and purified by flash silica gel chromatography using EtOAc / petroleum ether as the eluent. The product-containing fractions were concentrated to give the title compound as a pale yellow solid (10.8 g, 64%). 1 H NMR (400 MHz, CDCl3) δ ppm 0.00 (s, 9 H), 1.38 (s, 12 H), 6.96 (s, 1 H), 7.06 - 7.10 (m, 2 H), 7.20 - 7.24 (m, 2 H).

[0199] Preparation 3: 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylic acid

[0200] [ka]

[0201] Step A: (E)-6-chloro-5-(1-(4-fluorophenyl)-2-(trimethylsilyl)vinyl)pyrazine-2-carboxylate methyl

[0202] [ka]

[0203] To a round-bottom flask containing methyl 5,6-dichloropyrazine-2-carboxylate (1.0 g, 4.83 mmol) and (Z)-(2-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)trimethylsilane (1.62 g, 5.07 mmol) in THF (3 mL) and water (0.5 mL) was added PdCl(dppf).CHCl (394.48 mg, 483.06 μmol) and NaCO (1.02 g, 9.66 mmol). The reaction mixture was stirred under N at 50 °C for 3 h, then diluted with water (50 mL) and extracted with EtOAc (100 mL × 2). The combined organic phase was washed with water (50 mL) and brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a gradient of petroleum ether / EtOAc (1:0 to 9:1) to give the title compound as a yellow solid (1.47 g, 57.1%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.00 (s, 9 H), 3.93 (s, 3 H), 6.41 (s, 1 H), 7.20 - 7.31 (m, 4 H), 9.15 (s, 1 H);ESI-MS m / z [M+H] + 364.8.

[0204] Step B: Methyl 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylate

[0205] [ka]

[0206] A mixture of (E)-methyl 6-chloro-5-(1-(4-fluorophenyl)-2-(trimethylsilyl)vinyl)pyrazine-2-carboxylate (650 mg, 1.78 mmol, 1.0 equiv) in TFA (7 mL) was stirred at 50° C. for 20 hours and then concentrated under reduced pressure. The resulting residue was dissolved in EtOAc (30 mL), and saturated aqueous NaCO was added to adjust the mixture to pH 8. The organic layer was separated, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a gradient of petroleum ether / EtOAc (1:0 to 8:1) to give the title compound (440 mg, 82.7%) as a pale yellow solid. 1 ESI-MS m / z [M+H] + 293.1.

[0207] Step C: 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylic acid

[0208] A solution of LiOH.HO (118.01 mg, 2.81 mmol) in water (1.25 mL) was added to a solution of methyl 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylate (420 mg, 1.41 mmol) in THF (5 mL). The mixture was stirred at 30° C. for 1 hour, then acidified to pH 3 by adding 1.0 N HCl and extracted with EtOAc (60 mL×2). The organic layer was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give the title compound as a white solid (370 mg, 94.4%). 1H NMR (400 MHz, DMSO-d6) δ ppm 5.65 (s, 1 H), 6.17 (s, 1 H), 7.07 - 7.26 (m, 2 H), 7.30 - 7.43 (m, 2 H), 9.20 (s, 1 H), 13.63 - 14.42 (m, 1 H);ESI-MS m / z [M+H] + 279.1.

[0209] Preparation 4: 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylic acid

[0210] [ka]

[0211] Step A: (R)-6-chloro-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylate methyl

[0212] [ka]

[0213] To a solution of methyl 5,6-dichloropyrazine-2-carboxylate (1 g, 4.83 mmol) in dioxane (48.3 mL) was added DIPEA (1.266 mL, 7.25 mmol) and (R)-1-methylpyrrolidin-3-amine (0.629 g, 6.28 mmol). The solution was stirred at room temperature for 16 hours and then purified by silica gel column chromatography (ISCO® NH column) to give the title compound as a yellow solid (570 mg, 43.6%).

[0214] Step B: (R)-6-(1-(4-fluorophenyl)vinyl)-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylate methyl

[0215] [ka]

[0216] A mixture of (R)-6-chloro-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-methyl carboxylate (370 mg, 1.367 mmol), 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (576 mg, 2.323 mmol), Pd(dppf)Cl (100 mg, 0.137 mmol), and NaCO (1367 μL, 2.73 mmol) in dioxane (6834 μL) was degassed with N for 5 minutes and then heated in a sealed tube at 110 °C for 16 hours. After the reaction, the mixture was purified by silica gel column chromatography (ISCO® NH column) to give the title compound as a brown oil (170 mg, 34.9%).

[0217] Step C: Methyl 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylate

[0218] [ka]

[0219] A mixture of (R)-methyl 6-(1-(4-fluorophenyl)vinyl)-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylate (170 mg, 0.477 mmol) and palladium on carbon (15.23 mg, 0.143 mmol, 10%) in EtOAc (4.8 mL) was stirred under H at room temperature for 5 hours. After the reaction, the mixture was filtered and concentrated to give the title compound as a yellow oil, which was used without further purification.

[0220] Step D: 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylic acid

[0221] To a solution of methyl 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylate (171 mg, 0.477 mmol) in dioxane (3.2 mL) and MeOH (1590 μL) was added a solution of KOH (716 μL, 1.431 mmol). The mixture was stirred at room temperature overnight and then adjusted to pH 5 by the addition of 1.0 M HCl. The solvent was removed to give the title compound as a pale yellow solid (280 mg, 99%).

[0222] Preparation 5: 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0223] [ka]

[0224] Step A: Methyl 6-chloro-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0225] [ka]

[0226] To a mixture of methyl 5,6-dichloropyrazine-2-carboxylate (57 g, 275.34 mmol) in dioxane (1.3 L), DIPEA (72 mL, 53.42 g, 413.36 mmol) and 2-pyrrolidin-1-ylethanamine (32.38 g, 283.60 mmol) in dioxane (130 mL) was added dropwise at 25 °C. The mixture was stirred at 25 °C for 72 h and then concentrated to dryness. The product was triturated with petroleum ether / EtOAc (3:1, 500 mL) at 25 °C for 10 min. The resulting solid was filtered, dissolved in EtOAc (1000 mL), and washed with saturated aqueous NaHCO (500 mL). The aqueous layer was extracted with EtOAc (1000 mL × 2). The combined organic phase was washed with brine (500 mL x 2), dried over Na2SO4 and concentrated to give the title compound as a brown oil (71 g, 88%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.82 (dt, J=6.9, 3.3 Hz, 4 H), 2.55 - 2.61 (m, 4 H), 2.77 (t, J=6.1 Hz, 2 H), 3.55 - 3.64 (m, 2 H), 3.95 (s, 3 H), 6.52 (br s, 1 H), 8.73 (s, 1 H);ESI-MS m / z [M+H] + 285.1.

[0227] Step B: Methyl 6-(1-(4-fluorophenyl)vinyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0228] [ka]

[0229] To a stirred mixture of methyl 6-chloro-5-(2-pyrrolidin-1-ylethylamino)pyrazine-2-carboxylate (50 g, 175.60 mmol) in dioxane (1500 mL) and water (230 mL) was added 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (52.28 g, 210.72 mmol), PdCl(dppf).CHCl (11.47 g, 14.05 mmol), and EtN (195.53 mL, 1.40 mol). The mixture was degassed and purged with N (3×), then stirred under N at 110 °C for 16 h. The reaction mixture was purified by silica gel column chromatography using a gradient of petroleum ether / EtOAc (10:1 to 0:1) and then triturated with petroleum ether / EtOAc (3:1, 80 mL) at 25° C. for 10 min to give the title compound as a pale yellow solid (36 g, 55%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.63 (br s, 4 H), 2.30 (br s, 4 H), 2.50 (br t, J=5.7 Hz, 2 H), 3.30 - 3.46 (m, 2 H), 3.93 (s, 3 H), 5.67 (s, 2 H), 5.85 (s, 1 H), 7.00 (br t, J=8.5 Hz, 2 H), 7.19 - 7.37 (m, 2 H), 8.80 (s, 1 H);ESI-MS m / z [M+H] + 371.2.

[0230] Step C: Methyl 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0231] [ka]

[0232] To a round-bottom flask containing methyl 6-(1-(4-fluorophenyl)vinyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (12 g, 32.40 mmol) in MeOH (100 mL) was added Pd / C (2 g, 10%, wet basis). The suspension was degassed under vacuum and purged several times with H. The mixture was stirred under H (15 psi) at 25° C. for 16 h, then diluted with MeOH (100 mL) and filtered through a pad of Celite®. The filtrate was concentrated in vacuo to give the title compound as a red gum (12 g, 92.5%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.70 (br d, J=6.8 Hz, 4 H), 1.76 (br s, 3 H), 2.32 - 2.55 (m, 4 H), 2.61 - 2.74 (m, 1 H), 3.29 - 3.48 (m, 2 H), 3.50 (s, 1 H), 3.96 (s, 3 H), 4.10 (q, J=7.0 Hz, 1 H), 5.79 (br s, 1 H), 6.90 - 7.03 (m, 2 H), 7.13 - 7.23 (m, 2 H), 8.72 (s, 1 H);ESI-MS m / z [M+H] + 373.2.

[0233] Step D: 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0234] To a solution of methyl 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (5.3 g, 14.23 mmol) in THF (50 mL) was added a solution of LiOH.HO (895.68 mg, 21.35 mmol) in water (10 mL). The mixture was stirred at 25° C. for 16 h and then washed with MTBE (20×3 mL). The aqueous phase was acidified to pH 5 by adding 1 M HCl and then extracted with EtOAc (100 mL×3). The combined organic layers were concentrated in vacuo to give the title compound as a pale yellow solid (3 g, 56%).1 H NMR (400 MHz, CD3OD) δ ppm 1.68 (dd, J=6.7, 2.1 Hz, 3 H), 2.01 (br d, J=2.3 Hz, 4 H), 3.21 (br s, 2 H), 3.33 - 3.46 (m, 4 H), 3.80 (br s, 2 H), 4.31 (br d, J=7.3 Hz, 1 H), 6.94 - 7.05 (m, 2 H), 7.33 (br t, J=6.0 Hz, 2 H), 8.66 (s, 1 H);ESI-MS m / z [M+H] + 359.2.

[0235] Preparation 6: (S)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate methyl

[0236] [ka]

[0237] Preparation 7: (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate methyl

[0238] [ka]

[0239] and

[0240] Methyl 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (7.3 g, 19.60 μmol) was separated into two enantiomers by SFC (Chiralpak® IC-H, 5 μm, 30 mm ID×250 mm) using HO (0.1% NH) / MeOH (55:45). The faster-eluting enantiomer was assigned the S-stereochemical configuration and was isolated as a red gum (3 g, 46.2%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.71 (d, J=7.1 Hz, 3 H), 1.75 (dt, J=6.4, 3.1 Hz, 4 H), 2.30 - 2.37 (m, 2 H), 2.38 - 2.51 (m, 3 H), 2.64 (ddd, J=12.2, 7.7, 4.9 Hz, 1 H), 3.28 - 3.47 (m, 2 H), 3.73 (q, J=7.1 Hz, 1 H), 3.96 (s, 3 H), 5.73 (br s, 1 H), 6.93 - 7.02 (m, 2 H), 7.15 - 7.21 (m, 2 H), 8.72 (s, 1 H); ESI-MS m / z [M+H] + 373.1. The later eluting enantiomer was assigned the R-stereochemical configuration and was isolated as a red gum (3.5 g, 53.8%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.71 (d, J=7.1 Hz, 3 H), 1.76 (dt, J=6.3, 3.1 Hz, 4 H), 2.32 - 2.39 (m, 2 H), 2.40 - 2.52 (m, 3 H), 2.66 (ddd, J=12.1, 7.6, 4.6 Hz, 1 H), 3.29 - 3.48 (m, 2 H), 3.73 (q, J=6.9 Hz, 1 H), 3.96 (s, 3 H), 5.76 (br s, 1 H), 6.93 - 7.00 (m, 2 H), 7.15 - 7.22 (m, 2 H), 8.72 (s, 1 H); ESI-MS m / z [M+H] + 373.1.

[0241] Preparation 8: (S)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0242] [ka]

[0243] To a solution of (S)-methyl 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (0.2 g, 537.01 μmol) in THF (2 mL) was added a solution of LiOH.HO (45.07 mg, 1.07 mmol) in water (0.5 mL). The mixture was stirred at 25 °C for 16 h and then washed with MTBE (3 mL × 3). The aqueous phase was acidified to pH 6-7 using 1.0 N HCl and then concentrated under reduced pressure to give the title compound as a pale yellow gum (220 mg, containing 10% LiCl). 1 H NMR (400 MHz, CD3OD) δ ppm 1.67 (br d, J=6.0 Hz, 3 H), 1.92 - 2.00 (m, 6 H), 3.21 (br s, 4 H), 3.75 (t, J=5.4 Hz, 2 H), 4.29 (br d, J=6.4 Hz, 1 H), 6.96 (t, J=8.7 Hz, 2 H), 7.34 (br dd, J=8.3, 5.6 Hz, 2 H), 8.59 (s, 1 H).

[0244] Preparation 9: (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0245] [ka]

[0246] To a solution of (R)-methyl 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (2.9 g, 7.79 mmol) in THF (30 mL) and water (6 mL) was added LiOH.HO (653.51 mg, 15.57 mmol) at 25° C. The reaction mixture was stirred at 25° C. for 16 hours, then diluted with water (20 mL) and washed with EtOAc (10 mL×2). The aqueous layer was acidified to pH 6 by adding 1.0 N HCl, and the formed precipitate was collected by filtration. The filter cake was washed with water (4 mL×2), toluene, and EtOAc and dried in vacuo to give the title compound as a pale yellow solid (1.55 g, 55.5%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.65 (d, J=7.1 Hz, 3 H), 1.96 - 2.01 (m, 4 H), 3.18 - 3.29 (m, 4 H), 3.31 - 3.38 (m, 2 H), 3.74 (t, J=5.7 Hz, 2 H), 4.23 (q, J=7.1 Hz, 1 H), 6.94 (t, J=8.8 Hz, 2 H), 7.25 - 7.40 (m, 2 H), 8.56 (s, 1 H);ESI-MS m / z [M+H] + 359.2.

[0247] Preparation 10: 6-(4-Fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0248] [ka]

[0249] Step A: Methyl 6-chloro-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0250] [ka]

[0251] To a solution of methyl 5,6-dichloro-3-methylpyrazine-2-carboxylate (1.0 g, 4.52 mmol) in dioxane (30.2 mL) was added DIPEA (1.185 mL, 6.79 mmol) and 2-(pyrrolidin-1-yl)ethanamine (0.672 g, 5.88 mmol). The solution was stirred at room temperature for 16 hours and then purified by silica gel chromatography (NH column) to give the title compound as a yellow solid (1 g, 74%). ESI-MS m / z [M+H] + 299.1.

[0252] Step B: Methyl 6-(4-fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0253] [ka]

[0254] A mixture of methyl 6-chloro-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (300 mg, 1.004 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (427 mg, 1.807 mmol), NaCO (1004 μL, 2.008 mmol), and PdCl(dppf) (73.5 mg, 0.100 mmol) in dioxane (5.0 mL) was degassed with N for 5 min and then heated at 110 °C for 16 h. The mixture was purified by silica gel chromatography (NH column) using a gradient of 10-50% EtOAc / heptane to give the title compound as a yellow solid (210 mg, 56.2%). ESI-MS m / z [M+H] + 373.2.

[0255] Step C: 6-(4-Fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0256] To a solution of methyl 6-(4-fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (210 mg, 0.564 mmol) in dioxane (3.6 mL) and MeOH (1.9 mL) was added an aqueous solution of 2.0 N KOH (564 μL, 1.128 mmol). The reaction mixture was stirred at room temperature overnight, and then 1.0 M HCl was added to adjust the pH to 7. After removal of the solvent, water (10 mL) was added, and the aqueous solution was washed with EtOAc (10 mL×2). The aqueous solution was dried to give the title compound in a mixture with NaCl as a yellow solid (205 mg, 80% pure). The product was used without further purification. ESI-MS m / z [M+H] + 359.2.

[0257] Preparation 11: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0258] [ka]

[0259] Step A: Methyl 6-(1-(4-fluorophenyl)vinyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0260] [ka]

[0261] A mixture of methyl 6-chloro-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (120 mg, 0.402 mmol), 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (179 mg, 0.723 mmol), NaCO (446 μL, 0.803 mmol), and PdCl(dppf) (29.4 mg, 0.040 mmol) in dioxane (2.0 mL) was degassed with N for 5 min and then heated at 110 °C for 16 h. The reaction mixture was purified by silica gel chromatography (NH column) using a gradient of 10–50% EtOAc / heptane to give the title compound as a pale yellow oil (112 mg, 72.5%).

[0262] Step B: Methyl 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0263] [ka]

[0264] A mixture of methyl 6-(1-(4-fluorophenyl)vinyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (112 mg, 0.291 mmol) and dry 10% Pd / C (11 mg) in EtOAc (2.9 mL) was stirred under H at room temperature overnight. The solvent was removed in vacuo to give the title compound as a pale yellow solid, which was used without further purification. ESI-MS m / z [M+H] + 387.1.

[0265] Step C: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0266] To a solution of methyl 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (108 mg, 0.279 mmol) in dioxane (1.9 mL) and MeOH (0.9 mL) was added an aqueous solution of 2.0 N KOH (279 μL, 0.559 mmol). The reaction mixture was stirred overnight at room temperature and then adjusted to pH 7 by the addition of 1.0 N HCl. The solvent was removed to give the title compound (125 mg, 100%) in a mixture with NaCl (17%), which was used without further purification. ESI-MS m / z [M+H] + 373.2.

[0267] Preparation 12: 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane

[0268] [ka]

[0269] A mixture of 1-(chloromethyl)-3-methyl-benzene (6.00 g, 42.7 mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8.19 g, 64.0 mmol), DIPEA (22.35 mL, 128.0 mmol), and Pd(PPh)Cl (1.50 g, 2.13 mmol) in DCE (200 mL) was stirred at 80 °C under N for 48 h and then concentrated under reduced pressure. The resulting residue was dissolved in EtOAc (100 mL), washed with saturated aqueous NaCl (20 mL × 3), dried over NaSO, filtered, and concentrated under reduced pressure. The crude residue was purified by flash silica column chromatography using a gradient of petroleum ether / EtOAc (1000:1 to 30:1) to give the title compound (4.50 g, 45%) as a pale yellow oil. 1 H NMR (400 MHz, CDCl3) δ ppm 1.25 (s, 12 H), 2.27 (s, 2 H), 2.31 (s, 3 H), 6.91 - 7.04 (m, 3 H), 7.09 - 7.17 (m, 1 H).

[0270] Preparation 13: 3-Methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0271] [ka]

[0272] Step A: Methyl 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0273] [ka]

[0274] A mixture of methyl 6-chloro-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (260 mg, 0.870 mmol), 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (364 mg, 1.566 mmol), NaCO (967 μL, 1.740 mmol), and PdCl(dppf) (63.7 mg, 0.087 mmol) in dioxane (4.35 mL) was degassed with N for 5 min and then heated at 110 °C for 16 h. The reaction mixture was purified by silica gel chromatography (NH column) using a gradient of 10-50% EtOAc / heptane to give the title compound as a yellow solid (168 mg, 52.4%). ESI-MS m / z [M+H] + 369.1.

[0275] Step B: 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0276] To a solution of methyl 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (168 mg, 0.456 mmol) in dioxane (3.0 mL) and MeOH (1.5 mL) was added a solution of KOH (456 μL, 0.912 mmol). The reaction mixture was stirred overnight at room temperature and then adjusted to pH 7 by the addition of 1.0 N HCl. The organic solvent was removed and the aqueous phase was concentrated in vacuo to give the title compound as a yellow solid containing the NaCl salt (calculated to be approximately 70% pure). This product was used without further purification. ESI-MS m / z [M+H] + 355.1.

[0277] Preparation 14: 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylic acid

[0278] [ka]

[0279] Step A: Methyl 5-((trans-1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)-6-chloro-3-methylpyrazine-2-carboxylate

[0280] [ka]

[0281] To a solution of methyl 5,6-dichloro-3-methylpyrazine-2-carboxylate (105 mg, 0.474 mmol) in dioxane (4.74 mL) was added DIPEA (132 μL, 0.758 mmol) and tert-butyl (3R,4R)-4-amino-3-methylpiperidine-1-carboxylate (132 mg, 0.616 mmol). The solution was stirred at room temperature for 16 hours and then purified by silica gel chromatography (NH column) to give the title compound as a yellow solid (128 mg, 67.7%). ESI-MS m / z [M-55] + 343.00.

[0282] Step B: Methyl 5-((trans-1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylate

[0283] [ka]

[0284] A mixture of methyl 5-((trans-1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)-6-chloro-3-methylpyrazine-2-carboxylate (78 mg, 0.196 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (92 mg, 0.391 mmol), NaCO (196 μL, 0.391 mmol), and PdCl(dppf) (14.31 mg, 0.020 mmol) in dioxane (2.0 mL) was degassed with N for 5 minutes and then heated at 110 °C for 16 hours. The mixture was purified by silica gel chromatography (NH column) using a gradient of 10–50% EtOAc / heptane to give the title compound as a colorless oil (67 mg, 72.5%). ESI-MS m / z [M+H] + 473.10.

[0285] Step C: Methyl 6-(4-fluorobenzyl)-3-methyl-5-((trans-3-methylpiperidin-4-yl)amino)pyrazine-2-carboxylate

[0286] [ka]

[0287] To a solution of methyl 5-((trans-1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylate (67 mg, 0.142 mmol) in DCM (3.0 mL) was added TFA (1.5 mL). The solution was stirred at room temperature for 1 hour, and then the solvent was removed to give the TFA salt of the title compound as a sticky oil (69 mg, 100%), which was used without further purification.

[0288] Step D: Methyl 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylate

[0289] [ka]

[0290] A mixture of methyl 6-(4-fluorobenzyl)-3-methyl-5-((trans-3-methylpiperidin-4-yl)amino)pyrazine-2-carboxylate TFA salt (69 mg, 0.142 mmol), DIPEA (37.2 μL, 0.213 mmol), paraformaldehyde (12.78 mg, 0.426 mmol), and sodium triacetoxyborohydride (135 mg, 0.638 mmol) in DCM (1.4 mL) was stirred at room temperature for 2 days. LC / MS showed the reaction was complete. Ethyl acetate (10 mL) was added, followed by saturated aqueous NaHCO solution (8 mL). The resulting mixture was stirred vigorously for 2 hours. The organic layer was separated, washed with brine, dried over anhydrous NaSO, and concentrated in vacuo to give the title compound (49 mg, 89%) as a pale yellow oil, which was used without further purification. ESI-MS m / z [M+H] + 387.15.

[0291] Step E: 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylic acid

[0292] A mixture of methyl 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylate (49 mg, 0.127 mmol) and 2.0 N KOH (190 μL, 0.380 mmol) in MeOH (282 μL) and dioxane (564 μL) was stirred at room temperature for 24 h and then quenched by the addition of 1.0 N HCl (0.38 mL). The solvent was removed in vacuo to give the title compound in admixture with KCl (70 mg, calculated 60% purity). ESI-MS m / z [M+H] + 373.10.

[0293] Preparation 15: 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0294] [ka]

[0295] Step A: Methyl 6-chloro-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0296] [ka]

[0297] To a solution of methyl 5,6-dichloro-3-(methoxymethyl)pyrazine-2-carboxylate (100 mg, 0.398 mmol) and DIPEA (104 μL, 0.597 mmol) in dioxane (1992 μL) was added 2-(pyrrolidin-1-yl)ethan-1-amine (54.6 mg, 0.478 mmol, 1.2 equiv.). The solution was stirred at room temperature for 3 days and then purified by silica gel column chromatography (NH column) using a gradient of 10-80% EtOAc / heptane to give the title compound as a yellow oil (95 mg, 72.5%). ESI-MS m / z [M+H] + 329.05.

[0298] Step B: Methyl 6-(1-(4-fluorophenyl)vinyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0299] [ka]

[0300] A mixture of methyl 6-chloro-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (95 mg, 0.289 mmol), 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (129 mg, 0.520 mmol), Pd(dppf)Cl.CHCl (21.14 mg, 0.029 mmol), and NaCO (321 μL, 0.578 mmol) in dioxane (1.5 mL) was degassed with N and then heated in a sealed tube at 110 °C for 16 h. After the reaction, the mixture was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10 to 50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound as a yellow solid (74 mg, 48.5%).

[0301] Step C: Methyl 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate

[0302] [ka]

[0303] A mixture of methyl 6-(1-(4-fluorophenyl)vinyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate TFA salt (74 mg, 0.140 mmol), 10% Pd / C (10 mg), and DIPEA (36.7 μL, 0.210 mmol) in MeOH (1.4 mL) was stirred under a H atmosphere (balloon) at room temperature for 6 hours. After the reaction, the mixture was filtered, and the filtrate was concentrated in vacuo to give the title compound as a pale yellow oil (59 mg). ESI-MS m / z [M+H] + 417.1

[0304] Step D: 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0305] To a solution of methyl 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate (59 mg, 0.142 mmol) in dioxane (0.95 mL) and MeOH (0.47 mL) was added 2 M KOH (0.14 mL, 0.283 mmol). The solution was stirred at room temperature for 16 h. The reaction was quenched with HCl (0.35 mL), and the mixture was concentrated under reduced pressure to provide the title compound as a mixture with KCl (57% purity). This product was used without further purification.

[0306] Preparation 16: 3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-ol

[0307] [ka]

[0308] Step A: tert-butyl (1-((4-chloro-3-oxobutan-2-yl)amino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)carbamate

[0309] [ka]

[0310] A solution of 2-((tert-butoxycarbonyl)amino)-3-(4-fluorophenyl)propanoic acid (0.702 g, 2.48 mmol) and EtN (0.377 mL, 2.70 mmol) in THF (22.5 mL) was cooled to 0 °C. Isobutyl chloroformate (0.324 mL, 2.48 mmol) was added, and the mixture was stirred for 25 min. A solution of 3-amino-1-chlorobutan-2-one hydrochloride (0.356 g, 2.25 mmol) treated with EtN (0.377 mL, 2.70 mmol) in DMF (22.5 mL) was added, and the reaction mixture was stirred for 3 h while slowly warming to room temperature. The reaction mixture was partially concentrated under reduced pressure and then poured into EtOAc. The organic phase was washed with water, dried over NaSO, filtered, and concentrated under reduced pressure. The resulting residue was purified by automated flash silica column chromatography using a gradient of 0-50% EtOAc / heptane. Evaporation of product-containing fractions afforded the title compound as a white solid (363.8 mg, 42%). ESI-MS m / z [M+H] + 387.3.

[0311] Step B: 2-amino-N-(4-chloro-3-oxobutan-2-yl)-3-(4-fluorophenyl)propanamide

[0312] [ka]

[0313] To a solution of tert-butyl (1-((4-chloro-3-oxobutan-2-yl)amino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)carbamate (363.8 mg, 0.940 mmol) in dioxane (940 μL) was added dropwise HCl (4 M in dioxane, 2.35 mL, 9.40 mmol). The reaction mixture was stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure. Diethyl ether was added and removed under reduced pressure to give the HCl salt of the title compound (304 mg, estimated quantitative yield), which was used without further purification. ESI-MS m / z [M+H] + 287.1.

[0314] Step C: 3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-ol

[0315] A solution of 2-amino-N-(4-chloro-3-oxobutan-2-yl)-3-(4-fluorophenyl)propanamide hydrochloride (304 mg, 0.940 mmol) was taken up in MeOH (9.40 mL) and stirred at 65° C. for 2 hours. The reaction mixture was concentrated under reduced pressure. The resulting residue was extracted with CHCl, washed with water, dried over NaSO, filtered, and concentrated under reduced pressure to give the title compound as an off-white solid (176.3 mg, 81%). ESI-MS m / z [M+H] + 233.1.

[0316] Preparation 17: 3-chloro-5,6-dimethyl-N-(1-methylpiperidin-4-yl)pyrazin-2-amine

[0317] [ka]

[0318] A solution of 2,3-dichloro-5,6-dimethylpyrazine (250 mg, 1.412 mmol), 1-methylpiperidin-4-amine (242 mg, 2.118 mmol), and DIPEA (740 μL, 4.24 mmol) in dioxane (2.8 mL) was heated at 130° C. for 16 hours. The mixture was purified by silica gel column chromatography (NH column) to give the title compound as a colorless oil (60 mg, 17%). ESI-MS m / z [M+H] + 255.1.

[0319] Preparation 18: 3-chloro-5,6-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0320] [ka]

[0321] The title compound was prepared similarly to Preparation 17 using 2,3-dichloro-5,6-dimethylpyrazine (150 mg, 0.847 mmol) and 2-(pyrrolidin-1-yl)ethanamine (145 mg, 1.271 mmol) and isolated as a pale yellow oil (99 mg, 45.9%). ESI-MS m / z [M+H] + 255.15.

[0322] Preparation 19: (R)-3-chloro-5,6-dimethyl-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine

[0323] [ka]

[0324] The title compound was prepared similarly to Preparation 17 using 2,3-dichloro-5,6-dimethylpyrazine (250 mg, 1.412 mmol) and (R)-1-methylpyrrolidin-3-amine (212 mg, 2.12 mmol) and isolated as a colorless oil (40 mg, 12%). ESI-MS m / z [M+H] + 241.1.

[0325] Preparation 20: 6-Isopropyl-3-(3-methylbenzyl)pyrazin-2(1H)-one

[0326] [ka]

[0327] Step A: tert-Butyl (1-(methoxy(methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate

[0328] [ka]

[0329] To a solution of 2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid) (1 g, 4.60 mmol) and N,O-dimethylhydroxylamine hydrochloride (0.47 g, 4.86 mmol) in DCM (20 mL) at 0 °C was added a solution of DMAP (0.843, 6.90 mmol) and DCC (1 g, 5.06 mmol) in DCM (50 mL). The reaction mixture was stirred overnight at room temperature. The insoluble urea by-product was filtered off, and the filtrate was washed with 5% sodium hydrogen sulfate solution (100 mL × 3). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to give the title compound as a white solid (1.19 g, 99.9%). ESI-MS [M+H] + 261.2.

[0330] Step B: 2-Amino-N-methoxy-N,3-dimethylbutanamide

[0331] [ka]

[0332] To a 100 mL round-bottom flask containing tert-butyl (1-(methoxy(methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (1.19 g, 4.57 mmol) was added a 4.0 M solution of HCl in dioxane. The reaction mixture was stirred overnight, concentrated, and diluted with EtOAc. The organic layer was washed with saturated brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash silica gel column chromatography using a gradient of 0-100% EtOAc / heptane to afford the title compound as an off-white solid (460 mg g, 63%). ESI-MS [M+H] + 161.3.

[0333] Step C: tert-Butyl (1-((1-(methoxy(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-1-oxo-3-(m-tolyl)propan-2-yl)carbamate

[0334] [ka]

[0335] To a round-bottom flask containing 2-((tert-butoxycarbonyl)amino)-3-(m-tolyl)propanoic acid (0.80 g, 2.87 mmol) in THF (5 mL) at 0 °C, EtN (0.63 g, 6.32 mmol) was added, followed by isobutyl chloroformate (0.431 g, 3.16 mmol). The reaction mixture was stirred for 30 minutes. Next, 2-amino-N-methoxy-N,3-dimethylbutanamide (460 mg, 2.87 mmol) was added, and the reaction mixture was stirred at room temperature overnight. After the reaction, the mixture was diluted with EtOAc, washed with saturated brine, dried over NaSO, filtered, and concentrated to an oil. The crude product was purified by flash silica gel column chromatography using a gradient of 0 to 100% EtOAc / heptane to give the title compound as a clear oil (1.21 g, quantitative yield). ESI-MS [M+H] + 422.4.

[0336] Step D: tert-Butyl (1-((3-methyl-1-oxobutan-2-yl)amino)-1-oxo-3-(m-tolyl)propan-2-yl)carbamate

[0337] [ka]

[0338] To tert-butyl (1-((1-(methoxy(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-1-oxo-3-(m-tolyl)propan-2-yl)carbamate (1.22 g, 2.89 mmol) in THF (6 mL) at 0 °C was added a 2.0 N solution of LiAlH (4.34 mL, 8.68 mmol). Upon completion (approximately 1 h), the reaction was quenched by the dropwise addition of EtOAc (20 mL). After stirring for approximately 15 min, water (15 mL) was added to the reaction mixture and stirring was continued for an additional 30 min. The organic layer was separated and the aqueous layer was extracted with EtOAc (20 mL × 3). The combined organic extracts were dried over NaSO, filtered, and concentrated to an oil. The crude product was purified by flash silica gel column chromatography using a gradient of 0-100% EtOAc / heptane to give the title compound as an oil (1.02 g, 97%). ESI-MS [M+H] + 363.3.

[0339] Step E: 6-Isopropyl-3-(3-methylbenzyl)pyrazin-2(1H)-one

[0340] To tert-butyl (1-((3-methyl-1-oxobutan-2-yl)amino)-1-oxo-3-(m-tolyl)propan-2-yl)carbamate (1 g, 2.76 mmol) in DCM (10 mL) was added a 4 N solution of HCl in dioxane (6.90 mL, 27.6 mmol). Within minutes, the clear solution became warm and turned pale yellow. The reaction mixture was stirred at room temperature overnight, then concentrated under reduced pressure, diluted with water (75 mL), and adjusted to a pH greater than 12 with 50% NaOH. The reaction mixture was extracted with EtOAc, and the combined organic extracts were dried over Na2SO4, filtered, and concentrated to an oil. The oil was diluted with acetonitrile (5 mL) and stirred at room temperature overnight, then concentrated to an oil, which was purified by flash silica column chromatography using a gradient of 0-100% EtOAc / heptane to give the title compound as an oil (0.125 g, 18.70%). ESI-MS [M+H] + 243.1.

[0341] Preparation 21: 3-chloro-5-isopropyl-2-(3-methylbenzyl)pyrazine

[0342] [ka]

[0343] To a 100 mL round-bottom flask containing 6-isopropyl-3-(3-methylbenzyl)pyrazin-2(1H)-one (0.125 g, 0.516 mmol) was added POCl3 (0.475 g, 3.10 mmol). The solution was heated at 100 °C until the color changed from clear to light brown. Excess POCl3 was removed under reduced pressure, and the crude product was purified by flash silica gel column chromatography using a gradient of 0-100% EtOAc / heptane to give the title compound (28 mg, 21%) as a semi-solid. ESI-MS [M+H] + 261.1.

[0344] Preparation 22: N-(2-(azetidin-1-yl)ethyl)-6-chloro-3-(3-methylbenzyl)pyrazin-2-amine

[0345] [ka]

[0346] Step A: (3,5-Dichloropyrazin-2-yl)(m-tolyl)methanol

[0347] [ka]

[0348] A solution of n-BuLi (2.5 M in hexane, 6.44 mL) in THF (12 mL) was added dropwise to 2,2,6,6-tetramethylpiperidine (2.27 g, 16.10 mmol, 2.74 mL) in THF at −20° C. The resulting mixture was warmed to 0° C. and stirred for 30 minutes. The reaction mixture was then cooled to −78° C., and a solution of 2,6-dichloropyrazine (2 g, 13.42 mmol) in THF (4 mL) was added dropwise. The reaction mixture was stirred at −78° C. for 1 hour. A solution of 3-methylbenzaldehyde (2.42 g, 20.13 mmol) in THF (4 mL) was added dropwise at −78° C. The reaction mixture was stirred for 1 hour, then poured into ice-cold NH4Cl solution (50 mL) and extracted with EtOAc (20 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash silica gel column chromatography using a gradient of petroleum ether / EtOAc (100:1 to 5:1) to afford the title compound as a yellow oil (1.1 g, 29%). 1 H NMR (400 MHz, CDCl3) δ ppm 2.34 (s, 3 H), 4.18 (d, J=8.00 Hz, 1 H), 6.00 (d, J=8.40 Hz, 1 H), 7.71-7.27 (m, 4 H), 8.58 (s, 1 H).

[0349] Step B: 3,5-Dichloro-2-(3-methylbenzyl)pyrazine

[0350] [ka]

[0351] A mixture of TMSCl (1.45 g, 13.38 mmol, 1.69 mL) and NaI (2.01 g, 13.38 mmol) in ACN (10 mL) was stirred at 20 °C for 10 min. Then, a solution of (3,5-dichloropyrazin-2-yl)(m-tolyl)methanol (600 mg, 2.23 mmol) in ACN (8 mL) was added, and the reaction mixture was heated at 80 °C for 4 h. The mixture was cooled to room temperature and poured into a mixture of saturated NaSO solution (20 mL) and saturated NaHCO solution (20 mL), then extracted with EtOAc (10 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel using a gradient of petroleum ether / Et0Ac (1:0 to 20:1) to give the title compound as a yellow oil (400.0 mg, 29%). 1 H NMR (400 MHz, CDCl3) δ ppm 2.33 (s, 3 H), 4.21 - 4.31 (m, 2 H), 7.06 - 7.23 (m, 4 H), 8.47 (s, 1 H);ESI-MS m / z [M+H] + 253.0.

[0352] Step C: N-(2-(azetidin-1-yl)ethyl)-6-chloro-3-(3-methylbenzyl)pyrazin-2-amine hydrochloride

[0353] To a mixture of 3,5-dichloro-2-(3-methylbenzyl)pyrazine (350 mg, 1.38 mmol) and 2-(azetidin-1-yl)ethanamine (207.33 mg, 2.07 mmol) in DMSO (4 mL) was added CsF (628.87 mg, 4.14 mmol, 152.64 μL) at 20 °C. The mixture was stirred at 50 °C for 2 h and then diluted with EtOAc (20 mL) and saturated NH Cl solution (20 mL). The aqueous layer was separated and extracted with EtOAc (15 mL × 3). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (Phenomenex Synergi™ C18, 4 μm, ID 21.2 mm×250 mm) using a gradient of 22-52% ACN / water (0.05% HCl) to afford the HCl salt of the title compound as a yellow oil (63.0 mg, 94%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.99-2.06 (m, 2 H), 2.33 (s, 3 H), 2.51-2.54 (m, 2 H), 3.06-3.10 (m, 4 H), 3.21-3.25 (m, 2 H), 4.01 (s, 2 H), 5.33 (s, 1 H), 7.06-7.08 (m, 3 H), 7.20-7.24 (m, 1 H), 7.75 (s, 1 H);ESI-MS m / z [M+H] + 317.0.

[0354] Preparation 23: 3-Benzyl-6-ethylpyrazin-2-yl trifluoromethanesulfonate

[0355] [ka]

[0356] Step A: 3-benzyl-6-ethylpyrazin-2(1H)-one

[0357] [ka]

[0358] The title compound was prepared similarly to Preparation 20 starting from 2-(tert-butoxycarbonylamino)butanoic acid (5 g, 24.60 mmol) and obtained as a light brown solid (180.0 mg). 1 H NMR (400 MHz, CDCl3) δ ppm 1.31 (t, J=7.5 Hz, 3 H), 2.61 (q, J=7.5 Hz, 2 H), 4.13 (s, 2 H), 7.20 - 7.25 (m, 1 H), 7.28 - 7.33 (m, 2 H), 7.35 - 7.40 (m, 2 H), 7.42 (s, 1 H);ESI-MS m / z [M+H] + 214.8.

[0359] Step B: 3-benzyl-6-ethylpyrazin-2-yl trifluoromethanesulfonate

[0360] To a solution of 3-benzyl-6-ethylpyrazin-2(1H)-one (40 mg, 168.02 μmol) in DCM (3 mL) was added EtN (26.58 mg, 262.68 μmol, 36.41 μL) and trifluoromethylsulfonyl trifluoromethanesulfonate (94.81 mg, 336.04 μmol, 55.44 μL) at 0° C. The reaction mixture was stirred at 20° C. for 2 h and then concentrated in vacuo. The product was purified by silica gel column chromatography using a gradient of petroleum ether / EtOAc (20:1 to 10:1) to give the title compound as a yellow oil (30.0 mg, 51%). ESI-MS m / z [M+H] + 346.9.

[0361] Preparation 24: tert-Butyl trans-4-((3-chloro-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-ethylpiperidine-1-carboxylate

[0362] [ka]

[0363] Step A: 1-(tert-butyl) 4-ethyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1,4(2H)-dicarboxylate

[0364] [ka]

[0365] To a 250 mL round-bottom flask was added 1-(tert-butyl) 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (5.7 g, 21.01 mmol), 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (11.26 g, 31.5 mmol), and THF (80 mL) to give a colorless solution. NaH (1.260 g, 31.5 mmol) was then added at 0° C., and the reaction mixture was stirred at 0° C. for 1 h, then allowed to warm to room temperature and stirred overnight. The mixture was concentrated to half its volume, quenched with 10% Na2CO3, and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated. The residue was purified by silica gel column chromatography (120 g column) using a gradient of hexane / EtOAc (1:0 to 4:1) to give the title compound as a light brown syrup (8.56 g, 87%). ESI-MS m / z [M+H] + 404.4.

[0366] Step B: 1-(tert-butyl) 4-ethyl 5-vinyl-3,6-dihydropyridine-1,4(2H)-dicarboxylate

[0367] [ka]

[0368] A 250 mL round-bottom flask was charged with 1-(tert-butyl) 4-ethyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1,4(2H)-dicarboxylate (4.7 g, 11.65 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (2.372 mL, 13.98 mmol), RuPhos Pd G3 (0.455 g, 0.583 mmol), Cs2CO3 (7.59 g, 23.30 mmol), and dioxane (78 mL) to give a white suspension. Nitrogen was bubbled through the mixture for 5 minutes, and then the reaction mixture was heated at 75 °C overnight. The mixture was then filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (120 g column) using hexane / EtOAc (9:1) to give the title compound as a light brown syrup (2.52 g, 77%). ESI-MS m / z [M+H] + 282.1.

[0369] Step C: 1-(tert-butyl) 4-ethyl 3-ethylpiperidine-1,4-dicarboxylate

[0370] [ka]

[0371] To a 250 mL round-bottom flask was added 1-(tert-butyl) 4-ethyl 5-vinyl-3,6-dihydropyridine-1,4(2H)-dicarboxylate (2.52 g, 8.96 mmol) and dihydroxypalladium on carbon (0.314 g, 0.448 mmol) in EtOH (30 mL) and THF (30.0 mL), resulting in a black suspension. The flask was evacuated and refilled with hydrogen (3×). The reaction mixture was then stirred under hydrogen (50 psi) at room temperature for 10 days. The catalyst was filtered off, and the filtrate was concentrated to give the title compound as a colorless syrup (2.52 g, 99%), which was used without further purification. ESI-MS m / z [M+H] + 286.4.

[0372] Step D: 1-(tert-butyl) 4-ethyl trans-3-ethylpiperidine-1,4-dicarboxylate

[0373] [ka]

[0374] Sodium (0.406 g, 17.66 mmol) was added to ethanol (53.0 mL) in a 250 mL round-bottom flask. Once the sodium was completely dissolved, a solution of 1-(tert-butyl) 4-ethyl 3-ethylpiperidine-1,4-dicarboxylate (2.52 g, 8.83 mmol) in ethanol (35.3 mL) was added. The resulting mixture was heated at 85° C. overnight, then concentrated to half its original volume, quenched with water, and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO4, and concentrated to give the title compound as a brown syrup (2.11 g, 84%). ESI-MS m / z [M+H] + 286.4.

[0375] Step E: trans-1-(tert-butoxycarbonyl)-3-ethylpiperidine-4-carboxylic acid

[0376] [ka]

[0377] To a 250 mL round-bottom flask was added 1-(tert-butyl) 4-ethyl trans-3-ethylpiperidine-1,4-dicarboxylate (2.11 g, 7.39 mmol), lithium hydroxide (14.79 mL, 29.6 mmol), and dioxane (30 mL) to give a brown solution. The mixture was stirred at room temperature overnight, then heated at 50° C. overnight, concentrated under reduced pressure, and extracted with ether. The aqueous phase was acidified to pH 5 with 1N HCl and extracted with EtOAc. The organic layer was dried over anhydrous MgSO and concentrated under reduced pressure to give the title compound as a brown syrup. ESI-MS m / z [M+H]+ 258.3.

[0378] Step F: tert-Butyl trans-4-amino-3-ethylpiperidine-1-carboxylate

[0379] [ka]

[0380] To a 250 mL round-bottom flask was added trans-1-(tert-butoxycarbonyl)-3-ethylpiperidine-4-carboxylic acid (1.902 g, 7.39 mmol), diphenylphosphoryl azide (2.408 mL, 11.82 mmol), EtN (1.545 mL, 11.09 mmol), and toluene (49.3 mL) to give a brown solution. The solution was heated at 100 °C for 1 h and then cooled to room temperature. NaOH (7.39 mL, 73.9 mmol) was then added. The mixture was stirred at room temperature for 3 h and then concentrated under reduced pressure. The residue was suspended in EtOAc and filtered through a pad of Celite®. The filtrate was concentrated and purified by silica gel column chromatography (120 g NH column) using a gradient of hexanes / EtOAc (3:2 to 1:4) to give the title compound (1.11 g; 65.8%) as a syrup. ESI-MS m / z [M+H] + 229.3.

[0381] Step G: tert-Butyl trans-4-((3-chloro-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-ethylpiperidine-1-carboxylate

[0382] To a 40 mL vial was added 2,3-dichloro-5-(trifluoromethyl)pyrazine (0.1 g, 0.461 mmol), tert-butyl trans-4-amino-3-ethylpiperidine-1-carboxylate (0.137 g, 0.599 mmol), DIPEA (0.120 mL, 0.691 mmol), and dioxane (3 mL) to give a colorless solution. The solution was stirred at 75 °C for 3 days, then quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO4, and concentrated to give the title compound as a colorless film. ESI-MS m / z [M+H] + 409.8.

[0383] Preparation 25: tert-Butyl 4-((3-chloro-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-methylpiperidine-1-carboxylate

[0384] [ka]

[0385] To a 40 mL vial was added 2,3-dichloro-5-(trifluoromethyl)pyrazine (0.1 g, 0.461 mmol), tert-butyl 4-amino-3-methylpiperidine-1-carboxylate hydrochloride (0.150 g, 0.599 mmol), DIPEA (0.120 mL, 0.691 mmol), and dioxane (3 mL) to give a white suspension. The resulting mixture was stirred at 75 °C for 3 days. The mixture was treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated to give the title compound as a brown film, which was used without further purification. ESI-MS m / z [M+H] + 395.4.

[0386] Preparation 26: 3-chloro-2-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazine

[0387] [ka]

[0388] To a 100 mL round-bottom flask was added 2,3-dichloro-5-(trifluoromethyl)pyrazine (0.43 g, 1.982 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.842 g, 3.57 mmol), (dppf)PdCl (0.145 g, 0.198 mmol), NaCO (1.982 mL, 3.96 mmol), and dioxane (19.8 mL) to give an orange suspension. The suspension was degassed with N and heated at 110 °C overnight. The mixture was then quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using a gradient of hexane / EtOAc (4:1 to 1:1) to give the title compound (0.349 g, 60.6%). ESI-MS m / z [M+H] + 291.3.

[0389] Preparation 27: 5,6-Dichloro-3-methylpyrazine-2-carbonitrile

[0390] [ka]

[0391] Step A: 5-amino-6-chloro-3-methylpyrazine-2-carbonitrile

[0392] [ka]

[0393] A solution of 5-amino-3-methylpyrazine-2-carbonitrile (2.91 g, 21.7 mmol) and NCS (3.19 g, 23.9 mmol) in ACN (108 mL) was slowly heated to 75 °C over 3 h. The reaction mixture was cooled to room temperature and diluted with EtOAc. The organic phase was washed with saturated aqueous NaHCO (3x), then dried over NaSO, filtered, and concentrated under reduced pressure to give the title compound as an orange solid (3.66 g, quantitative), which was used without further purification. ESI-MS m / z [M+H] + 168.9.

[0394] Step B: 5,6-Dichloro-3-methylpyrazine-2-carbonitrile

[0395] To a solution of CuCl (6.23 g, 62.9 mmol), CuCl (8.46 g, 62.9 mmol), and 5-amino-6-chloro-3-methylpyrazine-2-carbonitrile (3.66 g, 21.7 mmol) in ACN (108 mL) at 0 °C was added tert-butyl nitrite (5.59 g, 54.2 mmol) dropwise. The reaction mixture was stirred at room temperature for 30 min, then heated to 65 °C for 45 min, and cooled to room temperature. The mixture was diluted with DCM, filtered through a pad of Celite®, and concentrated under reduced pressure to give a viscous brown solution, which was adsorbed onto silica and purified by automated flash column chromatography using an EtOAc / heptane gradient. Evaporation of fractions containing the desired product gave the title compound as a white solid (2.14 g, 52%). 1 H NMR (500 MHz, DMSO-d6) δ ppm 2.68 (d, J = 2.0 Hz, 3 H). The compound was not ionized by ESI-MS.

[0396] Preparation 28: 5-((2-(azetidin-1-yl)ethyl)amino)-6-chloro-3-methylpyrazine-2-carbonitrile

[0397] [ka]

[0398] A solution of 5,6-dichloro-3-methylpyrazine-2-carbonitrile (0.300 g, 1.60 mmol) (Preparation 27) in dioxane (10 mL) was treated with 2-(azetidin-1-yl)ethanamine (0.160 g, 1.60 mmol) and DIPEA (0.557 mL, 3.19 mmol). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The residue was taken up in MeOH and filtered through a hydrophilic PTFE 0.45 μm Millipore® filter. The filter was rinsed with MeOH, and the filtrate was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3). Fractions containing the desired product were evaporated and dried under vacuum to give the title compound as a pale yellow solid (157.9 mg, 39.3%). ESI-MS m / z [M+H] + 252.10.

[0399] Preparation 29: (R)-6-chloro-3-methyl-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile

[0400] [ka]

[0401] To a solution of 5,6-dichloro-3-methylpyrazine-2-carbonitrile (315 mg, 1.67 mmol) in DCM (8.37 mL) at 0 °C was added DIPEA (0.585 mL, 3.35 mmol) and (R)-1-methylpyrrolidin-3-amine (184 mg, 1.84 mmol). The reaction mixture was stirred overnight, gradually warming to room temperature. The mixture was then diluted with water and extracted with DCM. The organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was partially purified by automated flash silica column chromatography. Evaporation of fractions containing the desired product afforded the title compound as an orange solid (170.1 mg, 40%), which was used without further purification. ESI-MS m / z [M+H] + 252.10.

[0402] Preparation 30: 2-chloro-3-(4-fluorobenzyl)pyrazine

[0403] [ka]

[0404] A mixture of 2,3-dichloropyrazine (1.3 g, 8.73 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.08 g, 8.81 mmol), Na2CO3 (2 M, 9.82 mL), and PdCl2(dppf).CHCl2 (712.61 mg, 872.61 μmol) in dioxane (40 mL) was stirred at 105 °C for 16 h, then diluted with EtOAc (100 mL) and washed with water (100 mL × 3). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether / EtOAc (10:1) to give the title compound (1 g, 51.4%). 1H NMR (400 MHz, CDCl3) δ ppm 4.27 (s, 2 H), 6.97 (t, J=8.71 Hz, 2 H), 7.21 - 7.28 (m, 2 H), 8.23 ​​(d, J=2.43 Hz, 1 H), 8.43 (d, J=2.43 Hz, 1H);ESI-MS m / z [M+H] + 223.1.

[0405] Preparation 31: 2-chloro-3-(1-(4-fluorophenyl)ethyl)pyrazine

[0406] [ka]

[0407] Step A: (E)-2-chloro-3-(1-(4-fluorophenyl)-2-(trimethylsilyl)vinyl)pyrazine

[0408] [ka]

[0409] The title compound was prepared similarly to Step A of Preparation 3 using 2,3-dichloropyrazine (500 mg, 3.36 mmol), (Z)-(2-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)trimethylsilane (1.18 g, 3.69 mmol), PdCl(dppf) (245.57 mg, 335.62 μmol), and NaCO (4 M, 2.10 mL) in dioxane (8 mL) to give a yellow oil (797 mg, 77.3%). ESI-MS m / z [M+H] + 307.1.

[0410] Step B: 2-chloro-3-(1-(4-fluorophenyl)vinyl)pyrazine

[0411] [ka]

[0412] The title compound was prepared similarly to Step B of Preparation 3 using (E)-2-chloro-3-(1-(4-fluorophenyl)-2-(trimethylsilyl)vinyl)pyrazine (780 mg, 2.54 mmol) in TFA (16 mL, 216.10 mmol) and obtained as a yellow oil (290 mg, 48.7%). ESI-MS m / z [M+H] + 235.1.

[0413] Step C: 2-chloro-3-(1-(4-fluorophenyl)ethyl)pyrazine

[0414] To a solution of 2-chloro-3-(1-(4-fluorophenyl)vinyl)pyrazine (290 mg, 1.236 mmol) in EtOAc (5 mL) was added PtO (90 mg). The suspension was degassed under vacuum, purged with H several times, stirred under H (15 psi) at 20 °C for 16 h, and then filtered through a pad of Celite. The filtrate was concentrated in vacuo and purified by silica gel column chromatography using a gradient of petroleum ether / EtOAc (1:0 to 10:1) to give the title compound as a yellow oil (125 mg, 42.7%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.68 (d, J=7.1 Hz, 3 H), 4.70 (d, J=7.1 Hz, 1 H), 6.94 - 7.02 (m, 2 H), 7.27 - 7.32 (m, 2 H), 8.23 ​​(d, J=2.4 Hz, 1 H), 8.51 (d, J=2.4 Hz, 1 H);ESI-MS m / z [M+H] + 237.1.

[0415] Preparation 32: 3-chloro-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0416] [ka]

[0417] To a solution of 2,3-dichloropyrazine (500 mg, 3.36 mmol) in dioxane (22.4 mL) was added 2-(pyrrolidin-1-yl)ethan-1-amine (498 mg, 4.36 mmol), followed by DIPEA (879 μL, 5.03 mmol). The solution was heated at 80° C. overnight and purified by silica gel column chromatography (NH column) using a gradient of 10 to 100% EtOAc / heptane to give the title compound (450 mg, 59.1%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ ppm 1.82 (dt, J=6.88, 3.26 Hz, 4 H), 2.54 - 2.64 (m, 4 H), 2.77 (t, J=6.14 Hz, 2 H), 3.43 - 3.66 (m, 2 H), 5.86 (br s, 1 H), 7.56 (d, J=2.75 Hz, 1 H), 7.95 (d, J=2.75 Hz, 1 H).

[0418] Preparation 33: 3-chloro-2-(1-(4-fluorophenyl)ethyl)-5-(trifluoromethyl)pyrazine

[0419] [ka]

[0420] Step A: 3-chloro-2-(1-(4-fluorophenyl)vinyl)-5-(trifluoromethyl)pyrazine

[0421] [ka]

[0422] To a 250 mL round-bottom flask was added 2,3-dichloro-5-(trifluoromethyl)pyrazine (0.36 g, 1.659 mmol), 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.617 g, 2.489 mmol), PdCl(dppf) (0.121 g, 0.166 mmol), NaCO (1.659 mL, 3.32 mmol), and dioxane (16.59 mL) to give an orange suspension. The suspension was degassed with N and then heated at 110 °C overnight. The reaction mixture was treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4, concentrated under reduced pressure, and purified by silica gel column chromatography using a gradient of hexane / EtOAc (1:0 to 9:1) to give the title compound (0.216 g, 43%). ESI-MS m / z [M+H] + 303.1.

[0423] Step B: 3-chloro-2-(1-(4-fluorophenyl)ethyl)-5-(trifluoromethyl)pyrazine

[0424] To a 250 mL round-bottom flask was added 3-chloro-2-(1-(4-fluorophenyl)vinyl)-5-(trifluoromethyl)pyrazine (0.502 g, 1.659 mmol), platinum (0.065 g, 0.017 mmol), and MeOH (20 mL) to give a black suspension. The flask was evacuated and refilled with hydrogen (3×), and the suspension was stirred under a hydrogen atmosphere (balloon) at room temperature overnight. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give the title compound (487 mg), which was used without further purification. ESI-MS m / z [M+H] + 305.1.

[0425] Preparation 34: 5-(4-Fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinic acid

[0426] [ka]

[0427] Step A: 6-chloro-5-(4-fluorobenzyl)methyl nicotinate

[0428] [ka]

[0429] To a 250 mL round-bottom flask was added methyl 5-bromo-6-chloronicotinate (1.0 g, 3.99 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.414 g, 5.99 mmol), PdCl(dppf) (0.584 g, 0.798 mmol), and NaCO (1.269 g, 11.98 mmol) in dioxane (30 mL) and water (7.50 mL) to give an orange suspension. The suspension was sparged with nitrogen for 5 minutes, then heated at 100 °C for 2 hours and filtered. The filtrate was treated with water and extracted with EtOAc. The organic phase was dried over anhydrous MgSO4 and purified by Biotage column chromatography (40 g column) using a gradient of hexane / EtOAc (4:1 to 1:1) to give the title compound as a pale yellow syrup (0.516 g, 46.2%). ESI-MS m / z [M+H] + 280.3.

[0430] Step B: Methyl 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinate

[0431] [ka]

[0432] To a 40 mL vial was added methyl 6-chloro-5-(4-fluorobenzyl)nicotinate (0.15 g, 0.536 mmol), 2-(pyrrolidin-1-yl)ethan-1-amine (0.067 g, 0.590 mmol), (R)-2,2′-bis(diphenylphosphanyl)-1,1′-binaphthalene (0.033 g, 0.054 mmol), Pd(dba) (0.049 g, 0.054 mmol), and CsCO (0.349 g, 1.073 mmol) in toluene (4 mL) to give a brown suspension. The suspension was degassed and then heated at 90 °C overnight. The reaction mixture was treated with water and extracted with EtOAc. The organic layer was dried over anhydrous MgSO and concentrated to give a brown film (0.192 g), which was used without further purification. ESI-MS m / z [M+H] + 358.4.

[0433] Step C: 5-(4-Fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinic acid

[0434] To a 125 mL pear-bottomed flask was added methyl 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinate (0.192 g, 0.536 mmol) and lithium hydroxide (1.072 mL, 2.144 mmol) in dioxane (3 mL) to give a brown solution. The solution was stirred overnight at room temperature, then treated with dilute HCl and extracted with EtOAc. The aqueous phase was concentrated under reduced pressure to give a brown film, which was used without further purification. ESI-MS m / z [M+H] + 344.4.

[0435] Preparation 35: 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinic acid

[0436] [ka]

[0437] Step A: Methyl 5-bromo-6-((1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)nicotinate

[0438] [ka]

[0439] To a 40 mL vial, methyl 5-bromo-6-chloronicotinate (0.188 g, 0.751 mmol), tert-butyl 4-amino-3-methylpiperidine-1-carboxylate HCl (0.188 g, 0.751 mmol), and DIPEA (0.392 mL, 2.252 mmol) in dioxane (4 mL) were added to give a white suspension. The suspension was stirred at 80 °C for 2 days and then heated at 100 °C for 1 week. Approximately 50% conversion was observed. The reaction mixture was treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated. The resulting residue was purified by Biotage® column chromatography (40 g column) using a gradient of hexane / EtOAc (4:1 to 1:1) to give the title compound as a brown film (50.0 mg, 15.6%). ESI-MS m / z [M+H] + 428.3.

[0440] Step B: Methyl 6-((1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinate

[0441] [ka]

[0442] To a 100 mL round-bottom flask was added methyl 5-bromo-6-((1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)nicotinate (0.050 g, 0.117 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.050 g, 0.210 mmol), (dppf)PdCl (8.54 mg, 0.012 mmol), and NaCO (0.025 g, 0.233 mmol) in dioxane (3 mL) and water (0.750 mL) to give an orange solution. The solution was degassed with N and then heated at 110 °C overnight. After cooling to room temperature, the reaction mixture was treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4 and concentrated to give the title compound as a brown film, which was used without further purification. ESI-MS m / z [M+H] + 458.5.

[0443] Step C: Methyl 5-(4-fluorobenzyl)-6-((3-methylpiperidin-4-yl)amino)nicotinate

[0444] [ka]

[0445] To a 125 mL pear-bottomed flask was added methyl 6-((1-(tert-butoxycarbonyl)-3-methylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinate (0.054 g, 0.117 mmol) and hydrogen chloride (0.117 mL, 0.468 mmol) in dioxane (3 mL) to give a brown solution. The solution was stirred at 50° C. for 3 h and then concentrated to give the title compound as a brown solid, which was used without further purification. ESI-MS m / z [M+H] + 358.4.

[0446] Step D: Methyl 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinate

[0447] [ka]

[0448] To a 125 mL pear-bottomed flask was added methyl 5-(4-fluorobenzyl)-6-((3-methylpiperidin-4-yl)amino)nicotinate (0.042 g, 0.117 mmol) and formaldehyde (0.018 mL, 0.232 mmol) in methanol (3 mL) to give a brown solution. Sodium cyanotrihydroborate (0.015 g, 0.232 mmol) was added and the reaction mixture was stirred at room temperature for 3 hours, then treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated under reduced pressure to give the title compound as a brown film, which was used without further purification. ESI-MS m / z [M+H] + 372.4.

[0449] Step E: 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinic acid

[0450] To a 100 mL round-bottom flask was added methyl 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinate (0.043 g, 0.117 mmol) and lithium hydroxide (0.234 mL, 0.468 mmol) in dioxane (3 mL) to give a brown solution. The solution was stirred at room temperature for 3 days. The reaction mixture was treated with 1.0 N HCl to acidify to pH 4 and extracted with EtOAc. The aqueous phase was concentrated, and the resulting residue was redissolved in ethanol. The precipitate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound as a brown film, which was used without further purification. ESI-MS m / z [M+H] + 358.4.

[0451] Preparation 36: 3-Bromo-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine

[0452] [ka]

[0453] To a 125 mL round-bottom flask was added 3-bromo-2-chloro-6-(trifluoromethyl)pyridine (1.0 g, 3.84 mmol), 2-(pyrrolidin-1-yl)ethan-1-amine (0.482 g, 4.22 mmol), and potassium carbonate (1.061 g, 7.68 mmol) in DMF (8 mL) to give a white suspension. The suspension was heated at 100 °C overnight, then treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO and concentrated to give the title compound as a brown syrup (1.37 g, 94%), which was used without further purification. ESI-MS m / z [M+H] + 339.3.

[0454] Preparation 37: 6-(1-(4-fluorophenyl)ethyl)-N-(2-oxopropyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0455] [ka]

[0456] Step A: 6-(1-(4-fluorophenyl)ethyl)-N-(2-hydroxypropyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0457] [ka]

[0458] To a round-bottom flask containing 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (0.5 g, 1.40 mmol) and 1-aminopropan-2-ol (157.17 mg, 2.09 mmol, 163.89 μL) in DMF (5 mL) was added DIPEA (728.96 μL, 540.89 mg, 4.19 mmol) and HATU (1.06 g, 2.79 mmol). The reaction mixture was stirred at 25° C. for 16 h and then purified by silica gel column chromatography using a gradient of 0-10% MeOH / DCM to give the title compound as a yellow gum (0.2 g, 32.7%). ESI-MS m / z [M+H] + 416.3.

[0459] Step B: 6-(1-(4-fluorophenyl)ethyl)-N-(2-oxopropyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0460] To a round-bottom flask containing 6-(1-(4-fluorophenyl)ethyl)-N-(2-hydroxypropyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (0.2 g, 481.34 μmol) in DCM (2 mL) was added DMP (223.53 μL, 722.02 μmol) at 0° C. The reaction mixture was stirred at 25° C. for 16 h and then purified by silica gel column chromatography using a gradient of 0-10% MeOH / DCM to give the title compound as a yellow gum (0.18 g, 83.2%). ESI-MS m / z [M+H] + 414.3.

[0461] Preparation 38: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(2-oxopropyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0462] [ka]

[0463] Step A: 6-(1-(4-fluorophenyl)ethyl)-N-(2-hydroxypropyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0464] [ka]

[0465] To a solution of 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (300 mg, 0.532 mmol) and HATU (202 mg, 0.532 mmol) in DMF (5.3 mL) was added DIPEA (206 mg, 1.595 mmol). The solution was stirred at room temperature for 10 minutes, and then 1-aminopropan-2-ol (43.9 mg, 0.585 mmol) was added. The reaction mixture was stirred at room temperature for 6 hours and then purified by silica gel column chromatography (NH column) using a gradient of 0-10% MeOH / DCM to give the title compound as a colorless oil (174 mg, 0.405 mmol, 76%). ESI-MS m / z [M+H] + 430.20.

[0466] Step B: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(2-oxopropyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0467] A solution of 6-(1-(4-fluorophenyl)ethyl)-N-(2-hydroxypropyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (170 mg, 0.396 mmol) and Dess-Martin periodinane (218 mg, 0.515 mmol) in DCM (4.0 mL) was stirred at room temperature for 4 h and then diluted with saturated aqueous NaSO (3 mL) and NaHCO (3 mL). The mixture was stirred vigorously for 1 h and then purified by silica gel column chromatography using a gradient of 15-100% EtOAc / heptane to give the title compound as a colorless oil (52 mg, 30.7%). ESI-MS m / z [M+H] + 428.15.

[0468] Preparation 39: 3-chloro-6-(3-methylbenzyl)-5-(methylthio)-1,2,4-triazine

[0469] [ka]

[0470] Step A: 6-Iodo-1,2,4-triazine-3,5(2H,4H)-dione

[0471] [ka]

[0472] To a mixture of 2H-1,2,4-triazine-3,5-dione (17.00 g, 150.4 mmol) in water (530 mL) was added KI (79.87 g, 481.1 mmol), NaOH (24.06 g, 601.4 mmol), and I (114.48 g, 451.05 mmol) at 20 °C. The reaction mixture was stirred at 120 °C for 24 h, then quenched with saturated aqueous NaSO (250 mL), acidified to pH 2-3 with 4 M aqueous HCl, and extracted with EtOAc (500 mL × 3). The combined organic layers were dried, filtered, and concentrated in vacuo to give a pale yellow solid (14.0 g, 60% purity). The solid was purified by flash silica column chromatography using DCM / EtOH / HCO2H (100:2:1) to give the title compound as a pale yellow solid (10.0 g, 22% yield, 80% purity). 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.38 12.14 (br s, 1 H), 12.59 (br s, 1 H).

[0473] Step B: 6-(3-methylbenzyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0474] [ka]

[0475] A mixture of 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (2.80 g, 12.0 mmol), 6-iodo-1,2,4-triazine-3,5(2H,4H)-dione (3.00 g, 10.0 mmol), Pd(dppf)Cl (514.4 mg, 702.8 μmol), and aqueous NaCO (2.5 M, 11.32 mL, 28.2 mmol) in dioxane (50 mL) was stirred at 100 °C for 24 h. The reaction was quenched with water (100 mL), and the reaction mixture was acidified with 2 M aqueous HCl (2 M) to pH 2–3 and extracted with EtOAc (100 mL 3×). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude product was purified by flash silica column chromatography using petroleum ether / EtOAc / MeOH (50:50:1) to give a light brown gum (3 g). The gum was purified by preparative HPLC (Phenomenex Synergi Max-RP 10 μm, ID 50 mm × 250 mm) using a gradient of 5 to 55% ACN / water (0.225% FA) to give the title compound as an off-white solid (900 mg, 41%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.26 (s, 3 H), 3.73 (s, 2 H), 6.97 - 7.07 (m, 3 H), 7.12 - 7.20 (m, 1 H), 11.94 (br s, 1 H), 12.10 (s, 1 H);ESI-MS m / z [M+H] + 218.2.

[0476] Step C: 3,5-Dichloro-6-(3-methylbenzyl)-1,2,4-triazine

[0477] [ka]

[0478] A mixture of 6-(3-methylbenzyl)-1,2,4-triazine-3,5(2H,4H)-dione (850 mg, 3.91 mmol) in POCl (20.0 mL) was stirred at 110 °C for 24 h, then cooled and concentrated under reduced pressure. The resulting residue was diluted with DCM (50 mL), and the mixture was carefully added to cold water (100 mL). The organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give the crude product, which was purified by flash silica column chromatography using a gradient of petroleum ether / EtOAc (30:1 to 10:1). The title compound was obtained as a pale yellow oil (700 mg, 67%). 1 H NMR (400 MHz, CDCl3) δ ppm 2.33 (s, 3 H), 4.43 (s, 2 H), 7.04 - 7.14 (m, 3 H), 7.17 - 7.25 (m, 1 H).

[0479] Step D: 3-chloro-6-(3-methylbenzyl)-5-(methylthio)-1,2,4-triazine

[0480] To a solution of 3,5-dichloro-6-(3-methylbenzyl)-1,2,4-triazine (700 mg, 2.75 mmol) in THF (25.0 mL) was carefully added an aqueous solution of NaSMe (20%, 1.00 mL, 3.14 mmol) at 0 °C. The mixture was stirred at 15 °C for 16 hours, then diluted with water (20 mL) and extracted with EtOAc (20 mL × 2). The combined organic layers were washed with saturated aqueous NaCl (15 mL × 3), dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica column chromatography using petroleum ether / EtOAc (10:1) to give the title compound (190 mg, 24%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ ppm 2.32 (s, 3 H), 2.56 (s, 3 H), 4.23 (s, 2 H), 7.04 - 7.14 (m, 3 H), 7.17 - 7.23 (m, 1 H);ESI-MS m / z [M+H] + 265.9.

[0481] Preparation 40: 3-Ethyl-6-(3-methylbenzyl)-5-(methylthio)-1,2,4-triazine

[0482] [ka]

[0483] To a mixture of 3-chloro-6-(3-methylbenzyl)-5-(methylthio)-1,2,4-triazine (40.0 mg, 140 μmol) and Pd(dppf)Cl.CHCl (11.4 mg, 14.0 μmol) in dioxane (1.50 mL) was added 1 M diethylzinc in toluene (200 μL, 200 μmol) at 0° C. The reaction mixture was stirred under N at 85° C. for 1.5 h, then quenched with water (2 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by preparative TLC using petroleum ether / EtOAc (3:1) to give the title compound (30.0 mg, 78%) as a pale yellow oil. ESI-MS m / z [M+H] + 260.0.

[0484] Preparation 41: 3-Methyl-6-(3-methylbenzyl)-5-(methylthio)-1,2,4-triazine

[0485] [ka]

[0486] To a mixture of 3-chloro-6-(3-methylbenzyl)-5-(methylthio)-1,2,4-triazine (40.0 mg, 140 μmol) and Pd(PPh3)4 (16.2 mg, 14.0 μmol) in THF (1.20 mL) was added 2 M trimethylaluminum in toluene (200 μL, 400 μmol) at 0 °C. The mixture was stirred under N2 at 70 °C for 16 h, then quenched with water (2 mL), acidified to pH 3-4 by adding 1 N aqueous HCl, and extracted with EtOAc (15 mL 3×). The combined organic layers were dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by preparative TLC using petroleum ether / EtOAc (2:1) to give the title compound (28.0 mg, 78%) as a pale yellow oil. ESI-MS m / z [M+H] + 246.1.

[0487] Preparation 42: 3-Methyl-6-(1-phenylethyl)-1,2,4-triazin-5(4H)-one

[0488] [ka]

[0489] Step A: 2-oxo-3-phenylbutanoic acid

[0490] [ka]

[0491] The starting material, (Z)-2-hydroxy-3-phenylacrylic acid (7.917 g, 48.2 mmol), was dissolved in a heated solution of 1.0 M NaOH (101 mL, 101 mmol) and allowed to cool to room temperature. Next, MeI (3.00 mL, 48.2 mmol) was added. The reaction mixture was stirred at room temperature for 3 days and then acidified with 1 N HCl until the solution remained white. The mixture was extracted with EtO, dried over anhydrous NaSO, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography using a gradient of 25-30% EtOAc / heptane to give the title compound (3.502 g, 40.8%). 1 H NMR (500 MHz, DMSO-d6) δ ppm 1.34 (d, J=6.83 Hz, 3 H), 4.43 - 4.54 (m, 1 H), 7.18 - 7.23 (m, 2 H), 7.24 - 7.30 (m, 1 H), 7.32 - 7.37 (m, 2 H).

[0492] Step B: 3-methyl-6-(1-phenylethyl)-1,2,4-triazin-5(4H)-one

[0493] To a vial containing a solution of acetimidamide HCl (0.532 g, 5.63 mmol) in EtOH (2.84 mL) was added hydrazine hydrate (0.282 g, 5.63 mmol) in EtOH (2.84 mL). The mixture was stirred at room temperature for 10 minutes. Next, 2-oxo-3-phenylbutanoic acid (0.912 g, 5.12 mmol) in EtOH (2.84 mL) was added, and the mixture was stirred at room temperature for 1 hour. The vial was heated to 150 °C for 5 minutes. The solution was filtered and concentrated in vacuo. The crude material was taken up in DMF and MeOH, filtered, and purified by preparative HPLC (Phenomenex Gemini® 30 mm ID x 100 mm) using a gradient of 10-100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (0.539 g, 48.9%). 1H NMR (500 MHz, DMSO-d6) δ ppm 1.44 (d, J=6.83 Hz, 3 H), 2.21 - 2.28 (m, 3 H), 4.36 (d, J=6.35 Hz, 1 H), 7.15 - 7.21 (m, 1 H), 7.22 - 7.30 (m, 4H), 13.55 (br s, 1H).

[0494] Preparation 43: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-1,2,4-triazin-5(4H)-one

[0495] [ka]

[0496] Step A: 3-(4-fluorophenyl)-2-oxobutanoic acid

[0497] [ka]

[0498] To a solution of (Z)-3-(4-fluorophenyl)-2-hydroxyacrylic acid (2.469 g, 13.55 mmol) dissolved in aqueous NaOH (28.5 mL, 28.5 mmol) was added iodomethane (0.844 mL, 13.55 mmol). The resulting solution was stirred at room temperature for 6 days and then acidified with 1.0 N HCl until the solution remained white. The mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to give a dark red viscous oil. The crude product was purified by silica gel column chromatography using 40% EtOAc / heptane to give the title compound (1.5287 g, 57.5%). ESI-MS m / z [M+H] + 197.1.

[0499] Step B: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-1,2,4-triazin-5(4H)-one

[0500] To a vial containing a solution of acetimidamide HCl (0.814 g, 8.61 mmol) in EtOH (4.02 mL) was added hydrazine hydrate (0.431 g, 8.61 mmol). The solution was stirred at room temperature for 1 hour. Next, a solution of 3-(4-fluorophenyl)-2-oxobutanoic acid (1.536 g, 7.83 mmol) in EtOH (4.02 mL) was added, and the reaction mixture was stirred for 1 hour. The vial was sealed, and the reaction mixture was heated to 150 °C in a microwave reactor for 5 minutes. Ethyl acetate (5 mL) was slowly added to the stirred solution. The solids were filtered off, and the filter cake was washed with EtOAc. The filtrate and EtOAc washings were combined, concentrated under reduced pressure, taken up in DMF and MeOH, filtered, and purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 30–90% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (0.484 g, 26.5%).

[0501] Preparation 44: 3-chloro-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine

[0502] [ka]

[0503] Step A: 6-(4-Fluorobenzyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0504] [ka]

[0505] To a mixture of 3-(4-fluorophenyl)-2-oxo-propanoic acid (16 g, 87.84 mmol) and aminourea hydrochloride (11 g, 98.63 mmol) in water (130 mL) was added 1N NaOH (400 mL) at 80° C. The mixture was stirred at 80° C. for 16 h, then cooled to 0° C. and acidified to pH 3-4 by adding 12N aqueous HCl. The precipitate was collected by filtration to give a pale yellow solid, which was dissolved in EtOAc (500 mL) and washed with brine (50 mL×2). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to give the title compound as a pale yellow solid (14.8 g, 76%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 3.76 (s, 2 H), 7.02 - 7.17 (m, 2 H), 7.23 - 7.31 (m, 2 H), 11.96 (br s, 1 H), 12.12 (s, 1 H).

[0506] Step B: 3,5-Dichloro-6-(4-fluorobenzyl)-1,2,4-triazine

[0507] [ka]

[0508] A mixture of 6-(4-fluorobenzyl)-1,2,4-triazine-3,5(2H,4H)-dione (10 g, 45.21 mmol) in POCl (210 mL) was stirred at 110° C. for 8 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with EtOAc (200 mL), and the mixture was carefully added to cold water (400 mL). The organic layer was separated, washed with brine (20 mL×2), dried over Na SO , filtered, and concentrated in vacuo. The product was purified by silica gel flash column chromatography using petroleum ether / EtOAc (10:1) to give the title compound as a yellow oil (7.3 g, 63%). 1H NMR (400 MHz, CDCl3) δ ppm 4.44 (s, 2 H), 6.98 - 7.06 (m, 2 H), 7.29 (dd, J=8.5, 5.5 Hz, 2 H);ESI-MS m / z [M+H] + 257.9.

[0509] Step C: 3-chloro-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine

[0510] To a solution of 3,5-dichloro-6-(4-fluorobenzyl)-1,2,4-triazine (7.3 g, 28.29 mmol) in THF (70 mL) was carefully added 20% aqueous NaSMe (14.87 g, 42.44 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min, then diluted with water (100 mL) and extracted with EtOAc (300 mL × 2). The combined organic layers were washed with brine (100 mL × 3), dried over NaSO, filtered, and concentrated in vacuo. The product was purified by flash silica gel column chromatography using a gradient of EtOAc / petroleum ether (0:100 to 10:90) to give the title compound (5.2 g, 68%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ ppm 2.57 (s, 3 H), 4.23 (s, 2 H), 7.00 (t, J=8.5 Hz, 2 H), 7.23 - 7.32 (m, 2 H).

[0511] Preparation 45: 6-(4-fluorobenzyl)-3-methyl-5-(methylthio)-1,2,4-triazine

[0512] [ka]

[0513] To a mixture of 3-chloro-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine (4 g, 14.83 mmol) and Pd(PPh3)4 (1.71 g, 1.48 mmol) in THF (40 mL) was added 2 M trimethylaluminum solution in toluene (18.54 mL, 37.08 mmol) at 0 °C. The reaction mixture was heated to 70 °C under N2 for 6 h, then quenched with water (50 mL), acidified to pH 3-4 with 4.0 N aqueous HCl, and extracted with EtOAc (300 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The product was purified by flash silica gel column chromatography (ISCO® 40 g SepaFlash® column) using a gradient of EtOAc / petroleum ether (0:100 to 10:90) to afford the title compound as a yellow solid (3.1 g, 52%). 1 H NMR (400 MHz, CDCl3) δ ppm 2.52 (s, 3 H), 2.74 (s, 3 H), 4.22 (s, 2 H), 6.94 - 7.01 (m, 2 H), 7.27 - 7.31 (m, 2 H);ESI-MS m / z [M+H] + 250.2.

[0514] Preparation 46: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-(methylthio)-1,2,4-triazine

[0515] [ka]

[0516] To a solution of 6-(4-fluorobenzyl)-3-methyl-5-(methylthio)-1,2,4-triazine (2.85 g, 11.43 mmol) in THF (60 mL) was added 1 M LiHMDS in THF (13.72 mL, 13.72 mmol) dropwise at −78° C. The solution was stirred at −78° C. for 30 minutes. Iodomethane (3.24 g, 22.86 mmol, 1.42 mL) was then added. The reaction mixture was stirred at −78° C. for 2 hours, then quenched by careful addition of saturated NH4Cl (40 mL) and extracted with EtOAc (500 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The product was purified by flash silica gel chromatography (ISCO® 40 g SepaFlash® column) using a gradient of EtOAc / petroleum ether (0:100 to 10:90) to afford the title compound as a red oil (1.3 g, 43%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.76 (d, J=7.1 Hz, 3 H), 2.49 (s, 3 H), 2.73 (s, 3 H), 4.33 (q, J=6.9 Hz, 1 H), 6.97 (t, J=8.7 Hz, 2 H), 7.29 (dd, J=8.6, 5.5 Hz, 2H).

[0517] Preparation 47: 3-Cyclopropyl-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine

[0518] [ka]

[0519] A mixture of 3-chloro-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine (100 mg, 344.79 μmol), cyclopropylboronic acid (44.43 mg, 517.19 μmol), PdCl(dppf).CHCl (28.16 mg, 34.48 μmol), and CsCO (1 M, 1.03 mL) in toluene (7 mL) was stirred at 80 °C for 16 h. The reaction mixture was quenched with water (2 mL) and extracted with EtOAc (15 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The product was purified by flash silica gel column chromatography (ISCO® 4 g SepaFlash® column) using a gradient of EtOAc / petroleum ether (0:100 to 15:85) to afford the title compound as an off-white solid (30.0 mg, 30%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.06 - 1.20 (m, 4 H), 2.37 (br s, 1 H), 2.47 (s, 3 H), 4.19 (s, 2 H), 6.97 (t, J=8.4 Hz, 2 H), 7.29 (br s, 2 H);ESI-MS m / z [M+H] + 276.0.

[0520] Preparation 48: 3-Ethyl-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine

[0521] [ka]

[0522] To a mixture of 3-chloro-6-(4-fluorobenzyl)-5-(methylthio)-1,2,4-triazine (250 mg, 926.85 μmol) and PdCl(dppf).CHCl (75.69 mg, 92.69 μmol) in dioxane (7 mL) was added 1 M diethylzinc in toluene (926.9 μL, 926.9 μmol) at 25° C. The mixture was heated to 60° C. under N for 2 h, then quenched with water (20 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The product was purified by flash silica gel column chromatography (ISCO® 12 g SepaFlash® column) using a gradient of EtOAc / petroleum ether (0:100 to 10:90) to afford the title compound as a pale yellow oil (160.0 mg, 65%). 1 H NMR (400 MHz, CDCl3) δ ppm 1.40 (t, J=7.6 Hz, 3 H), 2.54 (s, 3 H), 3.03 (q, J=7.6 Hz, 2 H), 4.22 (s, 2 H), 6.96 - 7.02 (m, 2 H), 7.28 - 7.34 (m, 2 H).

[0523] Example 1: 3-benzyl-N-(2-(pyrrolidin-1-yl)ethyl)quinoxalin-2-amine

[0524] [ka]

[0525] To a 10 mL microwave vial was added 2-benzyl-3-chloroquinoxaline (0.065 g, 0.255 mmol) and 2-(pyrrolidin-1-yl)ethanamine (0.087 g, 0.766 mmol) in NMP (3 mL). The mixture was heated in a Biotage® microwave reactor at 150° C. for 2 h, then filtered and purified by preparative HPLC (Waters SunFire® C18, 5 μm, 30 mm ID×75 mm column) using a gradient of 10–35% ACN (0.035% TFA) / water (0.05% TFA). Pure fractions were combined and lyophilized to afford the title compound as an off-white solid (0.063 g, 74%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.90 - 2.16 (m, 4 H), 3.02 (br s, 2 H), 3.45 - 3.53 (m, 2 H), 3.67 (br s, 2 H), 3.86 - 3.92 (m, 2 H), 4.27 - 4.33 (m, 2 H), 7.20 - 7.34 (m, 5 H), 7.44 (ddd, J=8.34, 6.95, 1.39 Hz, 1 H), 7.56 - 7.64 (m, 1 H), 7.66 - 7.71 (m, 1 H), 7.85 (dd, J=8.34, 1.01 Hz, 1 H);ESI-MS m / z [M+H] + 333.2.

[0526] Example 2: N-(2-(azetidin-1-yl)ethyl)-3-benzyl-8-methylquinoxalin-2-amine

[0527] [ka]

[0528] and

[0529] Example 3: N-(2-(azetidin-1-yl)ethyl)-3-benzyl-5-methylquinoxalin-2-amine

[0530] [ka]

[0531] Step A: 3-benzyl-8-methylquinoxalin-2(1H)-one and 3-benzyl-5-methylquinoxalin-2(1H)-one

[0532] [ka]

[0533] A mixture of 3-methylbenzene-1,2-diamine (3 g, 24.56 mmol) and 2-oxo-3-phenylpropanoic acid (4.03 g, 24.56 mmol) in ethanol (70 mL) was refluxed overnight and then cooled to 0° C. The solid precipitate was filtered, washed with cold ethanol, and dried to give a mixture of the title compounds as an off-white solid (5.1 g, 83%), which was used without further purification.

[0534] Step B: 2-benzyl-3-chloro-5-methylquinoxaline and 3-benzyl-2-chloro-5-methylquinoxaline

[0535] [ka]

[0536] To a mixture of 3-benzyl-8-methylquinoxalin-2(1H)-one and 3-benzyl-5-methylquinoxalin-2(1H)-one (1 g, 4 mmol) was added POCl (6.13 g, 40 mmol). The resulting solution was heated at 120 °C for 3 h and then cooled to 0 °C. Cold water was added dropwise, and the gray solid precipitate was filtered, washed with water, and dried to give a mixture of the title compounds (0.2 g, 19%), which was used without further purification.

[0537] Step C: N-(2-(azetidin-1-yl)ethyl)-3-benzyl-8-methylquinoxalin-2-amine and N-(2-(azetidin-1-yl)ethyl)-3-benzyl-5-methylquinoxalin-2-amine

[0538] A 10 mL microwave vial was charged with a mixture of 2-benzyl-3-chloro-5-methylquinoxaline and 3-benzyl-2-chloro-5-methylquinoxaline (40 mg, 0.149 mmol) and 2-(azetidin-1-yl)ethanamine (0.045 g, 0.447 mmol) in DMSO (3 mL). The mixture was heated in a Biotage microwave reactor at 100° C. for 4 h, then filtered and purified by preparative HPLC (Waters SunFire C18, 5 μm, 30 mm ID×75 mm column) using a gradient of 10–35% ACN (0.035% TFA) / water (0.05% TFA) to give two regioisomers. The faster eluting regioisomer was assigned to the TFA salt of N-(2-(azetidin-1-yl)ethyl)-3-benzyl-8-methylquinoxalin-2-amine, and was obtained as a pale brown oil (11 mg, 22%). 1 H NMR (400 MHz, CD3OD) δ ppm 2.28 (dtt, J=11.87, 9.47, 9.47, 4.93, 4.93 Hz, 1 H), 2.40 - 2.54 (m, 1 H), 2.65 (s, 3 H), 3.54 (t, J=5.68 Hz, 2 H), 3.79 (t, J=5.68 Hz, 2 H), 3.91 - 4.08 (m, 4 H), 4.27 - 4.31 (m, 2 H), 7.19 - 7.36 (m, 6 H), 7.44 - 7.49 (m, 1 H), 7.67 - 7.72 (m, 1H);ESI-MS m / z [M+H] + 333.2. The later eluting regioisomer was assigned to the TFA salt of N-(2-(azetidin-1-yl)ethyl)-3-benzyl-5-methylquinoxalin-2-amine and was obtained as a light brown oil (14 mg, 28%). 1H NMR (400 MHz, CD3OD) δ ppm 2.30 - 2.58 (m, 2 H), 2.63 (s, 3 H), 3.44 - 3.51 (m, 2 H), 3.72 - 3.80 (m, 2 H), 3.96 - 4.10 (m, 2 H), 4.12 - 4.24 (m, 2 H), 4.27 (s, 2 H), 7.17 - 7.35 (m, 6 H), 7.42 - 7.49 (m, 1 H), 7.50 - 7.56 (m, 1 H);ESI-MS m / z [M+H] + 333.2.

[0539] Example 4: N-(2-(azetidin-1-yl)ethyl)-3-(3-methoxybenzyl)-8-methylquinoxalin-2-amine

[0540] [ka]

[0541] and

[0542] Example 5: N-(2-(azetidin-1-yl)ethyl)-3-(3-methoxybenzyl)-5-methylquinoxalin-2-amine

[0543] [ka]

[0544] The title compound was prepared similarly to Examples 2 and 3, except that 3-(3-methoxyphenyl)-2-oxopropanoic acid was used instead of 2-oxo-3-phenylpropanoic acid in Step A. The product was purified by preparative HPLC (Waters SunFire® C18, 5 μm, 30 mm ID × 75 mm column) using a gradient of 10 to 35% ACN (0.035% TFA) / water (0.05% TFA) to give two regioisomers. The faster-eluting regioisomer was assigned to the TFA salt of N-(2-(azetidin-1-yl)ethyl)-3-(3-methoxybenzyl)-8-methylquinoxalin-2-amine and was obtained as a light brown oil. 1 H NMR (400 MHz, CD3OD) δ ppm 2.29 (dtt, J=11.87, 9.44, 9.44, 4.83, 4.83 Hz, 1 H), 2.48 (dquin, J=11.87, 9.28, 9.28, 9.28, 9.28 Hz, 1 H), 2.65 (s, 3 H), 3.54 (t, J=5.68 Hz, 2 H), 3.72 - 3.75 (m, 3 H), 3.79 (t, J=5.68 Hz, 2 H), 3.92 - 4.10 (m, 4 H), 4.23 - 4.28 (m, 2 H), 6.76 - 6.85 (m, 3H), 7.20 (t, ESI-MS m / z [M+H] + The regioisomer eluting after 363.5 was assigned to the TFA salt of N-(2-(azetidin-1-yl)ethyl)-3-(3-methoxybenzyl)-5-methylquinoxalin-2-amine and was obtained as a light brown oil. 1H NMR (400 MHz, CD3OD) δ ppm 2.29 - 2.43 (m, 1 H), 2.45 - 2.58 (m, 1 H), 2.65 (s, 3 H), 3.45 - 3.51 (m, 2 H), 3.73 - 3.79 (m, 5 H), 4.03 (q, J=9.85 Hz, 2 H), 4.15 - 4.23 (m, 2 H), 4.25 (s, 2 H), 6.79 (dd, J=7.96, 2.15 Hz, 1 H), 6.83 - 6.90 (m, 2 H), 7.20 (t, J=7.83 Hz, 1 H), 7.26 - 7.30 (m, 1 H), 7.43 - 7.49 (m, 1 H), 7.51 - 7.56 (m, 1 H);ESI-MS m / z [M+H] + 363.5.

[0545] Example 6: N-(2-(azetidin-1-yl)ethyl)-8-methyl-3-(3-methylbenzyl)quinoxalin-2-amine

[0546] [ka]

[0547] The title compound was prepared similarly to Examples 2 and 3, using 2-oxo-3-(m-tolyl)propanoic acid instead of 2-oxo-3-phenylpropanoic acid in Step A. Purification by preparative HPLC gave a single pure isomer, which was assigned to the TFA salt of N-(2-(azetidin-1-yl)ethyl)-8-methyl-3-(3-methylbenzyl)quinoxalin-2-amine, and was obtained as a brown oil. 1H NMR (400 MHz, CD3OD) δ ppm 2.25 - 2.33 (m, 4 H), 2.42 - 2.51 (m, 1 H), 2.64 - 2.67 (m, 3 H), 3.34 (s, 2 H), 3.53 (t, J=5.68 Hz, 2 H), 3.79 (t, J=5.68 Hz, 2 H), 3.91 - 4.06 (m, 4 H), 4.25 (s, 2 H), 6.99 - 7.08 (m, 3 H), 7.14 - 7.21 (m, 1 H), 7.30 - 7.37 (m, 1 H), 7.47 (d, J=6.82 Hz, 1 H), 7.68 - 7.72 (m, 1 H).

[0548] Example 7: 8-methyl-3-(3-methylbenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-2-amine

[0549] [ka]

[0550] Step A: 3-(m-tolyl)-N-(o-tolyl)propanamide

[0551] [ka]

[0552] A mixture of 3-(m-tolyl)propanoic acid (0.589 g, 3.59 mmol), o-toluidine (0.461 g, 4.30 mmol), and DIPEA (1.867 mL, 1.391 g, 10.76 mmol) in DMF was treated with T3P (1.712 g, 5.38 mmol). The reaction mixture was stirred overnight at room temperature, then diluted with EtOAc, washed with saturated NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated. The resulting oil was purified by flash column chromatography using a gradient of 0-100% EtOAc / heptane to give the title compound as an oil (0.487 g, 53.6%). ESI-MS m / z [M+H] + 254.2.

[0553] Step B: 2-chloro-8-methyl-3-(3-methylbenzyl)quinoline

[0554] [ka]

[0555] To a 100 mL round-bottom flask containing DMF (0.447 mL) at 0 °C, POCl3 was added dropwise. 3-(m-tolyl)-N-(o-tolyl)propanamide was then added to the flask in one portion at room temperature. The resulting viscous oil was heated at 80 °C overnight. Excess POCl3 was removed on a rotary evaporator, and the product was purified by flash column chromatography using a gradient of 0-100% EtOAc / heptane to give the title compound (9 mg, 2%). ESI-MS m / z [M+H] + 282.3.

[0556] Step C: 8-methyl-3-(3-methylbenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-2-amine

[0557] To 2-chloro-8-methyl-3-(3-methylbenzyl)quinoline (9 mg, 0.032 mmol) in NMP (3 mL) was added 2-(pyrrolidin-1-yl)ethanamine (10.94 mg, 0.096 mmol). The solution was heated in a microwave reactor at 150° C. for 1 h, then filtered and purified by preparative HPLC (Waters SunFire® C18, 5 μm, 30 mm ID×75 mm column) using a gradient of 25-50% ACN (0.035% TFA) / water (0.05% TFA) to give the title compound (2 mg, 18%) as a clear film. 1 H NMR (400 MHz, CD3OD) δ ppm 1.76 - 1.83 (m, 4 H), 2.30 (s, 3 H), 2.56 - 2.63 (m, 7 H), 2.79 (t, J=6.69 Hz, 2 H), 3.34 (s, 1 H), 3.73 (t, ESI-MS m / z [M+H] + 360.3.

[0558] Example 8: (R)-(6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(pyrrolidin-1-yl)methanone

[0559] [ka]

[0560] To a solution of (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and HATU (15.91 mg, 0.042 mmol) in DMF (419 μL) was added DIPEA (14.62 μL, 0.084 mmol). The reaction mixture was stirred at room temperature for 5 minutes. Pyrrolidine (4.46 mg, 0.063 mmol) was then added. The reaction mixture was stirred at room temperature for 2 hours and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a white film (18 mg, 82%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.66 (d, J=6.88 Hz, 3 H), 1.89 - 2.01 (m, 6 H), 2.11 (br dd, J=6.42, 2.57 Hz, 2 H), 2.95 - 3.12 (m, 2 H), 3.38 - 3.47 (m, 2 H), 3.61 - 3.71 (m, 4 H), 3.72 - 3.84 (m, 2 H), 3.86 - 3.92 (m, 2 H), 4.34 (q, J=6.88 Hz, 1 H), 7.00 - 7.09 (m, 2 H), 7.24 - 7.32 (m, 2H), 8.54 (s, 1 H); ESI-MS m / z [M+H] + 412.1.

[0561] Example 9: (R)—N-cyclobutyl-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0562] [ka]

[0563] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and cyclobutanamine (4.46 mg, 0.063 mmol) and obtained as a white film (16 mg, 72.7%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.72 (d, J=6.97 Hz, 3 H), 1.80 - 1.89 (m, 2 H), 1.94 - 2.04 (m, 2 H), 2.07 - 2.21 (m, 4 H), 2.36 - 2.46 (m, 2 H), 2.95 - 3.11 (m, 2 H), 3.40 (td, J=5.89, 1.97 Hz, 2 H), 3.58 - 3.69 (m, 2 H), 3.74 - 3.89 (m, 2 H), 4.33 (q, J=6.97 Hz, 1 H), 4.53 (quin, J=8.30Hz, 1H), 7.00 - 7.12 (m, 2 H), 7.27 - 7.37 (m, 2 H), 8.62 (s, 1 H);ESI-MS m / z [M+H] + 412.1.

[0564] Example 10: (6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((S)-3-methoxypyrrolidin-1-yl)methanone

[0565] [ka]

[0566] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and (S)-3-methoxypyrrolidine (6.35 mg, 0.063 mmol) and obtained as a colorless film (5.4 mg, 23.2%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.54 (dd, J=6.88, 3.30 Hz, 3 H), 1.77 - 1.91 (m, 3 H), 1.94 - 2.10 (m, 3 H), 2.80 - 3.03 (m, 2 H), 3.18 (s, 1 H), 3.27 (s, 1 H), 3.28 - 3.36 (m, 2 H), 3.45 - 3.60 (m, 3 H), 3.62 - 3.74 (m, 3 H), 3.75 - 3.87 (m, 2 H), 3.89 - 3.99 (m, 1 H), 4.24 (dq, J=9.65, 6.93 Hz, 1 H), 6.85 - 6.98 (m, 2 H), 7.09 - 7.23 (m, 2 H), 8.43 (d, J=3.85 Hz, 1 H);ESI-MS m / z [M+H] + 442.1.

[0567] Example 11: (6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((R)-3-methoxypyrrolidin-1-yl)methanone

[0568] [ka]

[0569] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and (R)-3-methoxypyrrolidine (6.35 mg, 0.063 mmol) and obtained as a colorless film (5.8 mg, 24.9%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.67 (t, J=6.46 Hz, 3 H), 1.88 - 2.05 (m, 3 H), 2.07 - 2.23 (m, 3 H), 2.90 - 3.17 (m, 2 H), 3.38 - 3.46 (m, 3 H), 3.56 - 3.72 (m, 3 H), 3.74 - 3.91 (m, 3 H), 3.93 - 4.13 (m, 3 H), 4.30 - 4.43 (m, 1 H), 7.03 (t, J=8.76 Hz, 2 H), 7.23 - 7.31 (m, 2 H), 8.56 (d, J=3.94 Hz, 1 H);ESI-MS m / z [M+H] + 442.1.

[0570] Example 12: 6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((S)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide

[0571] [ka]

[0572] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and (S)-tetrahydrofuran-3-amine (4.74 mg, 0.054 mmol) and obtained as a white solid (5.8 mg, 25.6%). 1H NMR (400 MHz, CD3OD) δ ppm 1.69 (d, J=6.97 Hz, 3 H), 1.91 - 2.03 (m, 3 H), 2.06 - 2.19 (m, 2 H), 2.28 - 2.45 (m, 1 H), 2.87 - 3.13 (m, 2 H), 3.41 (td, J=5.75, 3.26 Hz, 2 H), 3.53 - 3.70 (m, 2 H), 3.73 - 3.90 (m, 4 H), 3.93 - 4.07 (m, 2 H), 4.33 (q, J=6.85 Hz, 1 H), 4.57 - 4.65 (m, 1 H), 7.05 (t, J=8.71 Hz, 2 H), 7.30 (dd, J=8.53, 5.41 Hz, 2 H), 8.63 (s, 1 H);ESI-MS m / z [M+H] + 428.1.

[0573] Example 13: 6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((R)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide

[0574] [ka]

[0575] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and (R)-tetrahydrofuran-3-amine (4.74 mg, 0.054 mmol) and obtained as a white film (6.3 mg, 27.8%). 1H NMR (400 MHz, CD3OD) δ ppm 1.69 (d, J=6.97 Hz, 3 H), 1.90 - 2.02 (m, 3 H), 2.11 (br d, J=2.75 Hz, 2 H), 2.36 (dq, J=13.11, 7.55 Hz, 1 H), 2.91 - 3.13 (m, 2 H), 3.41 (td, J=5.89, 3.07 Hz, 2 H), 3.57 - 3.72 (m, 2 H), 3.73 - 3.91 (m, 4 H), 3.92 - 4.04 (m, 2 H), 4.33 (q, J=6.91 Hz, 1H), 4.62 (ddt, J=7.45, 5.69, 3.75, 3.75 Hz, 1 H), 6.99 - 7.13 (m, 2 H), 7.26 - 7.35 (m, 2 H), 8.63 (s, 1 H).

[0576] Example 14: 6-((R)-1-(4-fluorophenyl)ethyl)-N-(cis-3-methoxycyclobutyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0577] [ka]

[0578] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and cis-3-methoxycyclobutan-1-amine hydrochloride (5.76 mg, 0.042 mmol) and obtained as a white film (8 mg, 34.4%). 1H NMR (400 MHz, CD3OD) δ ppm 1.72 (d, J=6.88 Hz, 3 H), 1.92 - 2.04 (m, 4 H), 2.10 (br d, J=3.03 Hz, 2 H), 2.75 - 2.86 (m, 2 H), 2.91 - 3.09 (m, 2 H), 3.30 (s, 3 H), 3.37 - 3.47 (m, 2 H), 3.55 - 3.71 (m, 2 H), 3.74 - 3.91 (m, 3 H), 4.11 - 4.22 (m, 1 H), 4.33 (q, J=6.82 Hz, 1 H), 7.00 - 7.11 (m, 2H), 7.28 - 7.37 (m, 2 H), 8.61 (s, 1 H);ESI-MS m / z [M+H] + 442.1.

[0579] Example 15: 6-((R)-1-(4-fluorophenyl)ethyl)-N-(trans-3-methoxycyclobutyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide 2,2,2-trifluoroacetate

[0580] [ka]

[0581] The TFA salt of the title compound was prepared similarly to Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and trans-3-methoxycyclobutan-1-amine hydrochloride (8.06 mg, 0.059 mmol) and obtained as a colorless film (6.8 mg, 29.2%). 1H NMR (400 MHz, CD3OD) δ ppm 1.72 (d, J=6.88 Hz, 3 H), 1.88 - 2.01 (m, 2 H), 2.04 - 2.19 (m, 2 H), 2.29 - 2.41 (m, 2 H), 2.42 - 2.52 (m, 2 H), 2.90 - 3.12 (m, 2 H), 3.30 (s, 2 H), 3.38 - 3.48 (m, 2 H), 3.51 - 3.69 (m, 2 H), 3.72 - 3.97 (m, 2 H), 4.10 (tt, J=6.76, 3.60 Hz, 1 H), 4.34 (q, J=6.88 Hz, 1 H), 4.53 - 4.68 (m, 1 H), 6.94 - 7.16 (m, 2 H), 7.26 - 7.41 (m, 2 H), 8.61 (s, 1 H);ESI-MS m / z [M+H] + 442.1.

[0582] Example 16: (R)-(6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(morpholino)methanone

[0583] [ka]

[0584] The title compound was prepared in the same manner as in Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and morpholine (5.5 mg, 0.059 mmol) and obtained as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 1.58 (d, J=6.8 Hz, 3 H), 1.71 - 1.74 (m, 4 H), 2.28 - 2.36 (m, 2 H), 2.39 - 2.51 (m, 3 H), 2.63 - 2.71 (m, 1 H), 3.26 - 3.45 (m, 2 H), 3.72 - 4.05 (m, 9 H), 5.55 (br s, 1 H), 6.92 - 7.00 (m, 2 H), 7.06 - 7.15 (m, 2 H), 8.52 (s, 1 H);ESI-MS m / z [M+H] + 428.3.

[0585] Example 17: (R)—N-cyclopropyl-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0586] [ka]

[0587] The title compound was prepared in the same manner as in Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and N-methylcyclopropanamine (4.1 mg, 0.059 mmol) and obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 0.38 - 0.74 (m, 4 H), 1.58 (br d, J=7.1 Hz, 3 H), 1.66 - 1.77 (m, 4 H), 2.23 - 2.34 (m, 2 H), 2.35 - 2.48 (m, 3 H), 2.62 - 2.73 (m, 1 H), 3.14 (br s, 3 H), 3.29 (td, J=8.4, 4.0 Hz, 2 H), 3.33 - 3.44 (m, 1 H), 3.92 - 4.04 (m, 1 H), 5.45 (br s, 1 H), 6.94 (br t, J=8.6 Hz, 2 H),7.04 - 7.17 (m, 2 H), 8.41 (br d, J=0.9 Hz, 1 H);ESI-MS m / z [M+H] + 412.1.

[0588] Example 18: (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-(tetrahydro-2H-pyran-4-yl)pyrazine-2-carboxamide

[0589] [ka]

[0590] The title compound was prepared in the same manner as in Example 8 using (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (15 mg, 0.042 mmol) and tetrahydro-2H-pyran-4-amine (6.0 mg, 0.059 mmol) and obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 1.64 (br s, 5 H), 1.68 - 1.76 (m, 4 H), 1.95 - 2.07 (m, 2 H), 2.24 - 2.33 (m, 2 H), 2.36 - 2.47 (m, 3 H), 2.64 (ddd, J=12.2, 7.8, 4.7 Hz, 1 H), 3.22 - 3.44 (m, 2 H), 3.50 - 3.63 (m, 2 H), 3.99 (br d, J=7.3 Hz, 3 H), 4.12 - 4.26 (m, 1 H), 5.59 (br s, 1 H), 6.90 - 7.01 (m, 2 H), 7.04 - 7.17 (m, 2 H), 7.53 (br d, J=7.9 Hz, 1 H), 8.74 (s, 1 H);ESI-MS m / z [M+H] + 442.2.

[0591] Example 19: 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0592] [ka]

[0593] The TFA salt of the title compound was prepared as a white solid similar to Example 8 using 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (30 mg, 0.065 mmol) and ammonium hydroxide (3.81 μL, 0.098 mmol). 1H NMR (500 MHz, CD3OD) δ ppm 1.69 (d, J=6.83 Hz, 3 H), 1.86 - 1.99 (m, 2 H), 2.08 (tq, J=7.83, 4.06 Hz, 2 H), 2.87 - 2.96 (m, 1 H), 2.98 - 3.09 (m, 1 H), 3.34 - 3.45 (m, 2 H), 3.53 - 3.67 (m, 2 H), 3.71 - 3.88 (m, 2 H), 4.29 (q, J=6.83 Hz, 1 H), 6.94 - 7.06 (m, 2 H), 7.24 - 7.37 (m, 2 H), 8.64 (s, 1 H); ESI-MS m / z [M+H] + 358.1.

[0594] Example 20: (S)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0595] [ka]

[0596] and

[0597] Example 21: (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0598] [ka]

[0599] Racemic 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide 2,2,2-trifluoroacetate (21 mg) was resolved into two enantiomers by chiral SFC separation (AD-H column, 25% MeOH + 20 mM NH4OH). The faster-eluting enantiomer was (S)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (8.0 mg, 40%). 1 H NMR (500 MHz, CD3OD) δ ppm 1.66 (d, J=6.83 Hz, 3 H), 1.76 (br t, J=6.22 Hz, 4 H), 2.40 - 2.50 (m, 4 H), 2.56 (dt, J=12.33, 6.28 Hz, 1 H), 2.62 - 2.74 (m, 1 H), 3.54 (td, J=6.47, 1.46 Hz, 2 H), 4.26 (q, J=6.83 Hz, 1 H), 6.94 - 7.07 (m, 2 H), 7.20 - 7.31 (m, 2 H), 8.58 (s, 1 H);ESI-MS m / z [M+H] + 358.1. The later eluting enantiomer was (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (3.2 mg, 16%). 1 H NMR (500 MHz, CD3OD) δ ppm 1.66 (d, J=6.83 Hz, 3 H), 1.77 (br t, J=6.10 Hz, 4 H), 2.41 - 2.50 (m, 4 H), 2.53 - 2.60 (m, 1 H), 2.67 (dt, J=12.45, 6.47 Hz, 1 H), 3.54 (td, J=6.47, 1.22 Hz, 2 H), 4.26 (q, J=6.75 Hz, 1 H), 6.90 - 7.06 (m, 2 H), 7.20 - 7.30 (m, 2 H), 8.58 (s, 1H);ESI-MS m / z [M+H] + 358.1.

[0600] Example 22: 6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0601] [ka]

[0602] The title compound was prepared similarly to Example 8 using 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (30 mg, 0.065 mmol) and methanamine (12.19 μL, 0.098 mmol). The product was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10-50% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a white solid (19 mg, 59.9%). 1 H NMR (500 MHz, CD3OD) δ ppm 1.70 (d, J=6.83 Hz, 3 H), 1.85 - 1.98 (m, 2 H), 2.00 - 2.15 (m, 2 H), 2.86 - 2.96 (m, 1 H), 2.97 - 3.10 (m, 4 H), 3.34 - 3.47 (m, 2 H), 3.52 - 3.68 (m, 2 H), 3.69 - 3.87 (m, 2 H), 4.28 (q, J=6.83 Hz, 1 H), 6.97 - 7.05 (m, 2 H), 7.24 - 7.34 (m, 2 H), 8.61 (s, 1 H);ESI-MS m / z [M+H] + 372.1.

[0603] Example 23: (S)-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0604] [ka]

[0605] and

[0606] Example 24: (R)-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0607] [ka]

[0608] Racemic 6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide 2,2,2-trifluoroacetate (19 mg) was resolved into two enantiomers by chiral SFC separation (AD-H column, 17% MeOH + 20 mM NH4OH). The faster-eluting enantiomer was (S)-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (5.1 mg, 26.8%). 1 H NMR (500 MHz, CD3OD) δ ppm 1.67 (d, J=6.83 Hz, 3 H), 1.74 - 1.81 (m, 4 H), 2.40 - 2.49 (m, 4 H), 2.54 (dt, J=12.14, 6.25 Hz, 1 H), 2.63 - 2.74 (m, 1 H), 2.97 (s, 3 H), 3.49 - 3.56 (m, 2 H), 4.25 (q, J=6.83 Hz, 1 H), 6.96 - 7.06 (m, 2 H), 7.24 - 7.31 (m, 2 H), 8.55 (s, 1 H);ESI-MS m / z [M+H] +The enantiomer eluting later than 372.1 was (R)-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (3.7 mg, 19.5%). 1 H NMR (500 MHz, CD3OD) δ ppm 1.66 (d, J=6.83 Hz, 3 H), 1.77 (br t, J=6.10 Hz, 4 H), 2.42 - 2.50 (m, 4 H), 2.55 (dt, J=12.26, 6.19 Hz, 1 H), 2.67 (dt, J=12.45, 6.47 Hz, 1 H), 3.54 (td, J=6.47, 1.22 Hz, 2 H), 4.26 (q, J=6.75 Hz, 1 H), 7.01 (t, J=8.66 Hz, 2 H), 7.20 - 7.30 (m, 2H), 8.58 (s, 1H);ESI-MS m / z [M+H] + 372.1.

[0609] Example 25: 6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0610] [ka]

[0611] The title compound was prepared similarly to Example 8 using 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (30 mg, 0.065 mmol) and dimethylamine (32.6 μL, 0.065 mmol). The product was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10-50% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a white solid (19 mg, 58.3%). 1H NMR (500 MHz, CD3OD) δ ppm 1.63 (d, J=6.83 Hz, 3 H), 1.89 - 2.00 (m, 2 H), 2.03 - 2.14 (m, 2 H), 2.88 - 2.98 (m, 1 H), 3.00 - 3.06 (m, 1 H), 3.12 (s, 3 H), 3.23 (s, 3 H), 3.36 - 3.43 (m, 2 H), 3.56 - 3.69 (m, 2 H), 3.70 - 3.86 (m, 2 H), 4.30 (q, J=6.83 Hz, 1 H), 6.93 - 7.05 (m, 2 H), 7.18 - 7.31 (m, 2 H), 8.34 (s, 1 H);ESI-MS m / z [M+H] + 386.1.

[0612] Example 26: (S)-6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0613] [ka]

[0614] and

[0615] Example 27: (R)-6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0616] [ka]

[0617] Racemic 6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (19 mg NHOH hydroxide) gave two enantiomers. The faster eluting enantiomer was ((S)-6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (3.8 mg, 20%). 1 H NMR (500 MHz, CD3OD) δ ppm 1.61 (d, J=6.83 Hz, 3 H), 1.59 - 1.63 (m, 1 H), 1.77 (br t, J=6.22 Hz, 4 H), 2.45 - 2.53 (m, 4 H), 2.56 - 2.63 (m, 1 H), 2.70 (dt, J=12.26, 6.44 Hz, 1 H), 3.11 (s, 3 H), 3.25 (s, 3 H), 3.53 (td, J=6.53, 2.32 Hz, 2 H), 4.27 (q, J=6.83 Hz, 1 H), 7.00 (t, J=8.66 Hz, 2 H), 7.21 - 7.29 (m, 2 H), 8.30 (s, 1 H);ESI-MS m / z [M+H] + 386.1. The later eluting enantiomer was (R)-6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide (3.5 mg, 18%). 1H NMR (500 MHz, CD3OD) δ ppm 1.61 (d, J=7.08 Hz, 4 H), 1.77 (br t, J=6.22 Hz, 4 H), 2.43 - 2.52 (m, 4 H), 2.57 (dt, J=12.33, 6.28 Hz, 1 H), 2.64 - 2.72 (m, 1 H), 3.11 (s, 4 H), 3.26 (s, 3 H), 3.53 (td, J=6.53, 2.07 Hz, 2 H), 4.27 (q, J=6.83 Hz, 1 H), 6.96 - 7.05 (m, 2 H), 7.18 - 7.28 (m, 2 H), 8.30 (s, 1 H); ESI-MS m / z [M+H] + 386.1.

[0618] Example 28: 5-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0619] [ka]

[0620] The title compound was prepared in the same manner as in Example 8 using 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylic acid (80 mg, 287.08 μmol) and N-methylmethanamine hydrogen chloride (52.61 μL, 46.82 mg, 574.16 μmol) and obtained as a pale yellow oil (15.1 mg, 74.5%). 1H NMR (400 MHz, CD3OD) δ ppm 1.63 (d, J=7.03 Hz, 3 H), 1.80 (br s, 4 H), 2.52 (br s, 4 H), 2.70 (br d, J=5.77 Hz, 2 H), 3.12 (d, J=2.51 Hz, 6 H), 3.45 - 3.56 (m, 2 H), 4.29 (d, J=6.78 Hz, 1 H), 7.02 (t, J=8.78 Hz, 2 H), 7.27 (dd, J=8.53, 5.52 Hz, 2 H), 7.98 (s, 1 H);ESI-MS m / z [M+H] + 386.2.

[0621] Example 29: (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate methyl

[0622] [ka]

[0623] To a solution of (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (51 mg, 0.142 mmol) in MeOH (2 mL) at 0 °C was added thionyl chloride (0.031 mL, 0.427 mmol) dropwise. The reaction mixture was allowed to warm to room temperature and then stirred for 8 h. The solvent was removed in vacuo, and the residue was redissolved in EtOAc (10 mL), washed with saturated aqueous NaHCO3 and brine, and purified by silica gel column chromatography (NH column) using a gradient of 10-80% EtOAc / heptane to give the title compound as a colorless oil (33 mg, 62.3%). ESI-MS m / z [M+H] + 373.3.

[0624] Example 30: 6-((R)-1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide

[0625] [ka]

[0626] and

[0627] Example 31: 6-((S)-1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide

[0628] [ka]

[0629] To a solution of 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylic acid (45 mg, 0.076 mmol) in DMF (379 μL) was added HATU (28.8 mg, 0.076 mmol) and DIPEA (39.7 μL, 0.227 mmol). The solution was stirred at room temperature for 5 minutes. Ammonium hydroxide (8.85 μL, 0.227 mmol) was then added. The reaction mixture was stirred at room temperature for 4 hours and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA). Each of the title compounds (diastereoisomers) was obtained as the TFA salt, and the stereochemical configuration was assigned accordingly. Example 30 (7.7 mg, 30%): 1H NMR (400 MHz, CD3OD) δ ppm 1.69 (br d, J=6.60 Hz, 3 H), 2.04 - 2.21 (m, 1 H), 2.42 - 2.65 (m, 1 H), 2.77 (br s, 1 H), 2.97 (br s, 3 H), 3.10 - 3.28 (m, 1 H), 3.38 - 3.49 (m, 1 H), 3.58 - 3.78 (m, 1 H), 3.82 - 4.02 (m, 1 H), 4.33 - 4.50 (m, 1 H), 4.62 - 4.73 (m, 1 H), 7.03 (br t, J=7.70 Hz, 2 H), 7.31 (dd, J=8.34, 5.50 Hz, 2 H), 8.67 (s, 1 H), 8.72 (s, 1 H);ESI-MS m / z [M+H] + 344.1. Example 31 (12 mg, 38%): 1 H NMR (400 MHz, CD3OD) δ ppm 1.69 (br d, J=6.88 Hz, 3 H), 2.07 - 2.22 (m, 1 H), 2.27 - 2.63 (m, 1 H), 2.29 - 2.45 (m, 1 H), 2.49 - 2.49 (m, 1 H), 2.98 (s, 3 H), 3.06 - 3.23 (m, 1 H), 3.39 (br dd, J=11.37, 9.08 Hz, 1 H), 3.62 - 3.78 (m, 1 H), 3.82 - 4.18 (m, 1 H), 4.28 - 4.52 (m, 1 H), 4.62 - 4.74 (m, 1 H), 7.03 (br t, J=8.67 Hz, 2 H), 7.31 (dd, J=8.53, 5.41 Hz, 2 H), 8.66 (s, 1 H);ESI-MS m / z [M+H] + 344.1.

[0630] Example 32: 6-((S)-1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide

[0631] [ka]

[0632] Example 33: 6-((R)-1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide

[0633] [ka]

[0634] To a solution of 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylic acid (45 mg, 0.076 mmol) in DMF (379 μL) was added HATU (28.8 mg, 0.076 mmol) and DIPEA (39.7 μL, 0.227 mmol). The solution was stirred at room temperature for 5 minutes. Dimethylamine (76 μL, 0.152 mmol) was then added. The reaction mixture was stirred at room temperature for 4 hours and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA). Each of the title compounds (diastereoisomers) was obtained as the TFA salt, and the stereochemical configuration was assigned accordingly. Example 32 (5.0 mg, 10%): 1H NMR (400 MHz, CD3OD) δ ppm 1.64 (br d, J=6.88 Hz, 3 H), 2.09 - 2.27 (m, 1 H), 2.34 - 2.62 (m, 1 H), 2.98 (s, 3 H), 3.13 (s, 4 H), 3.22 (s, 3 H), 3.39 (br dd, J=11.60, 8.57 Hz, 1 H), 3.68 (br d, J=11.28 Hz, 1 H), 3.86 - 4.18 (m, 1 H), 4.30 - 4.48 (m, 1 H), 4.61 - 4.70 (m, 1 H), 7.02 (br t, J=8.57 Hz, 2 H), 7.24 - 7.33 (m, 2 H), 8.31 - 8.40 (m, 1 H);ESI-MS m / z [M+H] + 372.1. Example 33 (5.7 mg, 12%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.64 (br d, J=6.60 Hz, 3 H), 2.09 - 2.38 (m, 1 H), 2.43 - 2.61 (m, 1 H), 2.97 (s, 3 H), 3.14 (s, 4 H), 3.22 (br s, 3 H), 3.40 - 3.50 (m, 1 H), 3.63 - 3.79 (m, 1 H), 3.81 - 4.03 (m, 1 H), 4.34 - 4.51 (m, 1 H), 4.59 - 4.70 (m, 1 H), 6.96 - 7.11 (m, 2 H), 7.23 - 7.32 (m, 2 H), 8.37 (s, 1H); ESI-MS m / z [M+H] + 372.1.

[0635] Example 34: 6-((S)-1-(4-fluorophenyl)ethyl)-N-methyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide

[0636] [ka]

[0637] Example 35: 6-((R)-1-(4-fluorophenyl)ethyl)-N-methyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide

[0638] [ka]

[0639] To a solution of 6-(1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxylic acid (45 mg, 0.076 mmol) in DMF (0.38 mL) was added HATU (28.8 mg, 0.076 mmol) and DIPEA (39.7 μL, 0.227 mmol). The solution was stirred at room temperature for 5 minutes. Methanamine (7.06 mg, 0.227 mmol) was then added. The reaction mixture was stirred at room temperature for 4 hours and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA). Each of the title compounds (diastereoisomers) was obtained as the TFA salt, and the stereochemical configuration was assigned accordingly. Example 34 (4 mg, 9%): 1 H NMR (400 MHz, CD3OD) δ ppm 1.71 (br d, J=6.79 Hz, 3 H), 2.06 - 2.23 (m, 1 H), 2.43 - 2.64 (m, 1 H), 3.07 - 3.21 (m, 1 H), 3.62 - 3.79 (m, 1 H), 3.83 - 4.16 (m, 1 H), 4.29 - 4.50 (m, 1 H), 4.59 - 4.73 (m, 1 H), 7.02 (br t, J=8.62 Hz, 2 H), 7.31 (dd, J=8.53, 5.50 Hz, 2 H), 8.54 - 8.69 (m, 1 H);ESI-MS m / z [M+H] + 358.1. Example 35 (4 mg, 9%): 1H NMR (400 MHz, CD3OD) δ ppm 1.71 (br d, J=6.60 Hz, 3 H), 2.07 - 2.20 (m, 1 H), 2.41 - 2.58 (m, 1 H), 2.92 - 3.04 (m, 6 H), 3.11 - 3.25 (m, 1 H), 3.38 - 3.49 (m, 1 H), 3.59 - 3.78 (m, 1 H), 3.80 - 4.01 (m, 1 H), 4.28 - 4.49 (m, 1 H), 4.58 - 4.70 (m, 1 H), 6.94 - 7.10 (m, 2 H), 7.31 (dd, J=8.39, 5.55 Hz, 2 H), 8.57 - 8.70 (m, 1 H).ESI-MS m / z [M+H] + 358.1.

[0640] Example 36: 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N-methylpyrazine-2-carboxamide

[0641] [ka]

[0642] Step A: Methyl 5-((trans-1-(tert-butoxycarbonyl)-3-ethylpiperidin-4-yl)amino)-6-chloropyrazine-2-carboxylate

[0643] [ka]

[0644] To a solution of methyl 5,6-dichloropyrazine-2-carboxylate (127 mg, 0.613 mmol) in dioxane (6.1 mL) was added DIPEA (321 μL, 1.839 mmol) and tert-butyl trans-4-amino-3-ethylpiperidine-1-carboxylate (200 mg, 0.613 mmol). The solution was stirred overnight at room temperature and then concentrated. The resulting residue was purified by silica gel column chromatography using a gradient of hexane / EtOAc (4:1 to 1:1) to give the title compound (0.120 g, 49.1%). ESI-MS m / z [M+H] + 399.3.

[0645] Step B: Methyl 5-((trans-1-(tert-butoxycarbonyl)-3-ethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylate

[0646] [ka]

[0647] A mixture of methyl 5-((trans-1-(tert-butoxycarbonyl)-3-ethylpiperidin-4-yl)amino)-6-chloropyrazine-2-carboxylate (120 mg, 0.301 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (128 mg, 0.542 mmol), Pd(dppf)Cl (22.01 mg, 0.030 mmol), and NaCO (334 μL, 0.602 mmol) in dioxane (3.0 mL) was degassed with nitrogen and then heated in a sealed tube at 110° C. for 16 h. The mixture was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10-50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound (77 mg, 43.6%). ESI-MS m / z [M+H] + 473.3.

[0648] Step C: Methyl 5-((trans-3-ethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylate

[0649] [ka]

[0650] To a 75 mL round-bottom flask was added methyl 5-((trans-1-(tert-butoxycarbonyl)-3-ethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylate 2,2,2-trifluoroacetate (77 mg, 0.131 mmol), hydrogen chloride (0.131 mL, 0.525 mmol), and dioxane (3 mL). The resulting colorless solution was stirred at 50° C. for 1 h and then concentrated under reduced pressure to give the title compound as a solid, which was used without further purification. ESI-MS m / z [M+H] + 373.4.

[0651] Step D: Methyl 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylate

[0652] [ka]

[0653] To a 50 mL round-bottom flask was added methyl 5-((trans-3-ethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylate (0.049 g, 0.131 mmol), formaldehyde (0.020 mL, 0.259 mmol), and methanol (3 mL) to give a colorless solution. Sodium cyanotrihydroborate (8.23 mg, 0.131 mmol) was then added. The reaction mixture was stirred at room temperature overnight, then treated with water and extracted with EtOAc. The organic layer was dried over anhydrous MgSO4 and concentrated to give the title compound, which was used without further purification. ESI-MS m / z [M+H] + 387.4.

[0654] Step E: 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylic acid

[0655] [ka]

[0656] To a 125 mL pear-bottomed flask was added methyl 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylate (0.051 g, 0.131 mmol), lithium hydroxide (0.262 mL, 0.524 mmol), and dioxane (3 mL). The resulting colorless solution was stirred at room temperature overnight and then concentrated to dryness to give the title compound, which was used without further purification. ESI-MS m / z [M+H] + 373.4.

[0657] Step F: 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N-methylpyrazine-2-carboxamide

[0658] To an 8 mL vial was added 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)pyrazine-2-carboxylic acid (16.02 mg, 0.043 mmol), methanamine (0.043 mL, 0.086 mmol), HATU (16.35 mg, 0.043 mmol), DIPEA (0.022 mL, 0.129 mmol), and DMF (2 mL). The resulting yellow solution was stirred overnight at room temperature and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 40–90% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (7.6 mg, 45.8%). 1 H NMR (400 MHz, CD3OD) δ ppm 0.66 - 0.78 (m, 3 H), 0.80 - 0.93 (m, 1 H), 1.10 - 1.24 (m, 1 H), 1.43 - 1.59 (m, 2 H), 1.76 (s, 2 H), 1.87 - 1.97 (m, 1 H), 2.05 - 2.14 (m, 1 H), 2.28 (s, 3 H), 2.77 - 2.88 (m, 1 H), 2.92 (s, 3 H), 3.67 - 3.84 (m, 1 H), 4.11 - 4.17 (m, 2 H), 6.97 - 7.14 (m, 2H), 7.21 - 7.33 (m, 2 H), 8.46 - 8.65 (m, 1 H);ESI-MS m / z [M+H] + 386.4.

[0659] Example 37: 5-(1-(4-fluorophenyl)ethyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0660] [ka]

[0661] Step A: 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxamide

[0662] [ka]

[0663] A mixture of 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylic acid (100 mg, 358.85 μmol), NH4Cl (38.39 mg, 717.71 μmol, 25.09 μL), HATU (204.67 mg, 538.28 μmol), and DIPEA (185.51 mg, 1.44 mmol, 250.02 μL) in DMF (2 mL) was stirred at 30 °C for 16 h. The mixture was then diluted with water (10 mL × 2) and extracted with EtOAc (15 mL × 2). The organic layer was separated, washed with saturated aqueous NaCl (20 mL × 2), dried, filtered, and concentrated under reduced pressure. The product was purified by preparative TLC (SiO2) using petroleum ether / EtOAc (1:1) to give the title compound (130 mg) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ ppm 5.68 (s, 2 H), 5.99 (s, 1 H), 6.99 - 7.08 (m, 2 H), 7.17 - 7.23 (m, 2 H), 7.40 - 7.52 (m, 1 H), 9.35 (s, 1 H).

[0664] Step B: 6-chloro-5-(1-(4-fluorophenyl)ethyl)pyrazine-2-carboxamide

[0665] [ka]

[0666] To a solution of 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxamide (130 mg, 468.16 μmol) in EtOH (10 mL) was added Raney nickel (46.45 mg). The suspension was degassed under vacuum, purged with H2 (3x), and stirred under H2 (15 psi) at 50 °C for 16 h. The mixture was then diluted with EtOH (5 mL) and filtered through a pad of Celite®. The filtrate was concentrated under reduced pressure to give the title compound as a yellow solid (100 mg). ESI-MS m / z [M+H] + 280.1.

[0667] Step C: 5-(1-(4-fluorophenyl)ethyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0668] To a solution of 6-chloro-5-(1-(4-fluorophenyl)ethyl)pyrazine-2-carboxamide (100 mg, 357.53 μmol) in DMSO (1.5 mL) was added 2-pyrrolidin-1-ylethanamine (262.51 mg, 2.30 mmol) and DIPEA (262.54 mg, 2.03 mmol, 353.8 μL). The mixture was stirred at 80° C. for 16 h and then purified by preparative HPLC (Phenomenex Gemini® C18, 10 μm, 25 mm ID×150 mm) using a gradient of 15–45% ACN / water (0.05% HCl) to afford the HCl salt of the title compound as a pale yellow solid (28.6 mg, 19.9%). 1H NMR (400 MHz, CD3OD) δ ppm 1.66 (d, J=6.8 Hz, 3 H), 2.03 (br d, J=5.6 Hz, 4 H), 2.83 - 3.04 (m, 2 H), 3.38 (br d, J=4.6 Hz, 2 H), 3.53 - 3.68 ESI-MS m / z [M+H] + 358.2.

[0669] Example 38: 5-(1-(4-fluorophenyl)ethyl)-N-methyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0670] [ka]

[0671] The HCl salt of the title compound was prepared similarly to Example 37 starting from 6-chloro-5-(1-(4-fluorophenyl)vinyl)pyrazine-2-carboxylic acid (100 mg, 358.85 μmol) and MeNHHCl (48.46 mg, 717.71 μmol) and obtained as a pale yellow solid (25.2 mg, 51.8%, final step). 1H NMR (400 MHz, CD3OD) δ ppm 1.64 (d, J=6.85 Hz, 3 H), 1.92 - 2.08 (m, 4 H), 2.95 (s, 5 H), 3.35 (q, J=5.54 Hz, 2 H), 3.59 (br dd, J=9.54, 4.16 Hz, 2 H), 3.85 (dt, J=10.52, 5.26 Hz, 2 H), 4.43 (d, J=6.85 Hz, 1 H), 7.00 (t, J=8.68 Hz, 2 H), 7.28 (dd, J=8.56, 5.38 Hz, 2 H), 8.44 (s, 1H);ESI-MS m / z [M+H] + 372.3.

[0672] Example 39: N,N,3-trimethyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0673] [ka]

[0674] To a solution of 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (33 mg, 0.065 mmol) and HATU (24.78 mg, 0.065 mmol) in DMF (0.65 mL) was added DIPEA (39.8 μL, 0.228 mmol). The solution was stirred at room temperature for 5 minutes. Dimethylamine (65.2 μL, 0.130 mmol) was then added, and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture was then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a colorless oil (16 mg, 49.5%). 1H NMR (400 MHz, CD3OD) δ ppm 1.90 - 1.99 (m, 2 H), 2.05 - 2.14 (m, 2 H), 2.27 (s, 3 H), 2.35 (s, 3 H), 2.91 (s, 3 H), 2.98 - 3.06 (m, 2 H), 3.11 (s, 3 H), 3.41 (t, J=5.86 Hz, 2 H), 3.61 - 3.68 (m, 2 H), 3.78 (t, J=5.86 Hz, 2 H), 4.02 (s, 2 H), 6.98 - 7.06 (m, 3 H), 7.12 - 7.18 (m, 1 H);ESI-MS m / z [M+H] + 382.1.

[0675] Example 40: N,3-Dimethyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0676] [ka]

[0677] The TFA salt of the title compound was prepared similarly to Example 39 using 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (33 mg, 0.093 mmol) and methanamine (17.5 mg, 0.186 mmol) and obtained as a colorless oil (14 mg, 31%). 1H NMR (400 MHz, CD3OD) δ ppm 1.94 (dd, J=7.08, 5.13 Hz, 2 H), 2.03 - 2.13 (m, 2 H), 2.29 (s, 3 H), 2.73 (s, 3 H), 2.87 (s, 3 H), 2.95 - 3.03 (m, 2 H), 3.41 (t, J=5.61 Hz, 2 H), 3.59 - 3.68 (m, 2 H), 3.81 (t, J=5.61 Hz, 2 H), 4.06 (s, 2 H), 6.97 - 7.09 (m, 3 H), 7.13 - 7.20 (m, 1H);ESI-MS m / z [M+H] + 368.1.

[0678] Example 41: 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0679] [ka]

[0680] The TFA salt of the title compound was prepared similarly to Example 39 using 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (33 mg, 0.093 mmol) and ammonium hydroxide (5.08 μL, 0.130 mmol) and obtained as a white solid (19 mg, 62%). 1H NMR (400 MHz, CD3OD) δ ppm 1.95 (dd, J=7.57, 5.13 Hz, 2 H), 2.05 - 2.19 (m, 2 H), 2.29 (s, 3 H), 2.72 (s, 3 H), 2.97 - 3.08 (m, 2 H), 3.43 ESI-MS m / z [M+H] + 354.1.

[0681] Example 42: 6-(4-Fluorobenzyl)-N,N,3-trimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0682] [ka]

[0683] To a solution of 6-(4-fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (33 mg, 0.074 mmol, 80% pure standard) and HATU (28.0 mg, 0.074 mmol) in DMF (0.74 mL) was added DIPEA (32.2 μL, 0.184 mmol). The solution was stirred at room temperature for 5 minutes. Dimethylamine (73.7 μL, 0.147 mmol) was then added. The resulting solution was stirred for 3 h and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a colorless oil (17 mg, 46.2%). 1H NMR (400 MHz, CD3OD) δ ppm 1.89 - 2.02 (m, 2 H), 2.14 (t, J=7.32 Hz, 2 H), 2.35 (s, 3 H), 2.88 (s, 3 H), 3.00 - 3.15 (m, 5 H), 3.43 (t, ESI-MS m / z [M+H] + 386.3.

[0684] Example 43: 6-(4-Fluorobenzyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0685] [ka]

[0686] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(4-fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (33 mg, 0.074 mmol, 80% pure standard) and methanamine (13.9 μL, 0.147 mmol) and obtained as a white film (21 mg, 58.7%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.87 - 2.05 (m, 2 H), 2.08 - 2.21 (m, 2 H), 2.73 (s, 3 H), 2.87 (s, 3 H), 3.01 - 3.13 (m, 2 H), 3.42 (t, J=5.86 ESI-MS m / z [M+H]+ 372.2.

[0687] Example 44: 6-(4-Fluorobenzyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0688] [ka]

[0689] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(4-fluorobenzyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (30 mg, 0.074 mmol, 80% pure standard) and ammonium hydroxide (5.2 μL, 0.134 mmol) and obtained as a white film (11 mg, 32%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.91 - 2.03 (m, 2 H), 2.07 - 2.20 (m, 2 H), 2.72 (s, 3 H), 3.03 - 3.17 (m, 3 H), 3.44 (t, J=5.61 Hz, 2 H), 3.72 (d, J=5.37 Hz, 2 H), 3.84 (t, J=5.86 Hz, 2 H), 4.05 (s, 2 H), 6.98 - 7.08 (m, 2 H), 7.15 - 7.34 (m, 2 H).

[0690] Example 45: 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxamide

[0691] [ka]

[0692] The TFA salt of the title compound was prepared similarly to Example 42 using 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylic acid (20 mg, 0.032 mmol) and ammonium hydroxide (2.5 μL, 0.064 mmol) and obtained as a pale green solid (10 mg, 63.9%). 1 H NMR (400 MHz, CD3OD) δ ppm 0.81 (d, J=6.59 Hz, 3 H), 1.71 - 1.83 (m, 1 H), 2.02 - 2.15 (m, 1 H), 2.19 - 2.26 (m, 1 H), 2.68 (s, 3H), 2.84 - 2.94 (m, 4 H), 3.16 (td, J=13.12, 2.81 Hz, 1 H), 3.46 - 3.58 (m, 2 H), 4.04 - 4.17 (m, 3 H), 7.02 (t, J=8.66 Hz, 2 H), 7.24 (dd, J=8.30, 5.61Hz, 2H);ESI-MS m / z [M+H] + 373.1.

[0693] Example 46: 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N,3-dimethylpyrazine-2-carboxamide

[0694] [ka]

[0695] The TFA salt of the title compound was prepared similarly to Example 42 using 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylic acid (20 mg, 0.032 mmol) and methanamine (8.0 μL, 0.064 mmol) and obtained as a white solid (8 mg, 49.7%). 1H NMR (400 MHz, CD3OD) δ ppm 0.78 (d, J=6.59 Hz, 3 H), 1.67 - 1.81 (m, 1 H), 2.00 - 2.13 (m, 1 H), 2.17 - 2.26 (m, 1 H), 2.68 (s, 3H), 2.87 (d, J=2.93 Hz, 7 H), 3.15 (td, J=13.06, 2.93 Hz, 1 H), 3.43 - 3.57 (m, 2 H), 4.04 - 4.16 (m, 3 H), 7.01 (t, J=8.66 Hz, 2 H), 7.23 (dd, J=8.30, 5.61 Hz, 2 H);ESI-MS m / z [M+H] + 386.2.

[0696] Example 47: 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N,N,3-trimethylpyrazine-2-carboxamide

[0697] [ka]

[0698] The TFA salt of the title compound was prepared similarly to Example 42 using 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxylic acid (20 mg, 0.032 mmol) and dimethylamine (32.0 μL, 0.064 mmol) and obtained as a white solid (6 mg, 36.3%). 1H NMR (400 MHz, CD3OD) δ ppm 0.79 (d, J=6.59 Hz, 3 H), 1.67 - 1.78 (m, 1 H), 1.99 - 2.10 (m, 1 H), 2.23 (br dd, J=14.28, 2.81 Hz, 1H), 2.31 (s, 3 H), 2.89 (d, J=18.31 Hz, 7 H), 3.07 - 3.19 (m, 4 H), 3.45 - 3.56 (m, 2 H), 3.99 - 4.12 (m, 3 H), 7.00 (t, J=8.42 Hz, 2 H), 7.21 (dd, J=8.18, 5.74 Hz, 2 H);ESI-MS m / z [M+H] + 400.2.

[0699] Example 48: 6-(1-(4-fluorophenyl)ethyl)-N,N,3-trimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0700] [ka]

[0701] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.056 mmol) and dimethylamine (41.8 μL, 0.084 mmol) and obtained as a white solid (24 mg, 84%). 1H NMR (400 MHz, CD3OD) δ ppm 1.60 (d, J=6.83 Hz, 3 H), 1.89 - 2.01 (m, 2 H), 2.06 - 2.17 (m, 2 H), 2.36 (s, 3 H), 2.94 - 3.00 (m, 4 H), 3.01 - 3.09 (m, 1 H), 3.14 (s, 3 H), 3.36 - 3.41 (m, 2 H), 3.58 - 3.70 (m, 2 H), 3.71 - 3.81 (m, 2 H), 4.25 (q, J=6.83 Hz, 1 H), 6.96 - 7.03 (m, 2 H), 7.23 - 7.30 (m, 2 H); ESI-MS m / z [M+H] + 400.1.

[0702] Example 49: 6-(1-(4-fluorophenyl)ethyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0703] [ka]

[0704] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.056 mmol) and methanamine (9.3 μL, 0.084 mmol) and obtained as a white film (18 mg, 64.7%). 1H NMR (400 MHz, CD3OD) δ ppm 1.67 (d, J=6.83 Hz, 3 H), 1.90 - 2.01 (m, 2 H), 2.05 - 2.15 (m, 2 H), 2.73 (s, 3 H), 2.90 - 2.97 (m, 4 H), 3.00 - 3.11 (m, 1 H), 3.34 - 3.43 (m, 2 H), 3.56 - 3.69 (m, 2 H), 3.71 - 3.85 (m, 2 H), 4.24 (q, J=6.83 Hz, 1 H), 6.93 - 7.05 (m, 2 H), 7.21 - 7.34 (m, 2 H);ESI-MS m / z [M+H] + 386.1.

[0705] Example 50: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0706] [ka]

[0707] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.056 mmol) and ammonium hydroxide (4.3 μL, 0.111 mmol) and obtained as a white solid (16 mg, 59.2%). 1H NMR (400 MHz, CD3OD) δ ppm 1.66 (d, J=6.83 Hz, 3 H), 1.90 - 2.02 (m, 2 H), 2.04 - 2.16 (m, 2 H), 2.73 (s, 3 H), 2.92 - 2.99 (m, 1 H), 3.01 - 3.10 (m, 1 H), 3.38 (td, J=5.80, 3.05 Hz, 2 H), 3.58 - 3.70 (m, 2 H), 3.71 - 3.86 (m, 2 H), 4.25 (q, J=6.83 Hz, 1 H), 6.97 - 7.05 (m, 2 H), 7.22 - 7.31 (m, 2 H; ESI-MS m / z [M+H] + 372.10.

[0708] Example 51: N-(2-fluoroethyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0709] [ka]

[0710] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (12.5 mg, 0.028 mmol) and 2-fluoroethan-1-amine hydrogen chloride (5.6 mg, 0.056 mmol) and obtained as a colorless oil (5 mg, 33.8%). 1H NMR (400 MHz, CD3OD) δ ppm 1.66 (d, J=6.83 Hz, 3 H), 1.90 - 1.99 (m, 2 H), 2.02 - 2.13 (m, 2 H), 2.73 (s, 3 H), 2.90 - 2.98 (m, 1H), 3.00 - 3.09 (m, 1 H), 3.36 - 3.43 (m, 2 H), 3.57 - 3.63 (m, 1 H), 3.63 - 3.69 (m, 2 H), 3.70 - 3.73 (m, 1 H), 3.76 - 3.85 (m, 2 H), 4.26 (q, J=6.83Hz, 1H), 4.51 (t, J=5.13 ESI-MS m / z [M+H] + 418.0.

[0711] Example 52: 6-(1-(4-fluorophenyl)ethyl)-N-(2-methoxyethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0712] [ka]

[0713] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (12.5 mg, 0.028 mmol) and 2-methoxyethan-1-amine (3.1 mg, 0.041 mmol) and obtained as a colorless oil (5 mg, 33.6%). 1H NMR (400 MHz, CD3OD) δ ppm 1.65 (d, J=7.08 Hz, 3 H), 1.89 - 2.00 (m, 2 H), 2.06 - 2.14 (m, 2 H), 2.73 (s, 3 H), 2.90 - 3.00 (m, 1H), 3.02 - 3.08 (m, 1 H), 3.34 - 3.44 (m, 5 H), 3.56 (s, 4 H), 3.61 (ddd, J=11.04, 7.38, 4.03 Hz, 1 H), 3.67 (ddd, J=11.47, 7.57, 3.91 Hz, 1 H), 3.73 -3.86 (m, 2H), 4.27 (q, J=6.83 Hz, 1 H), 6.98 - 7.04 (m, 2 H), 7.22 - 7.31 (m, 2 H);ESI-MS m / z [M+H] + 430.2.

[0714] Example 53: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-(tetrahydro-2H-pyran-4-yl)pyrazine-2-carboxamide

[0715] [ka]

[0716] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (12.5 mg, 0.028 mmol) and tetrahydro-2H-pyran-4-amine (4.2 mg, 0.042 mmol) and obtained as a colorless oil (7 mg, 44.1%). 1H NMR (400 MHz, CD3OD) δ ppm 1.52 - 1.63 (m, 2 H), 1.64 (d, J=7.08 Hz, 3 H), 1.87 - 2.02 (m, 4 H), 2.05 - 2.16 (m, 2 H), 2.72 (s, 3H), 2.93 - 3.01 (m, 1 H), 3.02 - 3.10 (m, 1 H), 3.40 (td, J=5.80, 2.56 Hz, 2 H), 3.51 - 3.59 (m, 2 H), 3.60 - 3.65 (m, 1 H), 3.66 - 3.72 (m, 1 H), 3.74 -3.87 (m, 2 H), 3.92 - 3.98 (m, 2 H), 4.03 (tt, J=10.49, 4.39 Hz, 1 H), 4.28 (q, J=6.83 Hz, 1 H), 7.00 - 7.07 (m, 2 H), 7.21 - 7.30 (m, 2 H);ESI-MS m / z [M+H] + 456.15.

[0717] Example 54: N-(3-(azetidin-1-yl)propyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0718] [ka]

[0719] The TFA salt of the title compound was prepared similarly to Example 42 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (12.5 mg, 0.028 mmol) and azetidine (2.9 mg, 0.050 mmol) and obtained as a colorless oil (5.8 mg, 29.7%). 1H NMR (400 MHz, CD3OD) δ ppm 1.67 (d, J=6.83 Hz, 3 H), 1.87 (quin, J=7.08 Hz, 2 H), 1.91 - 2.00 (m, 2 H), 2.03 - 2.13 (m, 2 H), 2.37 - 2.49 (m, 1 H), 2.56 - 2.69 (m, 1 H), 2.74 (s, 3 H), 2.88 - 2.96 (m, 1 H), 2.99 - 3.08 (m, 1 H), 3.20 - 3.26 (m, 2 H), 3.33 - 3.43 (m, 2 H), 3.46 (t, J=6.71 Hz, 2 H), 3.54 - 3.61 (m, 1 H), 3.66 (ddd, J=10.98, 7.32, 4.15 Hz, 1 H), 3.79 (td, J=5.74, 3.42 Hz, 2 H), 4.08 (q, J=9.84 Hz, 2 H), 4.23 - 4.31 (m, 3 H), 6.97 - 7.04 (m, 2 H), 7.24 - 7.31 (m, 2 H);ESI-MS m / z [M+H] + 469.2.

[0720] Example 55: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid

[0721] [ka]

[0722] A small amount of crude 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (Preparation 11) was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10-50% ACN (0.035% TFA) / water (0.05% TFA) to give the title compound for in vitro pharmacology studies. 1H NMR (500 MHz, CD3OD) δ ppm 1.67 (d, J=6.83 Hz, 3 H), 1.87 - 1.99 (m, 2 H), 2.04 - 2.15 (m, 2 H), 2.71 (s, 3 H), 2.90 - 2.98 (m, 1H), 3.00 - 3.09 (m, 1 H), 3.35 - 3.46 (m, 2 H), 3.56 - 3.70 (m, 2 H), 3.74 - 3.87 (m, 2 H), 4.25 (q, J=6.83 Hz, 1 H), 6.97 - 7.06 (m, 2 H), 7.25 - 7.33 (m, 2 H);ESI-MS m / z [M+H] + 373.1.

[0723] Example 56: 6-(1-(4-fluorophenyl)ethyl)-N-(cis-3-methoxycyclobutyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0724] [ka]

[0725] To a solution of 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (40 mg, 0.070 mmol), (1s,3s)-3-methoxycyclobutan-1-amine hydrochloride (11.53 mg, 0.084 mmol), and DIPEA (73.0 μL, 0.419 mmol) in NMP (0.5 mL) was added T3P (59.6 μL, 0.105 mmol). The reaction mixture was stirred at 35° C. for 18 h, and then MeOH (0.5 mL) was added to quench the reaction. The reaction mixture was purified by preparative HPLC (Shimadzu, Phenomenex Gemini® column) using a gradient of 10-60% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a pale orange semi-solid (30.7 mg, 97%). 1H NMR (500 MHz, CD3OD) δ ppm 1.65 (d, J=6.83 Hz, 3 H), 1.82 - 2.00 (m, 4 H), 2.07 (br s, 2 H), 2.70 (s, 3 H), 2.72 - 2.83 (m, 2 H), 2.86 - 2.96 (m, 1 H), 2.98 - 3.08 (m, 1 H), 3.27 (d, J=0.98 Hz, 3 H), 3.34 - 3.46 (m, 2 H), 3.54 - 3.63 (m, 1 H), 3.64 - 3.70 (m, 1 H), 3.70 - 3.76 (m, 1 H), 3.81 (q, J=5.94 Hz, ESI-MS m / z [M+H] + 456.25.

[0726] Example 57: N-cyclopentyl-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0727] [ka]

[0728] To a solution of 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol), cyclopentanamine (6.9 mg, 0.081 mmol), and DIPEA (70.0 μL, 0.403 mmol) in NMP (0.5 mL) was added T3P (30.6 μL, 0.101 mmol). The reaction mixture was stirred at 35° C. for 18 h, and then MeOH (0.5 mL) was added to quench the reaction. The reaction mixture was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10-100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (16 mg, 55%). ESI-MS m / z [M+H] + 440.3.

[0729] Example 58: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(piperidin-1-yl)methanone

[0730] [ka]

[0731] The title compound (17 mg, 57%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and piperidine (7 mg, 0.081 mmol). ESI-MS m / z [M+H] + 440.3.

[0732] Example 59: N,N-diethyl-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0733] [ka]

[0734] The title compound (13 mg, 45%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and diethylamine (6 mg, 0.81 mmol). ESI-MS m / z [M+H] + 428.3.

[0735] Example 60: (3,3-difluoropyrrolidin-1-yl)(6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)methanone

[0736] [ka]

[0737] The title compound (18 mg, 57%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and 3,3-difluoropyrrolidine (9 mg, 0.081 mmol). ESI-MS m / z [M+H] + 462.2.

[0738] Example 61: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((R)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide

[0739] [ka]

[0740] The title compound (13 mg, 42%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and (R)-tetrahydrofuran-3-amine (7 mg, 0.081 mmol). ESI-MS m / z [M+H] + 442.2.

[0741] Example 62: N-cyclopropyl-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0742] [ka]

[0743] The title compound (20 mg, 71%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and cyclopropanamine (5 mg, 0.081 mmol). ESI-MS m / z [M+H] + 412.2.

[0744] Example 63: N-ethyl-6-(1-(4-fluorophenyl)ethyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0745] [ka]

[0746] The title compound (14 mg, 49%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and N-methylethanamine (5 mg, 0.081 mmol). ESI-MS m / z [M+H] + 414.2.

[0747] Example 64: N-(cis-3-fluorocyclobutyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0748] [ka]

[0749] The title compound (20 mg, 68%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and cis-3-fluorocyclobutan-1-amine (10 mg, 0.081 mmol). ESI-MS m / z [M+H] + 444.2.

[0750] Example 65: N-cyclopropyl-6-(1-(4-fluorophenyl)ethyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0751] [ka]

[0752] The title compound (13 mg, 45%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and N-methylcyclopropanamine (9 mg, 0.081 mmol). ESI-MS m / z [M+H] + 426.2.

[0753] Example 66: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((S)-3-fluoropyrrolidin-1-yl)methanone

[0754] [ka]

[0755] The title compound (19 mg, 64%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and (S)-3-fluoropyrrolidine (7 mg, 0.081 mmol). ESI-MS m / z [M+H] + 444.2.

[0756] Example 67: 6-(1-(4-fluorophenyl)ethyl)-N-isopropyl-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0757] [ka]

[0758] The title compound (18 mg, 61%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and N-methylpropan-2-amine (6 mg, 0.081 mmol). ESI-MS m / z [M+H] + 428.3.

[0759] Example 68: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((S)-3-methoxypyrrolidin-1-yl)methanone

[0760] [ka]

[0761] The title compound (15 mg, 48%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and (S)-3-methoxypyrrolidine (11 mg, 0.081 mmol). ESI-MS m / z [M+H] + 456.3.

[0762] Example 69: 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((S)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide

[0763] [ka]

[0764] The title compound (17 mg, 58%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and (S)-tetrahydrofuran-3-amine (7 mg, 0.081 mmol). ESI-MS m / z [M+H] + 442.2.

[0765] Example 70: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(morpholino)methanone

[0766] [ka]

[0767] The title compound (9.8 mg, 33%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and morpholine (7 mg, 0.081 mmol). ESI-MS m / z [M+H] + 442.2.

[0768] Example 71: 6-(1-(4-fluorophenyl)ethyl)-N-(trans-3-methoxycyclobutyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0769] [ka]

[0770] The title compound (16 mg, 53%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and trans-3-methoxycyclobutan-1-amine (11 mg, 0.081 mmol). ESI-MS m / z [M+H] + 456.3.

[0771] Example 72: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((R)-3-methoxypyrrolidin-1-yl)methanone

[0772] [ka]

[0773] The title compound (14 mg, 45%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and (R)-3-methoxypyrrolidine (11 mg, 0.081 mmol). ESI-MS m / z [M+H] + 456.2.

[0774] Example 73: N-(3,3-difluorocyclobutyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0775] [ka]

[0776] The title compound (15 mg, 48%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and 3,3-difluorocyclobutan-1-amine (9 mg, 0.081 mmol). ESI-MS m / z [M+H] + 462.2.

[0777] Example 74: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((R)-3-fluoropyrrolidin-1-yl)methanone

[0778] [ka]

[0779] The title compound (15 mg, 49%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and (R)-3-fluoropyrrolidine (7 mg, 0.081 mmol). ESI-MS m / z [M+H] + 444.2.

[0780] Example 75: (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(pyrrolidin-1-yl)methanone

[0781] [ka]

[0782] The title compound (7.3 mg, 25%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and pyrrolidine (6 mg, 0.081 mmol). ESI-MS m / z [M+H] + 426.2.

[0783] Example 76: N-(trans-3-fluorocyclobutyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0784] [ka]

[0785] The title compound (15 mg, 50%) was prepared analogously to Example 57 using 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (25 mg, 0.067 mmol, 1 equiv.) and trans-3-fluorocyclobutan-1-amine (10 mg, 0.081 mmol). ESI-MS m / z [M+H] + 444.2.

[0786] Example 77: 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide

[0787] [ka]

[0788] To a solution of 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid (33 mg, 0.047 mmol) in DMF (0.5 mL) was added HATU (17.77 mg, 0.047 mmol) and DIPEA (24.49 μL, 0.140 mmol). The mixture was stirred at room temperature for 5 minutes, and then ammonium hydroxide (14.56 μL, 0.374 mmol) was added. The reaction mixture was stirred at room temperature for 2 days and then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to afford the TFA salt of the title compound as a white film (11.7 mg, 48.6%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.70 (d, J=6.90 Hz, 3 H), 2.01 - 2.20 (m, 4 H), 3.06 - 3.18 (m, 2 H), 3.35 - 3.44 (m, 2 H), 3.51 (s, 3 H), 3.67 - 3.80 (m, 4 H), 4.33 (q, J=6.82 Hz, 1 H), 5.02 - 5.13 (m, 2 H), 6.99 - 7.08 (m, 2 H), 7.27 - 7.37 (m, 2 H).

[0789] Example 78: N-(2-(azetidin-1-yl)ethyl)-3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-amine

[0790] [ka]

[0791] Step A: 3-(4-Fluorobenzyl)-5,6-dimethylpyrazin-2-yl trifluoromethanesulfonate

[0792] [ka]

[0793] A solution of 3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-ol (83.0 mg, 0.357 mmol) in DCM (3.57 mL) at 0 °C was treated with DIPEA (187 μL, 1.07 mmol) and trifluoromethanesulfonic anhydride (121 μL, 0.715 mmol). The reaction mixture was stirred at 0 °C for 15 min, then quenched with saturated aqueous NH Cl and extracted with DCM. The organic phase was dried over Na SO , filtered, and concentrated under reduced pressure to give the title compound (130 mg), which was used without further purification. ESI-MS m / z [M+H] + 365.1.

[0794] Step B: N-(2-(azetidin-1-yl)ethyl)-3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-amine

[0795] To a 5 mL microwave vial equipped with a stir bar and charged with a solution of 3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-yl trifluoromethanesulfonate (130 mg, 0.357 mmol) and 2-(azetidin-1-yl)ethanamine (71.5 mg, 0.714 mmol) in toluene (1.78 mL), cesium carbonate (233 mg, 0.714 mmol), BINAP (22.2 mg, 0.0357 mmol), and Pd(dba) (32.7 mg, 0.0357 mmol) were added. The vial was sealed, and the reaction mixture was stirred overnight at 100 °C in a heating block. It was then poured into water and extracted with EtOAc. The organic phase was dried over NaSO, filtered, and concentrated under reduced pressure. The residue was taken up in methanol and filtered through a hydrophilic PTFE 0.45 μm Millipore® filter, rinsing with methanol. The filtrate was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA). The product-containing fractions were concentrated under reduced pressure, then taken up in methanol and filtered through a basic Agilent PL-HCO3MP SPE cartridge (200 mg) to remove TFA. The filtrate was evaporated to give the title compound as a colorless film (0.7 mg, 0.6%). 1 H NMR (500 MHz, CD3OD) δ ppm 2.08 (quin, J = 7.2 Hz, 2 H), 2.37 (s, 6 H), 2.58 (t, J = 6.6 Hz, 2 H), 3.21 (t, J = 7.1 Hz, 4 H), 3.33 - 3.36 (m, 2 H), 4.00 (s, 2 H), 6.94 - 7.04 (m, 2 H), 7.14 - 7.25 (m, 2 H);ESI-MS m / z [M+H] + 315.25.

[0796] Example 79: 3-(4-fluorobenzyl)-5,6-dimethyl-N-(1-methylpiperidin-4-yl)pyrazin-2-amine

[0797] [ka]

[0798] A mixture of 3-chloro-5,6-dimethyl-N-(1-methylpiperidin-4-yl)pyrazin-2-amine (30 mg, 0.118 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (50.0 mg, 0.212 mmol), PdCl(dppf) (8.62 mg, 0.012 mmol) and NaCO (2 N, 118 μL, 0.236 mmol) in dioxane (0.6 mL) was heated at 110 °C for 16 h. The reaction mixture was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA), followed by a second preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–70% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to afford the title compound as a brown oil (14 mg, 36.2%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.25 (d, J=9.28 Hz, 2 H), 1.83 - 1.90 (m, 2 H), 2.11 (t, J=10.01 Hz, 2 H), 2.21 (s, 3 H), 2.36 (s, 3 H), 2.39 (s, 3 H), 2.42 - 2.57 (m, 2 H), 3.77 (d, J=7.32 Hz, 1 H), 3.82 - 3.91 (m, 1 H), 3.98 (s, 2 H), 6.94 - 7.01 (m, 2 H), 7.11 - 7.18 (m, 2 H);ESI-MS m / z [M+H] + 329.25.

[0799] Example 80: 3-(4-fluorobenzyl)-5,6-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0800] [ka]

[0801] The title compound was prepared in a similar manner to Example 79 using 3-chloro-5,6-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine (25 mg, 0.098 mmol, 1.0 equiv) and 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (41.7 mg, 0.176 mmol) to afford the title compound as a brown oil (13 mg, 40.3%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.77 (dt, J=7.08, 3.30 Hz, 4 H), 2.35 (s, 6 H), 2.53 (br s, 4 H), 2.64 (t, J=6.59 Hz, 2 H), 3.49 (t, J=6.59 Hz, 2 H), 3.99 (s, 2 H), 6.91 - 7.01 (m, 2 H), 7.13 - 7.22 (m, 2 H);ESI-MS m / z [M+H] + 329.20.

[0802] Example 81: (R)-3-(4-fluorobenzyl)-5,6-dimethyl-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine

[0803] [ka]

[0804] The title compound was prepared in a similar manner to Example 79 using (R)-3-chloro-5,6-dimethyl-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine (20 mg, 0.083 mmol, 1.0 equiv) and 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (35.3 mg, 0.150 mmol) to afford the title compound as a brown oil (12 mg, 45.9%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.57 (dddd, J=13.18, 8.30, 6.83, 4.88 Hz, 1 H), 2.24 - 2.31 (m, 1 H), 2.34 (s, 3 H), 2.35 (d, J=2.44 Hz, 6 H), 2.38 (dd, J=10.25, 4.39 Hz, 1 H), 2.48 (dt, J=9.28, 7.32 Hz, 1 H), 2.68 (td, J=8.79, 5.86 Hz, 1 H), 2.83 (dd, J=10.25, 6.83 Hz, 1 H), 4.01 (s, 2 H), 4.51 (ddt, ESI-MS m / z [M+H] + 315.20.

[0805] Example 82: 5,6-dimethyl-3-(3-methylbenzyl)-N-(1-methylpiperidin-4-yl)pyrazin-2-amine

[0806] [ka]

[0807] The title compound was prepared in the same manner as in Example 79 using 3-chloro-5,6-dimethyl-N-(1-methylpiperidin-4-yl)pyrazin-2-amine (20 mg, 0.079 mmol, 1.0 equiv) and 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (36.4 mg, 0.157 mmol) to afford the title compound as a brown oil (3.1 mg, 12.2%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.40 (d, J=8.79 Hz, 2 H), 1.84 (d, J=9.76 Hz, 2 H), 2.19 (br s, 2 H), 2.22 (s, 3 H), 2.28 (s, 3 H), 2.35 (s, 3 H), 2.37 (s, 3 H), 2.42 - 2.76 (m, 2 H), 3.88 (br s, 1 H), 4.00 (s, 2 H), 6.96 (d, J=7.32 Hz, 1 H), 7.00 - 7.07 (m, 2 H), 7.13 - 7.20 (m, 1 H);ESI-MS m / z [M+H] + 325.20.

[0808] Example 83: 5,6-dimethyl-3-(3-methylbenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0809] [ka]

[0810] The title compound was prepared in a similar manner to Example 79 using 3-chloro-5,6-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine (30 mg, 0.118 mmol, 1.0 equiv) and 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (49.2 mg, 0.212 mmol) to afford the title compound as a brown oil (14 mg, 36.6%). 1H NMR (400 MHz, CD3OD) δ ppm 1.72 - 1.79 (m, 4 H), 2.27 (s, 3 H), 2.36 (d, J=4.39 Hz, 6 H), 2.50 (br s, 4 H), 2.61 (t, J=6.35 Hz, 2 H), 3.48 (t, ESI-MS m / z [M+H] + 325.25.

[0811] Example 84: (R)-5,6-dimethyl-3-(3-methylbenzyl)-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine

[0812] [ka]

[0813] The title compound was prepared in the same manner as in Example 79 using (R)-3-chloro-5,6-dimethyl-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine (20 mg, 0.083 mmol, 1.0 equiv) and 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (34.7 mg, 0.150 mmol) to afford the title compound as a brown oil (8 mg, 31.0%). 1H NMR (400 MHz, CD3OD) δ ppm 1.46 - 1.55 (m, 1 H), 2.20 - 2.25 (m, 1 H), 2.27 (s, 3 H), 2.30 (d, J=4.39 Hz, 1 H), 2.32 (s, 3 H), 2.36 (d, J=7.32 Hz, 6 H), 2.44 - 2.53 (m, 1 H), 2.61 (td, J=8.79, 5.86 Hz, 1 H), 2.85 (dd, J=10.25, 6.83 Hz, 1 H), 3.99 (s, 2 H), 4.48 (ddt, J=8.79, 6.96, 4.58, 4.58 Hz, 1H), 6.96 (d, J=7.32 Hz, 1 H), 7.00 - 7.04 (m, 2 H), 7.11 - 7.17 (m, 1 H);ESI-MS m / z [M+H] + 311.20.

[0814] Example 85: 3-(1-(4-fluorophenyl)ethyl)-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0815] [ka]

[0816] and

[0817] Example 86: 3-(1-(4-fluorophenyl)ethyl)-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0818] [ka]

[0819] Step A: 3-chloro-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and 3-chloro-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0820] [ka]

[0821] To a solution of 2,3-dichloro-5-methylpyrazine (100 mg, 0.61 mmol) in dioxane (2.5 mL) was added DIPEA (214 μL, 1.23 mmol) and 2-(pyrrolidin-1-yl)ethan-1-amine (77 mg, 0.68 mmol). The resulting solution was heated at 100° C. overnight and then purified by silica gel chromatography (NH column) to give the mixture of title compounds (39 mg, 27%). ESI-MS m / z [M+H] + 241.1.

[0822] Step B: 3-(1-(4-fluorophenyl)vinyl)-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and 3-(1-(4-fluorophenyl)vinyl)-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0823] [ka]

[0824] A mixture of 3-chloro-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and 3-chloro-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine (35.0 mg, 0.145 mmol), 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (72.1 mg, 0.291 mmol), Pd(dppf)Cl (10.64 mg, 0.015 mmol) and NaCO (145 μL, 0.291 mmol) in dioxane (1.5 mL) was degassed with N and then heated in a sealed tube at 110 °C for 16 h. After the reaction, the mixture was purified by silica gel column chromatography (NH column) using a gradient of 5-50% EtOAc / heptane to give a crude mixture of the title compounds (70 mg). ESI-MS m / z [M+H] + 327.1.

[0825] Step C: 3-(1-(4-fluorophenyl)ethyl)-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and 3-(1-(4-fluorophenyl)ethyl)-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine

[0826] A mixture of 3-(1-(4-fluorophenyl)vinyl)-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and 3-(1-(4-fluorophenyl)vinyl)-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine (70 mg, crude) and palladium on carbon (11.41 mg, 0.107 mmol) in EtOAc (1.1 mL) was stirred at room temperature under a H atmosphere (balloon) for 5 hours. The reaction mixture was then purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to give two regioisomers. The major regioisomer was assigned to the TFA salt of 3-(1-(4-fluorophenyl)ethyl)-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and was obtained as a colorless oil (19 mg, 40.0%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.62 (d, J=6.88 Hz, 3 H), 1.88 - 2.03 (m, 2 H), 2.06 - 2.19 (m, 2 H), 2.38 (s, 3 H), 2.94 - 3.14 (m, 2H), 3.36 - 3.43 (m, 2 H), 3.60 - 3.84 (m, 4 H), 4.24 (q, J=6.91 Hz, 1 H), 6.95 - 7.10 (m, 2 H), 7.19 - 7.29 (m, 2 H), 7.78 (s, 1 H);ESI-MS m / z [M+H] + 329.20. The minor regioisomer was assigned to the TFA salt of 3-(1-(4-fluorophenyl)ethyl)-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine and was obtained as a colorless oil (1.2 mg, 2.5%). 1H NMR (400 MHz, CD3OD) δ ppm 1.63 (d, J=6.97 Hz, 3 H), 1.93 - 2.17 (m, 4 H), 2.42 (s, 3 H), 2.92 - 3.10 (m, 2 H), 3.35 - 3.41 (m, 2H), 3.55 - 3.77 (m, 4 H), 4.25 (q, J=6.91 Hz, 1 H), 7.01 (t, J=8.71 Hz, 2 H), 7.22 - 7.31 (m, 2 H), 7.82 (s, 1 H);ESI-MS m / z [M+H] + 329.2.

[0827] Example 87: N-(2-(azetidin-1-yl)ethyl)-6-isopropyl-3-(3-methylbenzyl)pyrazin-2-amine

[0828] [ka]

[0829] A 10 mL microwave vial was charged with 3-chloro-5-isopropyl-2-(3-methylbenzyl)pyrazine (28 mg, 0.107 mmol), 2-(azetidin-1-yl)ethanamine (0.022 g, 0.215 mmol), DIPEA (0.014 g, 0.107 mmol), and KF (6.2 mg, 0.107 mmol) in DMSO (3 mL). The reaction mixture was heated at 100° C. in a Biotage® microwave reactor for 5 h, then filtered and purified by preparative HPLC (Waters SunFire® C18, 5 μm, 30 mm ID×75 mm column) using a gradient of 10–35% ACN (0.035% TFA) in water (0.05% TFA). The product-containing fractions were combined to give the TFA salt of the title compound as a pale grey oil (1.2 mg, 3%). 1H NMR (400 MHz, CD3OD) δ ppm 1.30 (d, J=6.82 Hz, 6 H), 2.29 (s, 3 H), 2.30 - 2.39 (m, 1 H), 2.46 - 2.57 (m, 1 H), 2.91 - 3.01 (m, 1 H), 3.41 (t, J=5.56 Hz, 2 H), 3.66 (t, J=5.68 Hz, 2 H), 3.94 - 4.03 (m, 4 H), 4.04 - 4.13 (m, 2 H), 6.97 (d, J=7.58 Hz, 1 H), 7.01 - 7.06 (m, 2 H), 7.13 - 7.20 (m, 1H), 7.69 (s, 1H); ESI-MS m / z [M+H] + 325.2.

[0830] Example 88: N-(2-(azetidin-1-yl)ethyl)-6-ethoxy-3-(3-methylbenzyl)pyrazin-2-amine

[0831] [ka]

[0832] To a mixture of N-(2-(azetidin-1-yl)ethyl)-6-chloro-3-(3-methylbenzyl)pyrazin-2-amine (30 mg, 94.69 μmol) in EtOH (500 μL) was added EtONa (1 M in EtOH, 473.44 μL) at 20° C. The mixture was heated to 100° C. and stirred for 4 h. The mixture was then diluted with EtOAc (20 mL) and saturated aqueous NH4Cl (20 mL). The aqueous layer was separated and extracted with EtOAc (15 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (Phenomenex Gemini® 10 μm, 25 mm ID×150 mm) using a gradient of 56-86% ACN / water (0.05% NH4OH) to afford the title compound as a red oil (16.4 mg, 53%). 1H NMR (400 MHz, CDCl3) δ ppm 1.39 (t, J=7.1 Hz, 3 H), 2.03 (quin, J=6.9 Hz, 2 H), 2.32 (s, 3 H), 2.51 (t, J=6.0 Hz, 2 H), 3.09 (t, J=7.1 Hz, 4 H), 3.25 (q, J=5.7 Hz, 2 H), 3.97 (s, 2 H), 4.29 (q, J=7.1 Hz, 2 H), 4.89 (br s, 1 H), 6.95 - 7.09 (m, 3 H), 7.16 - 7.22 (m, 1 H), 7.42 (s, 1 H);ESI-MS m / z [M+H] + 327.0.

[0833] Example 89: N-(2-(azetidin-1-yl)ethyl)-3-benzyl-6-ethylpyrazin-2-amine

[0834] [ka]

[0835] To a solution of 3-benzyl-6-ethylpyrazin-2-yl trifluoromethanesulfonate (30 mg, 86.63 μmol) in NMP (750 μL) was added EtN (8.77 mg, 86.63 μmol, 12.01 μL) and 2-(azetidin-1-yl)ethanamine (10.41 mg, 103.96 μmol). The mixture was stirred at 80° C. for 1 h and then concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Synergi™ C18, 4 μm, 21.2 mm ID×250 mm) using a gradient of 15–45% ACN / water (0.05% HCl) to afford the HCl salt of the title compound as a yellow solid (9.0 mg, 31%). 1H NMR (400 MHz, CD3OD) δ ppm 1.35 (t, J=7.28 Hz, 3 H), 2.40 (d, J=7.53 Hz, 1 H), 2.57 (d, J=8.53 Hz, 1 H), 2.81 - 2.96 (m, 2 H), 3.51 (br s, 2 ESI-MS m / z [M+H] + 296.9.

[0836] Example 90: N-(2-(azetidin-1-yl)ethyl)-6-cyclopropyl-3-(3-methylbenzyl)pyrazin-2-amine

[0837] [ka]

[0838] The HCl salt of the title compound was prepared similarly to Example 89, using 6-cyclopropyl-3-(3-methylbenzyl)pyrazin-2-yl trifluoromethanesulfonate instead of 3-benzyl-6-ethylpyrazin-2-yl trifluoromethanesulfonate. The intermediate 6-cyclopropyl-3-(3-methylbenzyl)pyrazin-2-yl trifluoromethanesulfonate was prepared similarly to Preparation 23, using 2-(tert-butoxycarbonylamino)-2-cyclopropylacetic acid instead of 2-(tert-butoxycarbonylamino)butanoic acid. 1H NMR (400 MHz, CD3OD) δ ppm 1.18 (d, J=6.02 Hz, 4 H), 2.18 - 2.27 (m, 1 H), 2.29 - 2.44 (m, 4 H), 2.51 - 2.63 (m, 1 H), 3.40 - 3.51 (m, 2 H), 3.76 (br s, 2 H), 4.07 (q, J=9.20 Hz, 2 H), 4.21 (d, J=4.02 Hz, 2 H), 4.31 (s, 2 H), 7.10 (d, J=7.53 Hz, 1 H), 7.17 (br s, 2 H), 7.24 - 7.31 (m, 1 H), 7.79 (s, 1 H); ESI-MS m / z [M+H] + 323.0.

[0839] Example 91: N-(1,3-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine

[0840] [ka]

[0841] Step A: tert-butyl 4-((3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-methylpiperidine-1-carboxylate

[0842] [ka]

[0843] To a 40 mL vial was added PdCl(dppf) (0.034 g, 0.046 mmol), NaCO (0.098 g, 0.922 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.196 g, 0.830 mmol), tert-butyl 4-((3-chloro-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-methylpiperidine-1-carboxylate (0.182 g, 0.461 mmol), and dioxane (4.61 mL). The resulting orange suspension was degassed with N and heated at 110 °C overnight. The mixture was then treated with water and extracted with EtOAc. The organic layer was dried over anhydrous MgSO and concentrated to give the title compound as a brown film, which was used without further purification. ESI-MS m / z [M+H] + 469.4.

[0844] Step B: 3-(4-Fluorobenzyl)-N-(3-methylpiperidin-4-yl)-5-(trifluoromethyl)pyrazin-2-amine

[0845] [ka]

[0846] To a 125 mL pear-bottomed flask was added tert-butyl 4-((3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-methylpiperidine-1-carboxylate (0.216 g, 0.461 mmol), hydrogen chloride (0.461 mL, 1.844 mmol), and dioxane (3 mL). The resulting brown solution was stirred at 50° C. for 3 h and then concentrated to dryness to give the title compound as a brown solid, which was used without further purification. ESI-MS m / z [M+H] + 369.4.

[0847] Step C: N-(1,3-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine

[0848] A 125 mL pear-bottomed flask was charged with 3-(4-fluorobenzyl)-N-(3-methylpiperidin-4-yl)-5-(trifluoromethyl)pyrazin-2-amine (170 mg, 0.461 mmol), formaldehyde (0.071 mL, 0.913 mmol), and methanol (3 mL). To the resulting brown solution was added sodium cyanotrihydroborate (57.4 mg, 0.913 mmol). The mixture was stirred overnight at room temperature, then filtered and purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound as a mixture of cis and trans isomers (9.2 mg, 4.02%). 1 H NMR (400 MHz, CD3OD) δ ppm 0.77 (d, J=6.60 Hz, 3 H), 1.68 - 1.86 (m, 1 H), 2.04 - 2.15 (m, 1 H), 2.16 - 2.26 (m, 1 H), 2.82 - 2.89 (m, 4 H), 3.12 (s, 1 H), 3.44 - 3.57 (m, 2 H), 3.97 - 4.07 (m, 1 H), 4.04 - 4.07 (m, 1 H), 4.09 - 4.21 (m, 2 H), 6.94 - 7.07 (m, 2 H), 7.17 - 7.28 (m, 2 H), 8.23 ​​- 8.28 (m, 1 H); ESI-MS m / z [M+H] + 383.4.

[0849] Example 92: N-(1,3-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)-6-(trifluoromethyl)pyrazin-2-amine

[0850] [ka]

[0851] Step A: tert-butyl 4-((3-(4-fluorobenzyl)-6-(trifluoromethyl)pyrazin-2-yl)amino)-3-methylpiperidine-1-carboxylate

[0852] [ka]

[0853] A 30 mL microwave vial was charged with 3-chloro-2-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazine (0.105 g, 0.361 mmol), tert-butyl 4-amino-3-methylpiperidine-1-carboxylate hydrochloride (0.091 g, 0.361 mmol), (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene (0.022 g, 0.036 mmol), (dba)Pd (0.033 g, 0.036 mmol), cesium carbonate (0.235 g, 0.723 mmol), and toluene (3.61 mL). The resulting brown suspension was degassed with N and heated at 80 °C for 2 days. The mixture was then treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4 and concentrated to give the title compound, which was used without further purification. ESI-MS m / z [M+H] + 469.5.

[0854] Step B: 3-(4-Fluorobenzyl)-N-(3-methylpiperidin-4-yl)-6-(trifluoromethyl)pyrazin-2-amine

[0855] [ka]

[0856] To a 125 mL pear-bottomed flask was added tert-butyl 4-((3-(4-fluorobenzyl)-6-(trifluoromethyl)pyrazin-2-yl)amino)-3-methylpiperidine-1-carboxylate (0.169 g, 0.361 mmol) and hydrogen chloride (0.361 mL, 1.444 mmol) in dioxane (3 mL). The resulting brown solution was stirred at 50° C. for 3 h and then concentrated to dryness to give the title compound, which was used without further purification. ESI-MS m / z [M+H] + 369.4.

[0857] Step C: N-(1,3-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)-6-(trifluoromethyl)pyrazin-2-amine

[0858] A 125 mL pear-bottomed flask was charged with 3-(4-fluorobenzyl)-N-(3-methylpiperidin-4-yl)-6-(trifluoromethyl)pyrazin-2-amine (133 mg, 0.361 mmol) and formaldehyde (0.055 mL, 0.715 mmol) in methanol (3 mL). To the resulting brown solution was added sodium cyanotrihydroborate (44.9 mg, 0.715 mmol). The mixture was stirred overnight at room temperature, then filtered and purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound (11.5 mg, 6.42%). 1H NMR (400 MHz, CD3OD) δ ppm 0.81 (d, J=6.60 Hz, 3 H), 1.71 - 1.88 (m, 1 H), 2.02 - 2.14 (m, 1 H), 2.18 - 2.27 (m, 1 H), 2.87 (s, 5 H), 3.12 - 3.22 (m, 1 H), 3.46 - 3.59 (m, 2 H), 3.95 - 4.06 (m, 1 H), 4.08 - 4.24 (m, 2 H), 6.95 - 7.10 (m, 2 H), 7.17 - 7.32 (m, 2 H), 8.01 - 8.08 (m, 1 H);ESI-MS m / z [M+H] + 383.3.

[0859] Example 93: 3-(4-Fluorobenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyrazin-2-amine

[0860] [ka]

[0861] To a 40 mL vial was added 3-chloro-2-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazine (0.081 g, 0.279 mmol), 2-(pyrrolidin-1-yl)ethan-1-amine (0.038 g, 0.334 mmol), (R)-2,2′-bis(diphenylphosphanyl)-1,1′-binaphthalene (0.017 g, 0.028 mmol), Pd(dba) (0.026 g, 0.028 mmol), cesium carbonate (0.182 g, 0.557 mmol), and toluene (4 mL). The resulting brown suspension was degassed with N and heated at 90 °C overnight. The mixture was then stirred at room temperature for 3 hours, filtered, and purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10-50% ACN (0.035% TFA) / water (0.05% TFA) to give the title compound (9.3 mg, 6.9%). 1H NMR (400 MHz, CD3OD) δ ppm 1.90 - 2.02 (m, 2 H), 2.07 - 2.17 (m, 2 H), 3.02 - 3.13 (m, 2 H), 3.39 - 3.46 (m, 2 H), 3.65 - 3.77 (m, 2 H), 3.79 - 3.87 (m, 2 H), 4.09 - 4.16 (m, 2 H), 6.98 - 7.07 (m, 2 H), 7.19 - 7.28 (m, 2 H), 8.08 - 8.14 (m, 1 H);ESI-MS m / z [M+H] + 369.3.

[0862] Example 94: 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyrazin-2-amine

[0863] [ka]

[0864] To a 20 mL vial was added 3-chloro-2-(1-(4-fluorophenyl)ethyl)-5-(trifluoromethyl)pyrazine (487 mg, 1.6 mmol), 2-(pyrrolidin-1-yl)ethan-1-amine (201 mg, 1.760 mmol), DIPEA (0.557 mL, 3.20 mmol), and dioxane (2 mL). The resulting orange solution was heated at 110 °C overnight and then purified by preparative HPLC (Phenomenex Gemini C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 40–90% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (82.8 mg, 13.5%). 1H NMR (400 MHz, CD3OD) δ ppm 1.64 (d, J=6.90 Hz, 3 H) 1.90 - 2.14 (m, 4 H) 2.87 - 3.10 (m, 2 H) 3.33 - 3.45 (m, 2 H) 3.54 - 3.71 (m, 2 H) 3.73 - 3.83 (m, 2 H) 4.29 - 4.43 (m, 1 H) 7.01 (s, 2 H) 7.23 - 7.32 (m, 2 H) 8.17 - 8.27 (m, 1 H);ESI-MS m / z [M+H] + 383.5.

[0865] Example 95: N-(trans-3-ethyl-1-methylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine

[0866] [ka]

[0867] Step A: tert-butyl trans-3-ethyl-4-((3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-yl)amino)piperidine-1-carboxylate

[0868] [ka]

[0869] To a 40 mL vial was added (dppf)PdCl (0.034 g, 0.046 mmol), NaCO (0.098 g, 0.922 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.196 g, 0.830 mmol), tert-butyl trans-4-((3-chloro-5-(trifluoromethyl)pyrazin-2-yl)amino)-3-ethylpiperidine-1-carboxylate (0.188 g, 0.461 mmol), and dioxane (4.61 mL). The resulting orange suspension was degassed with N and heated at 110 °C overnight. The reaction mixture was then treated with water and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous MgSO, and concentrated to give the title compound as a brown syrup. ESI-MS m / z [M+H] + 483.4.

[0870] Step B: trans-N-(3-ethylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine

[0871] [ka]

[0872] To a 125 mL pear-bottomed flask was added tert-butyl trans-3-ethyl-4-((3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-yl)amino)piperidine-1-carboxylate (0.222 g, 0.461 mmol) and hydrogen chloride (0.461 mL, 1.844 mmol) in dioxane (3 mL). The resulting brown solution was stirred at 50° C. for 3 h and then concentrated to dryness to give the title compound as a brown film. ESI-MS m / z [M+H] + 383.4.

[0873] Step C: N-(trans-3-ethyl-1-methylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine

[0874] To a 125 mL pear-bottomed flask was added trans-N-(3-ethylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine (176 mg, 0.461 mmol), formaldehyde (0.071 mL, 0.913 mmol), and methanol (3 mL). To the resulting brown solution was added sodium cyanotrihydroborate (57.4 mg, 0.913 mmol). The resulting mixture was stirred overnight at room temperature, then filtered and purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound (25.6 mg, 10.9%). 1 H NMR (400 MHz, CD3OD) δ ppm 0.66 - 0.87 (m, 4 H), 0.94 - 1.07 (m, 1 H), 1.84 - 2.02 (m, 2 H), 2.12 - 2.30 (m, 1 H), 2.68 - 2.81 (m, 1 H), 2.84 - 2.91 (m, 4 H), 3.07 - 3.23 (m, 1 H), 3.42 - 3.59 (m, 1 H), 4.15 - 4.37 (m, 2 H), 4.45 - 4.58 (m, 1 H), 7.09 (s, 2 H), 7.19 - 7.31 (m, 2 H), 8.31 - 8.38 (m, 1 H); ESI-MS m / z [M+H] + 397.5.

[0875] Example 96: 5-((2-(azetidin-1-yl)ethyl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carbonitrile

[0876] [ka]

[0877] A 5 mL microwave vial equipped with a stir bar was charged with a solution of 5-((2-(azetidin-1-yl)ethyl)amino)-6-chloro-3-methylpyrazine-2-carbonitrile (50.0 mg, 0.199 mmol) and 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (56.3 mg, 0.238 mmol) in dioxane (1.32 mL) and 2 M aqueous NaCO (497 μL, 0.993 mmol). PdCl(dppf) (14.5 mg, 0.020 mmol) was then added. The mixture was sparged with nitrogen, and the vial was sealed. The reaction mixture was stirred overnight at 100° C. in a heated reaction block, then allowed to cool to room temperature and filtered through a hydrophilic PTFE 0.45 μm Millipore® filter, rinsing with methanol. The filtrate was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) followed by a gradient of 10–40% ACN (0.035% TFA) / water (0.05% TFA). The product-containing fractions were evaporated and dried under vacuum to give the TFA salt of the title compound as an off-white solid (25.0 mg, 29%). 1 H NMR (500 MHz, CD3OD) δ ppm 2.34 - 2.45 (m, 1 H), 2.54 (s, 4 H), 3.43 (t, J=5.9 Hz, 2 H), 3.72 (t, J=5.6 Hz, 2 H), 4.01 (s, 2 H), 4.05 (d, ESI-MS m / z [M+H] + 326.20.

[0878] Example 97: (R)-3-methyl-6-(3-methylbenzyl)-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile

[0879] [ka]

[0880] A 5 mL microwave vial equipped with a stir bar was charged with a solution of (R)-6-chloro-3-methyl-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile (93 mg, 0.37 mmol) and 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (129 mg, 0.555 mmol) in dioxane (1.85 mL). This solution was treated with 2 M aqueous NaCO (555 μL, 1.11 mmol). The vial was evacuated and refilled with nitrogen three times. PdCl(dppf) (27.1 mg, 0.037 mmol) was then added, and the vial was evacuated and refilled with nitrogen two more times. The vial was sealed, and the reaction mixture was stirred at 110° C. in a Biotage® microwave reactor for 2 h, then concentrated under reduced pressure. The resulting residue was taken up in methanol and filtered through a hydrophilic PTFE 0.45 μm Millipore® filter. The filtrate was purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID × 150 mm) using a gradient of 10–100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) followed by a gradient of 10–60% ACN (0.035% TFA) / water (0.05% TFA). The product-containing fractions were evaporated. The product was taken up in methanol and filtered through an Agilent PL-HCO3 500 mg basic cartridge to remove TFA. The filtrate was evaporated to give the title compound as a yellow oil (37.4 mg, 31%). 1H NMR (500 MHz, CD3OD) δ ppm 1.62 (dddd, J=13.2, 8.2, 6.6, 4.6 Hz, 1 H), 2.23 - 2.32 (m, 4 H), 2.34 (s, 3 H), 2.39 - 2.53 (m, 5 H), 2.70 (td, J=8.9, 5.6 Hz, 1 H), 2.80 (dd, J=10.2, 6.8 Hz, 1 H), 4.02 (s, 2 H), 4.59 (ddt, J=9.0, 7.0, 4.4, 4.4 Hz, 1 H), 6.96 - 7.07 (m, 3 H), 7.12 - 7.19 (m, 1 H);ESI-MS m / z [M+H] + 322.20.

[0881] Example 98: (R)-6-(3-methoxybenzyl)-3-methyl-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile

[0882] [ka]

[0883] The title compound was prepared in a similar manner to Example 97 using (R)-6-chloro-3-methyl-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile (81 mg, 0.32 mmol, 1 equiv.), 2-(3-methoxybenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (119 mg, 0.480 mmol), PdCl(dppf) (23.4 mg, 0.032 mmol) and 2 M aqueous NaCO (0.480 mL, 0.960 mmol) in dioxane (1.6 mL) to afford the title compound as an orange oil (34.9 mg, 32%). 1H NMR (500 MHz, CD3OD) δ ppm 1.58 - 1.70 (m, 1 H), 2.29 (dtd, J=13.7, 8.3, 8.3, 5.4 Hz, 1 H), 2.35 (s, 3 H), 2.41 - 2.53 (m, 5 H), 2.72 (td, J=8.9, 5.6 Hz, 1 H), 2.81 (dd, J=10.2, 6.8 Hz, 1 H), 3.74 (s, 3 H), 4.03 (s, 2 H), 4.60 (ddt, J=8.8, 6.9, 4.6, 4.6 Hz, 1 H), 6.75 - 6.82 (m, 3H), 7.18 (t, J=7.8 Hz, 1 H); ESI-MS m / z [M+H] + 338.20.

[0884] Example 99: 5-(4-fluorobenzyl)-N,N-dimethyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide

[0885] [ka]

[0886] An 8 mL vial was charged with 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinic acid (61.56 mg, 0.179 mmol), dimethylamine (0.179 mL, 0.358 mmol), HATU (74.9 mg, 0.197 mmol), and DIPEA (0.094 mL, 0.537 mmol) in DMF (2 mL). The resulting brown solution was stirred overnight at room temperature and then purified by preparative HPLC (Phenomenex Gemini® 30 mm ID × 100 mm) using a gradient of 10–100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (26.3 mg, 39.7%). 1H NMR (400 MHz, CD3OD) δ ppm 1.78 (s, 4 H), 2.53 (s, 4 H), 2.68 (s, 2 H), 3.05 (s, 6 H), 3.56 (s, 2 H), 3.83 (s, 2 H), 7.03 (s, 2 H), 7.18 - 7.27 (m, 3 H), 8.09 (d, J=2.26 Hz, 1 H);ESI-MS m / z [M+H] + 371.4.

[0887] Example 100: 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide

[0888] [ka]

[0889] The title compound (32.4 mg, 52.9%) was prepared analogously to Example 99 using 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinic acid (61.5 mg, 0.179 mmol, 1 equiv.) and ammonium chloride (19.15 mg, 0.358 mmol). 1 H NMR (400 MHz, CDCl3) δ ppm 1.76 (br s, 4 H) 2.44 - 2.59 (m, 4 H), 2.65 - 2.74 (m, 2 H), 3.47 - 3.60 (m, 2 H), 3.78 - 3.88 (m, 2 H), 6.98 (s, 2 H), 7.12 - 7.19 (m, 2 H), 7.70 - 7.79 (m, 1 H), 8.46 - 8.53 (m, 1 H);ESI-MS m / z [M+H] + 343.4.

[0890] Example 101: 5-(4-fluorobenzyl)-N-methyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide

[0891] [ka]

[0892] The title compound (26.3 mg, 41.2%) was prepared analogously to Example 99 using 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinic acid (61.5 mg, 0.179 mmol, 1 equiv.) and methanamine (0.179 mL, 0.358 mmol). 1 H NMR (400 MHz, CD3OD) δ ppm 1.76 (s, 4 H), 2.50 (s, 4 H), 2.66 (s, 2 H), 2.86 (s, 3 H), 3.55 (s, 2 H), 3.84 (s, 2 H), 6.93 - 7.08 (m, 2 H), 7.15 - 7.24 (m, 2 H), 7.57 - 7.66 (m, 1 H), 8.40 - 8.47 (m, 1 H);ESI-MS m / z [M+H] + 357.3.

[0893] Example 102: 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinamide

[0894] [ka]

[0895] To a 100 mL round-bottom flask was added 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinic acid (41.8 mg, 0.117 mmol), ammonium chloride (12.52 mg, 0.234 mmol), HATU (66.7 mg, 0.176 mmol), and DIPEA (0.082 mL, 0.468 mmol) in DMF (2 mL). The resulting brown solution was stirred overnight at room temperature and then purified by preparative HPLC (Gemini® 30 mm ID × 100 mm) using a gradient of 10–100% aqueous ACN (80%, 10 mM NH4HCO3) / water (10 mM NH4HCO3) to give the title compound (15.1 mg, 36.2%) as a mixture of cis and trans isomers. 1 H NMR (400 MHz, CD3OD) δ ppm 0.67 (d, J=6.51 Hz, 3 H), 1.32 - 1.49 (m, 1 H), 1.58 - 1.72 (m, 1 H), 1.74 - 1.84 (m, 1 H), 1.88 - 2.01 (m, 1 H), 2.06 - 2.17 (m, 1 H), 2.26 (s, 3 H), 2.79 - 2.91 (m, 2 H), 3.62 - 3.76 (m, 1 H), 3.88 (s, 2 H), 7.02 (s, 2 H), 7.17 - 7.27 (m, 2 H), 7.68 - 7.79 (m, 1 H), 8.48 (d, J=2.29 Hz, 1 H);ESI-MS m / z [M+H] + 357.4.

[0896] Example 103: 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine

[0897] [ka]

[0898] Step A: 3-(1-(4-fluorophenyl)vinyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine

[0899] [ka]

[0900] To an 8 mL microwave vial was added 3-bromo-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine (0.1 g, 0.278 mmol), 2-(1-(4-fluorophenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.103 g, 0.417 mmol), PdCl(dppf) (0.041 g, 0.056 mmol), and NaCO (0.088 g, 0.834 mmol) in dioxane (2.224 mL) and water (0.556 mL). The resulting orange suspension was degassed with N and heated at 100 °C for 6 h. The reaction mixture was then treated with water and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4 and concentrated to give the title compound as a brown syrup which was used without further purification. ESI-MS m / z [M+H] + 380.5.

[0901] Step B: 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine

[0902] To a 125 mL pear-bottom flask was added 3-(1-(4-fluorophenyl)vinyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine (105 mg, 0.278 mmol) and 10% palladium on carbon (29.6 mg, 0.028 mmol) in methanol (4 mL). The resulting black suspension was stirred overnight at room temperature under a hydrogen atmosphere (balloon). The reaction mixture was then filtered and purified by preparative HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10–50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound (22.9 mg, 16.6%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.54 (d, J=7.03 Hz, 3 H), 1.83 - 2.08 (m, 4 H), 2.87 - 3.05 (m, 2 H), 3.28 - 3.37 (m, 2 H), 3.49 - 3.74 (m, 4 H), 4.04 - 4.15 (m, 1 H), 6.93 - 7.00 (m, 2 H), 7.00 - 7.05 (m, 1 H), 7.12 - 7.23 (m, 2 H), 7.53 (s, 1 H);ESI-MS m / z [M+H] + 382.5.

[0903] Example 104: 3-(4-Fluorobenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine

[0904] [ka]

[0905] To an 8 mL microwave vial was added 3-bromo-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine (0.1 g, 0.278 mmol), 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.098 g, 0.417 mmol), PdCl(dppf) (0.041 g, 0.056 mmol), and NaCO (0.088 g, 0.834 mmol) in dioxane (2.22 mL) and water (0.560 mL). The resulting orange suspension was degassed with N and then heated at 100 °C for 6 h. The mixture was then filtered and purified by HPLC (Phenomenex Gemini® C18, 5 μm, 30 mm ID×150 mm) using a gradient of 10-50% ACN (0.035% TFA) / water (0.05% TFA) to give the TFA salt of the title compound (25.4 mg, 19.0%). 1 H NMR (400 MHz, CD3OD) δ ppm 1.94 - 2.07 (m, 2 H), 2.10 - 2.22 (m, 2 H), 3.05 - 3.18 (m, 2 H), 3.42 - 3.51 (m, 2 H), 3.71 - 3.81 (m, 2 H), 3.81 - 3.86 (m, 2 H), 3.90 (s, 2 H), 6.98 - 7.03 (m, 1 H), 7.08 (s, 2 H), 7.20 - 7.26 (m, 2 H), 7.27 - 7.32 (m, 1 H);ESI-MS m / z [M+H] + 368.4.

[0906] Example 105: 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine

[0907] [ka]

[0908] Step A: 3-iodo-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine

[0909] [ka]

[0910] To a solution of 2-fluoro-3-iodopyridine (200 mg, 896.92 μmol) and 2-pyrrolidin-1-ylethanamine (153.63 mg, 1.35 mmol) in dioxane (2 mL) was added DIPEA (1.56 mL, 8.97 mmol) at room temperature. The reaction mixture was stirred at 60 °C for 16 h. For workup, four reactions (200 mg × 4) on the same scale were combined. The reaction mixture was poured into water (20 mL) and extracted with DCM (30 mL × 2). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo. The resulting concentrate was purified by silica gel column chromatography using a petroleum ether / EtOAc (1:0 to 1:1) gradient to give the title compound (487 mg, 42%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ ppm 1.77 - 1.82 (m, 4 H), 2.55 - 2.60 (m, 4 H), 2.75 (t, J=6.3 Hz, 2 H), 3.51 (td, J=6.2, 5.0 Hz, 2 H), 5.58 (br s, 1 ESI-MS m / z [M+H] + 318.0.

[0911] Step B: (E)-3-(1-(4-fluorophenyl)-2-(trimethylsilyl)vinyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine

[0912] [ka]

[0913] To a round-bottom flask containing 3-iodo-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine (300 mg, 945.87 μmol) and (Z)-(2-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)trimethylsilane (454.42 mg, 1.42 mmol) in dioxane (3 mL) was added PdCl(dppf) (138.42 mg, 189.17 μmol) and 2 M NaCO (1.18 mL). The suspension was degassed several times with N....

Claims

1. A compound of formula 1, 【Chemical 1】 or a pharmaceutically acceptable salt thereof, X ２ is CR ２ and X ３ is N and CR ３ or X ２ is N and X ３ is N, R １ and R ２ is hydrogen, halo, cyano, R ａ , -OR ｂ , -C(O)R ｂ , -C(O)OR ｂ , -C(O)N(R ｃ ) R ｂ and -C(O)N(R ｃ ) OR ｂ are each independently selected from where: R ａ is C １－４ Alkyl, C ３－６ Cycloalkyl, C ２－６ Heterocyclyl and C １－５ heteroaryl, each of which is unsubstituted or selected from halo, C １－４ Alkyl and C １－４ substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein said C １－４ Alkyl and C １－４ The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R ｂ is hydrogen, and C １－４ Alkyl, C ３－６ Cycloalkyl, C ２－６ Heterocyclyl and C １－５ heteroaryl, each of which is unsubstituted or selected from halo, C １－４ Alkyl and C １－４ substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein said C １－４ Alkyl and C １－４ The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R ｃ is hydrogen and C １－４ alkyl, Here, R ａ and R ｂ Regarding the above C ２－６ A heterocyclyl substituent is a monocyclic ring of 3 to 8 ring members, of which 1 or 2 ring members are heteroatoms, each of which is independently selected from N, O and S; １－５ The heteroaryl substituent is a 5- or 6-membered monocyclic ring of which 1 to 4 ring members are heteroatoms, each of which is independently selected from N, O, and S, with the proviso that only one of the ring members is O or S; R ３ is hydrogen, halo, cyano and C １－４ alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo); R ４ and R ５ is hydrogen, halo and C １－４ alkyl (unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo), or R ４ and R ５ together with the carbon atoms to which they are attached, form C ３－５ forming a cycloalkylidene, X １２ is the bond and CR １２ R １３ is selected from (a) R ６ is hydrogen, halo and C １－４ alkyl, R ７ and R ８ together with the carbon atom and nitrogen atom to which they are respectively attached, form a C having one ring heteroatom ３－５ forming a heterocyclyl, R ９ is hydrogen and C １－４ alkyl, R １０ , R １１ , R １２ and R １３ is hydrogen, halo and C １－４ alkyl; or (b) R ６ and R ７ is hydrogen, halo and C １－４ alkyl, or R ６ and R ７ together with the carbon atoms to which they are attached, form C ３－５ forming a cycloalkylidene, R ８ and R ９ together with the nitrogen atom to which they are attached, form C ３－５ heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C １－４ substituted with 1 to 3 optional substituents independently selected from alkyl; R １０ , R １１ , R １２ and R １３ is hydrogen, halo and C １－４ alkyl; or (c) R ６ and R ７ is hydrogen, halo and C １－４ are each independently selected from alkyl, R ８ is hydrogen and C １－４ alkyl, R ９ and R １０ together with the nitrogen and carbon atoms to which they are respectively attached, represent C ３－５ heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C １－４ substituted with 1 to 3 optional substituents independently selected from alkyl; R １１ , R １２ and R １３ is hydrogen, halo and C １－４ are each independently selected from alkyl, n is selected from 0, 1, 2, 3, 4 and 5; Each R １４ Ha, Halo, C １－４ Alkyl and C １－４ alkoxy, wherein said C １－４ Alkyl and C １－４ each alkoxy substituent is independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; However, X ２ is CR ２ and X ３ is N and X １２ is a bond, n is 1, and R １ , R ４ , R ５ , R ６ , R ７ , R ８ , and R １１ are hydrogen, and R ９ and R １０ together with the nitrogen and carbon atoms to which they are respectively attached form an unsubstituted pyrrolidin-2-yl, R １４ is methoxy, R ２ cannot be unsubstituted pyridin-3-yl or unsubstituted pyrimidin-5-yl).

2. R ａ But C １－４ Alkyl, C ３－６ Cycloalkyl, C ３－５ Heterocyclyl and C １－５ heteroaryl, each of which is unsubstituted or selected from halo, C １－４ Alkyl and C １－４ substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein said C １－４ Alkyl and C １－４ The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R ｂ is hydrogen, and C １－４ Alkyl, C ３－６ Cycloalkyl, C ３－５ Heterocyclyl and C １－５ heteroaryl, each of which is unsubstituted or selected from halo, C １－４ Alkyl and C １－４ substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein said C １－４ Alkyl and C １－４ The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R ｃ is hydrogen and C １－４ alkyl, Here, R ａ and R ｂ Regarding the above C ３－５ A heterocyclyl substituent is a monocyclic ring of 4 to 7 ring members, of which 1 or 2 ring members are heteroatoms, each of which is independently selected from N, O and S; １－５ The heteroaryl substituent is a 5- or 6-membered monocyclic ring of which 1 to 4 ring members are heteroatoms, each of which is independently selected from N, O, and S, with the proviso that only one of the ring members is O or S.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. R ａ and R ｂ Regarding the above C ３－５ 3. The compound or pharmaceutically acceptable salt of claim 2, wherein the heterocyclyl substituent is selected from azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, and morpholinyl.

4. R ａ and R ｂ Regarding the above C １－５ 4. A compound or a pharmaceutically acceptable salt according to any one of claims 2 and 3, wherein the heteroaryl substituent is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl and thiazolyl.

5. X ２ is CR ２ and X ３ The compound or pharmaceutically acceptable salt according to any one of claims 1 to 4, wherein is N.

6. X ２ is CR ２ and X ３ is CR ３ 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein:

7. R ３ 7. The compound or pharmaceutically acceptable salt of claim 6, wherein is selected from hydrogen.

8. X ２ is N and X ３ 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

9. R １ is hydrogen, R ａ , -OR ｂ , -C(O)R ｂ , -C(O)OR ｂ and -C(O)N(R ｃ ) R ｂ is selected from R ａ But C １－４ Alkyl and C ３－６ cycloalkyl, each of which is unsubstituted or selected from halo, C １－４ Alkyl and C １－４ substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein said C １－４ Alkyl and C １－４ The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R ｂ is hydrogen, and C １－４ Alkyl and C ３－６ cycloalkyl, each of which is unsubstituted or selected from halo, C １－４ Alkyl and C １－４ substituted with 1 to 3 optional substituents independently selected from alkoxy, wherein said C １－４ Alkyl and C １－４ The optional substituents of the alkoxy are each independently unsubstituted or substituted with 1 to 3 optional substituents independently selected from halo; R ｃ is hydrogen and C １－４ selected from alkyl, 9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 8.

10. R ４ and R ５ 10. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 9, wherein are each independently selected from hydrogen and methyl.

11. X １２ The compound or pharmaceutically acceptable salt of any one of claims 1 to 10, wherein is a bond.

12. X １２ is a bond, R ６ and R ７ is hydrogen, halo and C １－４ alkyl, or R ６ and R ７ together with the carbon atom to which they are attached, ３－５ forming a cycloalkylidene, R ８ and R ９ together with the nitrogen atom to which they are bonded, form C ３－５ heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C １－４ substituted with 1 to 3 optional substituents independently selected from alkyl; R １０ and R １１ is hydrogen, halo and C １－４ alkyl, 11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10.

13. R ６ and R ７ are each independently selected from hydrogen and methyl, or together with the carbon atom to which they are attached form a cyclopropylidene; or a pharmaceutically acceptable salt thereof.

14. R ８ and R ９ together with the nitrogen atom to which they are attached, form a C selected from azetidinyl and pyrrolidinyl ３－５ heterocyclyl, each of which is unsubstituted or selected from halo and C １－４ 14. The compound or pharmaceutically acceptable salt of any one of claims 12 and 13, substituted with 1 to 3 optional substituents independently selected from alkyl.

15. R ８ and R ９ together with the nitrogen atom to which they are attached, form a C selected from azetidinyl and pyrrolidinyl ３－５ 15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, which forms heterocyclyls, each of which is unsubstituted or substituted with 1 or 2 fluoro.

16. R １０ and R １１ 16. The compound or pharmaceutically acceptable salt of any one of claims 12 to 15, wherein each is hydrogen.

17. X １２ is a bond, R ６ and R ７ is hydrogen, halo and C １－４ are each independently selected from alkyl, R ８ is hydrogen and C １－４ alkyl, R ９ and R １０ together with the nitrogen and carbon atoms to which they are respectively attached, ３－５ heterocyclyl, which has one ring heteroatom and is unsubstituted or includes halo and C １－４ substituted with 1 to 3 optional substituents independently selected from alkyl; R １１ is hydrogen, halo and C １－４ selected from alkyl, 11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10.

18. R ６ and R ７ 18. The compound or pharmaceutically acceptable salt of claim 17, wherein each is hydrogen.

19. R ８ 19. The compound or pharmaceutically acceptable salt of any one of claims 17 and 18, wherein is selected from hydrogen and methyl.

20. R ９ and R １０ taken together with the nitrogen and carbon atoms to which they are respectively attached form an azetidinyl, which is unsubstituted or is selected from the group consisting of halo and C １－４ 20. The compound or pharmaceutically acceptable salt of any one of claims 17 to 19, substituted with 1 to 3 optional substituents independently selected from alkyl.

21. R ９ and R １０ taken together with the nitrogen and carbon atoms to which they are respectively attached form a pyrrolidinyl, which is unsubstituted or is selected from the group consisting of halo and C １－４ 20. The compound or pharmaceutically acceptable salt of any one of claims 17 to 19, substituted with 1 to 3 optional substituents independently selected from alkyl.

22. R ９ and R １０ together with the nitrogen and carbon atoms to which they are respectively attached form piperidinyl, which is unsubstituted or is selected from the group consisting of halo and C １－４ 20. The compound or pharmaceutically acceptable salt of any one of claims 17 to 19, substituted with 1 to 3 optional substituents independently selected from alkyl.

23. R １１ 23. The compound or pharmaceutically acceptable salt of any one of claims 17 to 22, wherein is hydrogen.

24. X １２ is CR １２ R １３ 11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein:

25. X １２ But, CR １２ R １３ and R ６ is hydrogen, halo and C １－４ alkyl, R ７ and R ８ together with the carbon atom and nitrogen atom to which they are respectively attached, form a C having one ring heteroatom ３－５ forming a heterocyclyl, R ９ is hydrogen and C １－４ alkyl, R １０ , R １１ , R １２ and R １３ is hydrogen, halo and C １－４ alkyl, 25. The compound of claim 24 or a pharmaceutically acceptable salt thereof.

26. R ６ 26. The compound or pharmaceutically acceptable salt of claim 25, wherein is hydrogen.

27. R ７ and R ８ together with the carbon atom and nitrogen atom to which they are respectively attached, a C selected from pyrrolidinyl and piperidinyl ３－５ 27. A compound or a pharmaceutically acceptable salt according to any one of claims 25 and 26, which forms a heterocyclyl.

28. R ９ 28. The compound or pharmaceutically acceptable salt of any one of claims 25 to 27, wherein is selected from hydrogen and methyl.

29. R １０ and R １１ 29. The compound or pharmaceutically acceptable salt of any one of claims 25 to 28, wherein: are each independently selected from hydrogen and methyl.

30. R １２ and R １３ 30. The compound or pharmaceutically acceptable salt of any one of claims 25 to 29, wherein are each independently selected from hydrogen, fluoro, methyl and ethyl.

31. Each R １４ or a pharmaceutically acceptable salt thereof, wherein:

32. 3-benzyl-N-(2-(pyrrolidin-1-yl)ethyl)quinoxalin-2-amine; N-(2-(azetidin-1-yl)ethyl)-3-benzyl-8-methylquinoxalin-2-amine; N-(2-(azetidin-1-yl)ethyl)-3-benzyl-5-methylquinoxalin-2-amine; N-(2-(azetidin-1-yl)ethyl)-3-(3-methoxybenzyl)-8-methylquinoxalin-2-amine; N-(2-(azetidin-1-yl)ethyl)-3-(3-methoxybenzyl)-5-methylquinoxalin-2-amine; N-(2-(azetidin-1-yl)ethyl)-8-methyl-3-(3-methylbenzyl)quinoxalin-2-amine; 8-methyl-3-(3-methylbenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-2-amine; (R)-(6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(pyrrolidin-1-yl)methanone; (R)—N-cyclobutyl-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((S)-3-methoxypyrrolidin-1-yl)methanone; (6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((R)-3-methoxypyrrolidin-1-yl)methanone; 6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((S)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide; 6-((R)-1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((R)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide; 6-((R)-1-(4-fluorophenyl)ethyl)-N-(cis-3-methoxycyclobutyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-((R)-1-(4-fluorophenyl)ethyl)-N-(trans-3-methoxycyclobutyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide 2,2,2-trifluoroacetate; (R)-(6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(morpholino)methanone; (R)-N-cyclopropyl-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-(tetrahydro-2H-pyran-4-yl)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (S)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (S)-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (R)-6-(1-(4-fluorophenyl)ethyl)-N-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (S)-6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (R)-6-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 5-(1-(4-fluorophenyl)ethyl)-N,N-dimethyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (R)-6-(1-(4-fluorophenyl)ethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylate methyl; 6-((R)-1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide; 6-((S)-1-(4-fluorophenyl)ethyl)-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide; 6-((S)-1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide; 6-((R)-1-(4-fluorophenyl)ethyl)-N,N-dimethyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide; 6-((S)-1-(4-fluorophenyl)ethyl)-N-methyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide; 6-((R)-1-(4-fluorophenyl)ethyl)-N-methyl-5-(((R)-1-methylpyrrolidin-3-yl)amino)pyrazine-2-carboxamide; 5-((trans-3-ethyl-1-methylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N-methylpyrazine-2-carboxamide; 5-(1-(4-fluorophenyl)ethyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 5-(1-(4-fluorophenyl)ethyl)-N-methyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N,N,3-trimethyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N,3-dimethyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 3-methyl-6-(3-methylbenzyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(4-fluorobenzyl)-N,N,3-trimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(4-fluorobenzyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(4-fluorobenzyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carboxamide; 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N,3-dimethylpyrazine-2-carboxamide; 5-((trans-1,3-dimethylpiperidin-4-yl)amino)-6-(4-fluorobenzyl)-N,N,3-trimethylpyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-N,N,3-trimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N-(2-fluoroethyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-N-(2-methoxyethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-(tetrahydro-2H-pyran-4-yl)pyrazine-2-carboxamide; N-(3-(azetidin-1-yl)propyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxylic acid; 6-(1-(4-fluorophenyl)ethyl)-N-(cis-3-methoxycyclobutyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N-cyclopentyl-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(piperidin-1-yl)methanone; N,N-diethyl-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (3,3-difluoropyrrolidin-1-yl)(6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)methanone; 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((R)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide; N-cyclopropyl-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N-ethyl-6-(1-(4-fluorophenyl)ethyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N-(cis-3-fluorocyclobutyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N-cyclopropyl-6-(1-(4-fluorophenyl)ethyl)-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((S)-3-fluoropyrrolidin-1-yl)methanone; 6-(1-(4-fluorophenyl)ethyl)-N-isopropyl-N,3-dimethyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((S)-3-methoxypyrrolidin-1-yl)methanone; 6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)-N-((S)-tetrahydrofuran-3-yl)pyrazine-2-carboxamide; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(morpholino)methanone; 6-(1-(4-fluorophenyl)ethyl)-N-(trans-3-methoxycyclobutyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((R)-3-methoxypyrrolidin-1-yl)methanone; N-(3,3-difluorocyclobutyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)((R)-3-fluoropyrrolidin-1-yl)methanone; (6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazin-2-yl)(pyrrolidin-1-yl)methanone; N-(trans-3-fluorocyclobutyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; 6-(1-(4-fluorophenyl)ethyl)-3-(methoxymethyl)-5-((2-(pyrrolidin-1-yl)ethyl)amino)pyrazine-2-carboxamide; N-(2-(azetidin-1-yl)ethyl)-3-(4-fluorobenzyl)-5,6-dimethylpyrazin-2-amine; 3-(4-fluorobenzyl)-5,6-dimethyl-N-(1-methylpiperidin-4-yl)pyrazin-2-amine; 3-(4-fluorobenzyl)-5,6-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; (R)-3-(4-fluorobenzyl)-5,6-dimethyl-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine; 5,6-dimethyl-3-(3-methylbenzyl)-N-(1-methylpiperidin-4-yl)pyrazin-2-amine; 5,6-dimethyl-3-(3-methylbenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; (R)-5,6-dimethyl-3-(3-methylbenzyl)-N-(1-methylpyrrolidin-3-yl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-6-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-5-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; N-(2-(azetidin-1-yl)ethyl)-6-isopropyl-3-(3-methylbenzyl)pyrazin-2-amine; N-(2-(azetidin-1-yl)ethyl)-6-ethoxy-3-(3-methylbenzyl)pyrazin-2-amine; N-(2-(azetidin-1-yl)ethyl)-3-benzyl-6-ethylpyrazin-2-amine; N-(2-(azetidin-1-yl)ethyl)-6-cyclopropyl-3-(3-methylbenzyl)pyrazin-2-amine; N-(1,3-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine; N-(1,3-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)-6-(trifluoromethyl)pyrazin-2-amine; 3-(4-fluorobenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyrazin-2-amine; N-(trans-3-ethyl-1-methylpiperidin-4-yl)-3-(4-fluorobenzyl)-5-(trifluoromethyl)pyrazin-2-amine; 5-((2-(azetidin-1-yl)ethyl)amino)-6-(4-fluorobenzyl)-3-methylpyrazine-2-carbonitrile; (R)-3-methyl-6-(3-methylbenzyl)-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile; (R)-6-(3-methoxybenzyl)-3-methyl-5-((1-methylpyrrolidin-3-yl)amino)pyrazine-2-carbonitrile; 5-(4-fluorobenzyl)-N,N-dimethyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide; 5-(4-fluorobenzyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide; 5-(4-fluorobenzyl)-N-methyl-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide; 6-((1,3-dimethylpiperidin-4-yl)amino)-5-(4-fluorobenzyl)nicotinamide; 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine; 3-(4-fluorobenzyl)-N-(2-(pyrrolidin-1-yl)ethyl)-6-(trifluoromethyl)pyridin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine; 5-(1-(4-fluorophenyl)ethyl)-6-((2-(pyrrolidin-1-yl)ethyl)amino)nicotinamide; N-(1-(azetidin-1-yl)propan-2-yl)-3-(4-fluorobenzyl)pyrazin-2-amine; N-(1-(azetidin-1-ylmethyl)cyclopropyl)-3-(4-fluorobenzyl)pyrazin-2-amine; 3-(4-fluorobenzyl)-N-((1-methylpyrrolidin-2-yl)methyl)pyrazin-2-amine; 3-(4-fluorobenzyl)-N-((1-methylazetidin-2-yl)methyl)pyrazin-2-amine; 3-(4-fluorobenzyl)-N-(1-(pyrrolidin-1-yl)propan-2-yl)pyrazin-2-amine; 3-(4-fluorobenzyl)-N-((1-methylpiperidin-2-yl)methyl)pyrazin-2-amine; N-(trans-1,2-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)pyrazin-2-amine; N-(cis-1,2-dimethylpiperidin-4-yl)-3-(4-fluorobenzyl)pyrazin-2-amine; 3-(4-fluorobenzyl)-N-(trans-3-fluoropiperidin-4-yl)pyrazin-2-amine; N-(trans-3-fluoro-1-methylpiperidin-4-yl)-3-(4-fluorobenzyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-N-(2-(3-fluoropyrrolidin-1-yl)ethyl)pyrazin-2-amine; N-(2-(3,3-difluoropyrrolidin-1-yl)ethyl)-3-(1-(4-fluorophenyl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-phenylethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; (R)-3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; (S)-3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-5-(oxazol-2-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-5-(1-methyl-1H-imidazol-2-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)-5-(thiazol-2-yl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-5-(5-methyloxazol-2-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-5-(5-methylthiazol-2-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 5-(1,5-dimethyl-1H-imidazol-2-yl)-3-(1-(4-fluorophenyl)ethyl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; 3-(1-(4-fluorophenyl)ethyl)-6-methyl-5-(5-methyloxazol-2-yl)-N-(2-(pyrrolidin-1-yl)ethyl)pyrazin-2-amine; N-(2-(azetidin-1-yl)ethyl)-3-ethyl-6-(3-methylbenzyl)-1,2,4-triazin-5-amine; N-(trans-1,3-dimethylpiperidin-4-yl)-6-(4-fluorobenzyl)-3-methyl-1,2,4-triazin-5-amine; N-(2-(azetidin-1-yl)ethyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-1,2,4-triazin-5-amine; (R)—N-(2-(azetidin-1-yl)ethyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-1,2,4-triazin-5-amine; (S)—N-(2-(azetidin-1-yl)ethyl)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-1,2,4-triazin-5-amine; N-(2-(azetidin-1-yl)ethyl)-6-(4-fluorobenzyl)-3-methyl-1,2,4-triazin-5-amine; N-(2-(azetidin-1-yl)ethyl)-3-ethyl-6-(4-fluorobenzyl)-1,2,4-triazin-5-amine; 6-(4-fluorobenzyl)-3-methyl-N-(1-methylpiperidin-4-yl)-1,2,4-triazin-5-amine; N-(2-(azetidin-1-yl)ethyl)-3-cyclopropyl-6-(4-fluorobenzyl)-1,2,4-triazin-5-amine; (R)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(1-methylpiperidin-4-yl)-1,2,4-triazin-5-amine; (S)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(1-methylpiperidin-4-yl)-1,2,4-triazin-5-amine; 6-((R)-1-(4-fluorophenyl)ethyl)-3-methyl-N-((R)-1-methylpyrrolidin-3-yl)-1,2,4-triazin-5-amine; 6-((S)-1-(4-fluorophenyl)ethyl)-3-methyl-N-((R)-1-methylpyrrolidin-3-yl)-1,2,4-triazin-5-amine; N-(2-(azetidin-1-yl)ethyl)-3-methyl-6-(1-phenylethyl)-1,2,4-triazin-5-amine; (R)—N-(2-(azetidin-1-yl)ethyl)-3-methyl-6-(1-phenylethyl)-1,2,4-triazin-5-amine; (S)—N-(2-(azetidin-1-yl)ethyl)-3-methyl-6-(1-phenylethyl)-1,2,4-triazin-5-amine; 6-((R)-1-(4-fluorophenyl)ethyl)-3-methyl-N-((S)-1-methylpyrrolidin-3-yl)-1,2,4-triazin-5-amine; 6-((S)-1-(4-fluorophenyl)ethyl)-3-methyl-N-((S)-1-methylpyrrolidin-3-yl)-1,2,4-triazin-5-amine; N-(2-(azetidin-1-yl)ethyl)-3-methyl-6-(3-methylbenzyl)-1,2,4-triazin-5-amine; 3-methyl-N-((R)-1-methylpyrrolidin-3-yl)-6-((R)-1-phenylethyl)-1,2,4-triazin-5-amine; 3-methyl-N-((R)-1-methylpyrrolidin-3-yl)-6-((S)-1-phenylethyl)-1,2,4-triazin-5-amine; 3-methyl-N-((S)-1-methylpyrrolidin-3-yl)-6-((R)-1-phenylethyl)-1,2,4-triazin-5-amine; 3-methyl-N-((S)-1-methylpyrrolidin-3-yl)-6-((S)-1-phenylethyl)-1,2,4-triazin-5-amine; 3-methyl-N-(1-methylpiperidin-4-yl)-6-(1-phenylethyl)-1,2,4-triazin-5-amine; (S)-3-methyl-N-(1-methylpiperidin-4-yl)-6-(1-phenylethyl)-1,2,4-triazin-5-amine; (R)-3-methyl-N-(1-methylpiperidin-4-yl)-6-(1-phenylethyl)-1,2,4-triazin-5-amine; 6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-1,2,4-triazin-5-amine; (R)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-1,2,4-triazin-5-amine; and (S)-6-(1-(4-fluorophenyl)ethyl)-3-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-1,2,4-triazin-5-amine; a compound selected from the group consisting of: or a pharmaceutically acceptable salt of any one of the foregoing compounds.

33. A compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 32; a pharmaceutically acceptable excipient; A pharmaceutical composition comprising:

34. A compound or a pharmaceutically acceptable salt as defined in any one of claims 1 to 32 for use as a medicament.

35. 33. A compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32 for the treatment of a disease, disorder, or condition selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

36. A composition comprising a compound or a pharmaceutically acceptable salt as defined in any one of claims 1 to 32 and at least one additional pharmacologically active agent.

37. 37. The composition of claim 36, wherein the additional pharmacologically active agent is selected from a beta-secretase inhibitor, a gamma-secretase inhibitor, an HMG-CoA reductase inhibitor, a nonsteroidal anti-inflammatory drug, vitamin E, an anti-amyloid antibody, an antidepressant, an antipsychotic, an anxiolytic, and an anticonvulsant.

Images